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Methods were developed to measure and characterise 1) amounts and
types of cyclic AMP binding proteins 2) cyclic AMP levels and 3)
expression of the ras protein, p21, in breast cancers. There
were wide variations in the levels of all parameters between
different primary tumours from patients with non-disseminated
breast cancers.
Specific cAMP binding activity was detectable in all 245 tumour
cytosols assayed and levels ranged from 0.77 to 15.05 pmol/mg
cytosol protein (median 3.85).
cAMP, p21 and typing of cyclic AMP were measured in a subset of
160 breast tumours.
Types of binding proteins were characterized using a photoaffinity
labelling technique followed by SDS-polyacrylamide gel
electrophoresis. Proteins of molecular weight 52K (R2), 48K (Rl),
43K and 39K were detected in 75, 100, 44 and 92% , and were
predominant in 12, 71, 2 and 15%, of breast tumours, respectively.
Levels ranged from 0-5.450 (median 0.559), 0.105-7.912 (1.922),
0-2.445 (0) and 0-7.345 (0.742) pmol/mg cytosol protein,
respectively.
Cyclic AMP was detected by radioimmunoassay in all tumours assayed
and levels ranged from 43-861 pmol/mg wet weight (median 258).
P21 levels were analysed by Western blotting and expressed on an
ix
arbitrary scale of 1-5, based on increasing overexpression
compared with p21 in normal breast. Units 1, 2, 3, 4 and 5
contained 12, 28, 27.5, 25 and 7.5% of the tumour population,
respectively.
Levels of the above parameters were then related to established
prognostic factors such as steroid receptors, lymph node
involvement, histological grade and clinical stage, as well as to
each other, and to the patients' disease-free interval and
survival.
P21 levels were significantly higher in tumours with lymph node
involvement (p<0.05). Otherwise no statistically significant
correlations were apparent between the levels of any one parameter
and known prognostic factors.
However, there was a significant correlation between levels of
cAMP binding proteins and levels of cAMP (p<0.001). There was also
a significant correlation between levels of p21 and levels of both
cAMP (p<0.001) and its binding protein (p<0.001).
It is suggested that overexpression of p21 accompanies an
augmentation of the cAMP system.
Furthermore, tumour levels of cAMP binding proteins were
significantly higher in patients whose disease recurred within 3
years of primary treatment compared with those who remained
disease-free (p<0.001). Cox analysis of the total follow-up
available showed that patients with tumour cAMP binding greater
than 8 pmol/mg cytosol protein had a significantly greater chance
of developing recurrent disease and poorer survival rates (p<0.001
by Cox Analysis) than those with lower levels. This remained true
when other prognostic factors were taken into account in a
multivariate analysis.
Investigation of individual types of binding protein did not
improve the prognostic value of total binding measurements.
Levels of cAMP were related to disease recurrence at 36 months
(p<0.04) but not to survival. However, Cox analysis of cAMP level
quartiles in relation to overall disease free interval and
survival showed significant trends for increasing cAMP levels to
be significantly associated with increased chance of recurrence
(p<0.001) and reduced probability of survival (p<0.001).
Increased expression of p21 was also significantly related to
reduced disease-free interval (p<0.001) and survival (p<0.001) by
both Wilcoxon Rank Test at 36 months and Cox Analysis.
However, multivariate analysis of the data revealed that when
results were adjusted for the effect of cAMP binding, the
prognostic value became non-significant for cAMP and of marginal
significance for p21.
In 31 patients with ER-positive inoperable breast cancer it was
shown that the ratio of tumour cAMP binding : ER activities
provided complete discrimination between patients responding and
not responding to endocrine therapy, improving the predictive
value of the ER alone.
It is suggested that cAMP binding activity is related to
expression of p21 and tumour behaviour. The binding protein
appears to be of clinical value as a new independent prognostic
factor for non-disseminated breast cancer and in predicting
endocrine responsiveness in advanced disease.
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a) Epidemiology of Breast Cancer
Breast cancer is the most common form of cancer in women
throughout the world, apart from the generally non fatal, non
melanoma skin cancers. In 1980 over half a million women were
first diagnosed as having breast cancer (Parkin et al.,1988).Of
these, an estimated 350,000 of new cases were diagnosed among the
inhabitants of developed countries. It is estimated that in
Britain 1 in every 11 women will develop the disease, while in the
U.S.A. the ratio is 1 in 14 (Kelsey,1979). Annually, there are
3000 new registrations in Scotland, and 21,000 in England and
Wales (Brinkley & Haybritle, 1984).
Examination of time trends in breast cancer mortality from
1950-1983 in high-risk Anglo-Saxon and Scandinavian populations
have shown either no real increases in mortality or small
increases which have generally been followed by a levelling off
(Pascua, 1956; Boyle, 1988). An increasing trend in breast cancer
incidence worldwide of approximately 2% per annum has emerged
(Hakulinen et al.,1987; Heston et al.,1986; Boyle &
Robertson,1987). Further examination of Nordic data revealed that
the risk among birth cohorts has been increasing in all Nordic
countries at postmenopausal ages (Hakulinen et al.,1987). However,
it was noted that the risk for those born in the 1920s and 1930s
was the same although these groups had only been observed at
premenopausal ages. MacMahon (1982) reported a levelling off in
risk among cohorts of women in Connecticut born since 1925.
Similarly, using data up until 1984, it has been shown that the
risk of breast cancer among younger cohorts of women in Scotland
has been declining (Boyle & Robertson,1987). The possibility that
the rate of incidence of breast cancer risk in younger cohorts is
slowing down or even falling is one that defies current knowledge
of risk factors and requires close surveillance.
b) Hormone Responsiveness in Breast Cancer
The involvement of steroid hormones, particularly those produced
by the ovary, in the development and growth of the normal human
female breast is well known. The concept that malignant tumour
arising within the breast should be under the same endocrine
influence was first exploited by Beatson, in Glasgow,in 1896. In a
study of three premenopausal patients with advanced disease he
showed that removal of the ovaries induced tumour regression in
two patients. Castration remains the first line treatment in
premenopausal women with advanced disease while surgical
manoeuvres such as adrenalectomy and hypophysectomy have already
been replaced by medical administration of anti-oestrogens,
progestogens and drug regimes such as aminoglutethimide-
hydrocortisone (Miller, 1987).
However, since Beatson's time it has been shown that only about
one third of women with advanced breast cancer respond to hormonal
manipulations.Non selective administration of endocrine therapy is
inefficient and delays the implementation of potentially more
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beneficial treatment.The problem of identifying those individuals
who have a chance of benefiting from such treatments and hence
avoiding unnecessary and often unpleasant treatment is
considerable and there is an obvious need for a method of
selecting patients for such therapy.
More than 60 years after Beatson it was shown that oestrogens are
concentrated in endocrine responsive tissues such as breast
tumours (Glascock & Hoekstra,1959; Jensen & Jacobsen,1960)and that
this ability to concentrate oestradiol is related to the response
to endocrine ablation. The mechanism whereby steroid hormones
influence mammary tumour growth appears to depend on their
association with specific intracellular receptor proteins
(Edelman, 1975; Lippman & Allegra,1978) and measurement of
oestrogen receptors (ER) is now the single most useful parameter
used to identify breast tumours likely to respond to endocrine
ablative therapy (Jensen, 1975; McGuire, 1978).
It has been established that tumours containing ER (about 75% of
cancers) have a 50% chance of responding to endocrine treatment
while tumours lacking detectable ER activity display only low
response rates, generally less than 10% (Hawkins,1985). There
is,therefore,a need to improve on the discrimination given by the
present assays of ER.
The concomitant presence of ER and a second steroid receptor, the
progesterone receptor (PgR), appreciably increases the predictive,
value of the test (Leclerq et al.,1983). The presence of PgR
probably indicates that the tumour has maintained its sensitivity
to oestrogen since it is well established that in ER target
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tissues PgR synthesis is induced by oestrogenic stimulation
(Horwitz & McGuire,1978). However, this combination still does not
provide discrimination for individual patients and additional
predictive factors are required.
A quantitative relationship between ER concentration and the
probability of a favourable response to endocrine therapy has been
demonstrated (DeSombre & Jensen,1980) suggesting the existence of
a continuous gradient of hormone dependence among mammary tumours.
There is now experimental and clinical evidence that tumours are
in fact very heterogeneous and that most contain two or more
populations, or clones, of cells which differ markedly in their
hormonal sensitivity (Sluyser & Van Nie,1974; Kiss et al.,1986).
Development of monoclonal antibodies to the oestrogen receptor
(King & Green,1984) which can be used on histological preparations
and small tumour specimens for accurate receptor visualisation at
the cellular level has already confirmed that most tumours contain
two phenotypes of cell which are present in variable proportions.
Tumour cell heterogeneity may account for the changing patterns of
hormonal sensitivity often observed as the disease progresses. As
tumours evolve under the selective pressures produced by hormone
deprivation therapy, a process of clonal selection of hormone
independent cells has been shown to be responsible for the relapse
of initially responsive breast tumours following endocrine
treatment (Kim 6c Depowski,1975). Not suprisingly, therefore,
despite the increasing numbers of anti-steroidal regimes, survival
rates for patients with breast cancer have not markedly improved.
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It is apparent that, even allowing for these refinements in the ER
assay, additional parameters are needed which can discriminate
between hormone dependent and hormone independent tumours.
c) Prognostic Factors in Breast Cancer
Breast cancer was initially believed to be a localised disease but
is now recognised as systemic in view of its great propensity to
early metastatic dissemination, even in very small tumours
(Brinkley & Haybritle, 1984). This means that the majority of
so-called "early" breast cancers are biologically late when
detected. However, the course of the disease is extremely variable
so that time to first recurrence (disease free interval) and time
to death (overall survival) may range from several months to
several decades. About 50% of patients will live with their
disease, whether manifest or occult, for 5 to 30 years as a result
of slow tumour growth or delayed metastases.
Although the primary management of early breast cancer
predominantly involves local surgery and other non-hormonal
modalities which control the disease at least in the short term,
clinical trials are now providing evidence of survival benefit
from adjuvant endocrine therapy. Predicting whether a patient will
have an early recurrence or poor survival is extremely important
in selecting high risk groups for such prophylactic treatment or
identifying patient subsets with relatively good prognosis where
the unpleasant side effects of intensive systemic treatment can be
avoided.
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It is now generally agreed that the prognosis of patients with
early breast cancer depends upon a series of factors. The most
important clinical prognostic indicators in patients with
apparently localised disease are the tumour size, and the presence
of metastases in the axillary lymph nodes ( Stenkvist et
al.,1982). However, most evidence suggests that these parameters
reflect mainly the chronological age or natural history of the
tumour. They permit the recognition of patients with a high
likelihood of dying within 5 years but they do not appear to
reflect the growth aggressiveness or metastatic potential of the
tumour.For this, an additional set of markers is required.
Histopathological grading of tumour cells (including their mitotic
activity, degree of differentiation and nuclear pleomorphism) is
believed to provide a measure of the biological aggressiveness of
the tumour although this does not encompass invasive or metastatic
potential (Olszewski et al.,1981;Tickle et al.,1978). A
combination of clinical staging and histopathological grading is
at present the most widely used prognostic index in breast cancer.
Although such an index works reasonably well at the two extremes
of prognosis, it has little discriminatory power in the majority
of patients with intermediate stage and grade. For this reason,
the introduction of the oestrogen receptor as a potentially useful
biochemical prognostic parameter was welcomed (Stenkvist et
al.,1982; Stewart et al.,1982; Thoresen et al.,1982). Added to
staging and grading, ER increases the ability to predict the risk
of recurrence (Pari et al.,1984).
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By itself, however, ER status is of limited value. In some studies
the disease free interval was found to be significantly longer in
ER positive cases (Cooke et al.,1979; Crowe et al.,1982; Knight et
al.,1977) while in others there was no difference (Blarney et
al.,1980; Saez et al.,1983). In others the effect was transient.
It has been reported that lack of ER is associated with early
recurrence when the patient series is analysed a few years after
mastectomy but that after follow-up of more than 4 or 5 years this
predictive effect disappears and the life table analyses curves of
patients with and without tumour ER converge (Hahnel et al.,1979).
Studies on the relationship between PgR status and prognosis are
also conflicting. An increased disease free interval in PgR
positive cases has been reported by some (Clark et al.,1983; Saez
et al.,1983) but is disputed by others (Allegra et al.,1979;
Howell et al.,1984).
The importance of steroid hormone receptors as prognostic factors
remains unresolved and there is, to date, no clear biological
basis for the relationship between the presence of steroid
receptors and prolonged survival.
New techniques for the measurement of cell proliferation rates and
DNA content of nuclei in tumours have become available, namely
nuclear labelling with [3H] thymidine and DNA flow cytometry. The
prognostic potential of these methods is still being evaluated.
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d) Cyclic AMP Binding in Breast Cancer
Whilst the role of steroid hormones has been extensively
researched, the role of protein and polypeptide hormones,
including certain growth factors, in the growth of malignant
mammary cells is less well documented.
The initial molecular action of some protein hormones involves
binding to cell surface receptors.This activates or deactivates
membrane bound adenylate cyclase which catalyses the formation of
cAMP from ATP (Sutherland, 1972).
It is now established that cAMP is the second messenger of a
number of protein hormones (Robinson & Sutherland, 1971) . Although
cAMP, a nucleotide present in a wide variety of organisms ranging
from bacteria to man, is considered to be a major regulator of
numerous cellular activities including growth and differentiation
(Sutherland,1972) , the precise mechanism by which cAMP achieves
these effects is still unknown.
The action of cAMP is mediated via an interaction with its
"receptor" protein (a high affinity binding protein), which
appears to be the regulatory subunit of cAMP-dependent protein
kinase. CAMP-dependent protein kinase may phosphorylate specific
proteins whose biological activity may be modified (Kuo &
Greengard,1969).
There is now extensive evidence, accrued from in vitro studies and
animal models, that cAMP mediated events are implicated in the
regulation of mammary tumour growth and that the action of cAMP is
antagonistic to that of oestrogen. Increased intracellular cAMP,
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whether endogenously generated or exogenously supplied, has been
shown to inhibit growth of hormone dependent rat mammary tumours
(Cho-Chung,1979) . Tumour regression was observed to be triggered*
by an increased translocation from the cytoplasm to the nucleus of
a complex consisting of cAMP, its binding protein, and the
catalytic subunit of cAMP-dependent protein kinase. In the nucleus
phosphorylation of nuclear proteins occured and initiated genetic
events leading to cellular regression (Cho-Chung,1980a).
One of the major genetic events initiated by the administration of
cAMP appears to be a dramatic decrease in the expression of the
cellular Harvey ras oncogene, p21 (Huang & Cho-Chung,1984).
These changes appear to occur in advance of any morphological or
histological signs of regression,suggesting that they are the
cause, rather than the result, of cell death.
Such studies,therefore, suggest a connection between the action of
cAMP in growth control and expression of the cellular ras oncogene
in mammary cancer.
In this chapter it is intended to (1) review in more detail the
evidence implicating cAMP and its binding proteins in the
regulation of mammary tumour growth and (2) investigate the
potential interrelationship with ras oncogene expression.
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1:2 Cyclic AMP and Regulation of Growth of the Mammary Gland
a) Cyclic AMP and the Normal Mammary Gland
It is useful to outline the role of cAMP in the functional
development of the normal mammary gland as a prerequisite for
studying the abnormal or neoplastic breast.
Animal studies have implicated cAMP in the regulation of normal
mammary gland development. Thus, a biphasic pattern in the cAMP
content of the rat mammary gland during gestation has been
observed (Sapag-Hagar & Greenbaum, 1974), cAMP levels rising
continuously towards the end of pregnancy, then progressively
falling. The transition, at the time of parturition, coincided
with a considerable increase in the metabolic activity of the
gland consequent to the onset of lactation.
Studies with explants of rat mammary gland in culture have also
shown that cAMP inhibited the increase of enzymes associated with
lactogenesis (Sapag-Hagar et al.,1974). Similarly cAMP, has been
identified as a negative control factor for the induction of the
milk proteins, alpha-lactalbumin and casein, in organ cultures of
mouse mammary gland organ culture (Perry & Oka,1980).
These observations illustrate the importance of tissue levels of
cAMP in the regulation of the functional differentiation and
development of the normal mammary gland.
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In most animal cells, cAMP seems to promote the expression of
differentiated characteristics. In contrast, it is much more
difficult to define a general function for the nucleotide in the
regulation of cell proliferation.
b)Cvclic AMP and Mammary Cancer
Cyclic AMP is implicated in the regulation of the proliferation of
both normal and neoplastic cells. However, it seems reasonable to
expect that the cAMP-dependent regulatory mechanism would be
altered in tumour cells.
Neoplastic transformation is a multistage process. According to
Hunt and Martin (1980) the most consistent change in cAMP
metabolism during the initial stages of carcinogenesis is an
increase in basal adenylate cyclase activity and a heightened
responsiveness to b-adrenergic agonist. However,there is no
consensus of opinion after the cells have become transformed, when
adenylate cyclase, phosphodiesterase and type 1 and type 2
cAMP-dependent protein kinase activities may be increased or
decreased.
It would seem that whether cAMP levels differ between normal and
malignant mammary tissue depends in part upon the form in which
data are expressed. Levels of cAMP were found to be elevated in
DMBA-induced rat mammary tumours (Cohen & Chan, 1975; Rillema et
al.,1978) and human breast cancers (Minton et al.,1974; Kung et
al.,1977; Guerinot et al.,1977; Israeli et al.,1985), compared
with normal adjacent mammary tissue, when values were expressed
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per unit weight of cellular protein. However, when results were
expressed per unit cell density or DNA content, these differences
disappeared or were reversed (Kung et al.,1977, Rillema et
al.,1978). In a single study (Israeli et al.,1985) higher levels
of cAMP were found in human mammary tumours irrespective of how
the results were expressed.
In vitro studies using cell lines derived from DMBA-induced rat
mammary tumours and normal mammary tissue have also shown lower
levels of cAMP in the cancerous cell line (Cohen & Chan, 1975).
However, it cannot be assumed that cAMP levels exhibited by
cultured cells are indicative of their true in situ values.
These data suggest that there may be no single type of alteration
in cAMP level typical of malignant transformation of mammary
cells.
Various observations now point to an inverse relationship between
cAMP levels and the rate of cell growth (Heidrick & Ryan, 1970;
Otten et al.,1971; Sheppard,1972).
Raised intracellular cAMP, either endogenously generated or
exogenously supplied, has been shown to inhibit the growth of both
normal and cancerous mammary cells in vivo and in vitro
(Cho-Chung,1979). Administration in vivo of the cAMP derivative,
dBcAMP and an agent which specifically increases intracellular
cAMP levels, cholera toxin (Holmgren, 1981), caused growth
inhibition in hormone dependent rat mammary tumours (Cho-Chung and
Gullino,1974; Cho-Chung et al.,1983). Inhibition of tumour growth
was dose dependent, reversible and no toxic effect was observed.
1 2
Matusik and Hilf (1976) measured levels of cAMP (expressed in
pmoles/mg protein) in hormone dependent DMBA-induced mammary
tumours, before and after oophorectomy, and observed an inverse
correlation with tumour growth.
Growth of oestrogen dependent MCF-7 human breast cancer cells in
culture was also arrested by dBcAMP (Shafie & Brooks, 1977;
Cho-Chung et al.,1981) or cholera toxin (Cho-Chung et al. , 1983).
However, unrestrained growth, a characteristic of hormone
independent breast cancer cells, is not always associated with
diminished levels of cAMP. Autonomously growing mammary tumours
may contain high levels of cAMP initially, which do not alter on
endocrine manipulation (Cho-Chung, 1980a).
These effects are not limited to mammary tumours. CAMP has been
found to regulate the rate of cell division in other normal and
cancerous cell types both in vivo and in vitro. For example, cAMP
inhibits the growth of a lymphosarcoma in mice when injected in
the vicinity of the tumour (Gericke & Chandra, 1969). Reddi and
Constantinides (1972) reported reduced tumour growth of CELO
virus - transformed hamster cells if the cells were pretreated in
culture with dBcAMP and theophylline, which inhibits cAMP
degradation by phosphodiesterase.
In vitro and animal studies have yielded interesting results
concerning the role of cAMP in the regulation of mammary tumour
growth. The corresponding information in human breast cancer is
not yet available.
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1:3 Cyclic AMP Binding Proteins
a)Cvclic AMP Binding Proteins: Molecular Characterisation
It is now recognised that many of the actions of cAMP are mediated
via complex formation with its receptor protein (a high affinity
binding protein), the regulatory subunit of cAMP-dependent protein
kinase (Kuo & Greengard,1969). This protein kinase was first
detected in 1968 by Walsh et al. and has been purified from all
mammalian tissues studied to date, as well as some tissues from
lower eukaryotes, including yeast (Takai et al.,1974).
CAMP-dependent protein kinase consists of a tetramer of 2
monomeric catalytic (C) subunits and a dimeric regulatory (R)
subunit, the cAMP receptor protein, containing two cAMP binding
sites per monomeric chain (Rubin et al.,1972; Beavo et al.,1974;
Corbin et al.,1978). These intrachain cAMP binding sites can be
differentiated based on their cAMP dissociation rates (Doskeland,
1978) and cAMP analogue specificity (Rannels and Corbin,1981).
Activation of the cytosolic enzyme occurs by a cAMP-promoted
dissociation of the holoenzyme to yield 2 active C, and a dimeric
R.cAMP complex (Tao et al.,1970). The catalytically active C then
phosphorylates specific cytosolic proteins, by transfering the
gamma-phosphate of ATP to serine or threonine hydroxyl groups in
proteins, thereby modifying their biological activity. Thus cAMP
requires to bind to its receptor protein in order to initiate a
1 4
sequence of events leading to a modification in cell function.
Upon removal of cAMP, the R and C components reassociate to form a
cAMP-dependent holoenzyme.
Two major types of cAMP-dependent protein kinase have been
identified. These have been designated as Type 1 and Type 2 based
on their elution on DEAE-cellulose chromatography (Kuo and
Greengard,1969; Krebs,1972; Rubin & Rosen,1975). These two types
of protein kinase differ in their regulatory subunit , the cAMP
binding protein, with respect to several physiochemical and
immunological properties, (Rubin & Rosen,1975; Hofmann et
al.,1975) but their catalytic subunits are similar (Sugden et
al.,1976; Bechtel et al.,1977).
The regulatory subunits of cAMP-dependent protein kinase Types 1
and 2 (R1 and R2) have now been characterised in cytosolic
fractions of various tissues using a photoaffinity label specific
for cAMP binding proteins, 32P 8-N3-cAMP. In many tissues R1 has
an apparent molecular weight of 49,000 and R2 ,54,000.
Interestingly it has been shown that R and C subunits, even from
unrelated species, are capable of forming heterologous holoenzyme
hybrids (Yamamura et al.,1971). This indicates that the C and R
proteins are well conserved structures in evolution, and are
essential for viable cell function.
It has also been suggested that the two types of cAMP-dependent
protein kinase have differing roles. Changes in the ratio of
protein kinase Type 1 to protein kinase Type 2 during the cell
cycle (Costa et al.,1976), in differentiation processes
(Eppenberger et al.,1979; Lee et al.,1976) and in regression of
hormone responsive mammary tumours (Cho-Chung et al.,1979) have
led to the hypothesis (Handschin & Eppenberger,1979) that protein
kinase Type 2 is primarily involved in differentiation and tumour
regression processes, whereas Type 1 relates to cell
proliferation.
b) Cyclic AMP Binding Proteins and Mammary Cancer
The role of cAMP binding proteins in the regulation of mammary
tumour growth has largely been derived from investigations in
experimental animals and relatively little information is
available in human breast cancers. The evidence implicating cAMP
binding proteins is based on the following experimental
observations.
Growing hormone dependent rat mammary tumours have lower levels of
cytoplasmic cAMP binding proteins than hormone independent tumours
(Bodwin et al.,1980).
Endocrine ablation or administration of dBcAMP does not appear to
influence cAMP binding protein levels or growth in hormone
independent rat mammary tumours. However, in hormone dependent
tumours levels of cAMP binding proteins rise rapidly following a
variety of anti-hormone therapies including dBcAMP, oophorectomy
(Cho-Chung,1980a,b), the anti-oestrogen, Tamoxifen,or
pharmacological doses of oestrogen (Bodwin et al.,1981).
Furthermore this increase in binding protein activity precedes any
physical or histological signs of regression, suggesting that it
is the cause rather than the result of cell death.
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The level of cAMP-dependent protein kinase also increases in the
nucleus. This is accompanied by new phosphorylation of a specific
non-histone protein of MW 76K (Cho-Chung and Redler,1977). Because
phosphorylation of this protein is associated with regression it
has been called "Regression Associated Protein" (RAP).
Phosphorylation of RAP ceases when tumour growth is resumed
following either oestrogen replacement or cessation of dBcAMP
treatment. Phosphorylation of RAP was also induced in regressing
DMBA tumours following Tamoxifen or high dose oestrogen injection
(Bodwin et al.,1981), and was inversely related to the
phosphorylation of a lower molecular weight nuclear protein,
"Growth Associated Protein" (GAP),(Cho-Chung et al.,1978b), which
is the major substrate for endogenous phosphorylation in growing
tumour nuclei.
In hormone independent mammary tumours which failed to regress
following oophorectomy or dBcAMP treatment, neither nuclear
translocation of cAMP receptor protein nor phosphorylation of the
76K nuclear protein occured (Cho-Chung and Redler,1977).
In an attempt to find an explanation for these results, a
recombinant experiment was carried out using activated cytosol and
isolated nuclei from hormone dependent and hormone independent
DMBA tumours (Cho-Chung,1980b).It was found that activated cytosol
derived from the hormone dependent tumour was able to induce
phosphorylation of the 76K protein in the nuclei derived from both
hormone dependent and hormone independent tumours, whereas
activated cytosol derived from the hormone independent tumour
failed to induce phosphorylation of this protein in either hormone
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dependent or independent tumour nuclei. These data might be
interpreted to indicate that both nuclear binding of cAMP receptor
and subsequent phosphorylation of the 76K protein depend on the
nature of the cAMP receptor complex in the cytosol.
The increase in cAMP binding activity on tumour regression is
particularly associated with the 54-56,000 MW protein (R2) which
also appears in the nucleus of hormone dependent tumours
(Cho-Chung, 1980b). Although hormone independent tumours contain
high levels of this protein these do not increase in the cytoplasm
or migrate to the nucleus following hormone manipulation.
It has been postulated that the inability of this abnormal binding
protein to translocate to the tumour cell nucleus is implicated in
the unrestrained growth of hormone independent tumours. This is
based on the concept that regression of hormone dependent tumours
is dependent on increased cAMP-mediated translocation of protein
kinase from the cytoplasm to the nucleus.
In support of this, several groups have identified abnormalities
in cAMP binding proteins in a range of autonomously growing
cancers.
Daniel et al. (1973) observed a relationship between resistance to
the cytotoxic effect of dBcAMP and aberrant cAMP receptor proteins
in cultured mouse lymphoma cells. Physical differences in the
binding proteins were observed but not identified.
A similar phenomenon was subsequently found in a clone of neuro¬
blastoma cells (Simantov and Sachs,1975). Neuroblastoma cells
resistant to the growth inhibitory effect of dBcAMP were found to
contain temperature sensitive cAMP binding proteins compared to
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dBcAMP responsive cells. Incubation at 37°C decreased both the
dissociation constant and the specific activity of cAMP binding to
proteins from resistant cells by about 50%, but there was no such
decrease in nonresistant cells.
An abnormal cAMP binding protein, showing charge alterations, was
also present in S49 lymphosarcoma mutant cells resistant to the
cytolytic effect of cAMP(Steinberg et al.,1977).
Yet another aberrant cAMP receptor protein has been isolated from
adrenocortical carcinomas (Shanker et al.,1979). This protein
differs from that in normal adrenal as it binds cAMP but fails to
phosphorylate histone.
Similar abnormalities have also been described in mammary tumours.
Several qualitative and quantitative differences in the cAMP
binding protein have been reported in a W256 rat mammary carcinoma
line which is dBcAMP unresponsive (Cho-Chung et al.,1977). These
aberrant binding proteins which fail to accumulate in the nucleus
have been shown to possess different 2 dimensional electrophoretic
mobility from that of hormone dependent cancers. The R2 receptor
of hormone independent tumours migrates as a doublet with a shift
to a more acidic charge than that of the binding protein of a
hormone dependent tumour. This charge alteration does not affect
cAMP binding since both receptors exhibit a dissociation constant
for cAMP of lOnM. However,a defective association with the
catalytic subunit is apparent which has several consequences
including decreased autophosphorylation of the binding protein.
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Phosphorylation of the regulatory subunit of protein kinase by its
own catalytic subunit has been shown to be a characteristic of
cAMP-dependent protein kinase Type 2 from various tissues (Rosen &
Erlichman, 1975) . When hormone dependent tumour cytosols are
incubated under conditions favouring autophosphorylation, i.e. low
concentration of [32P] ATP,low temperature (0°C) and no cAMP
(Rosen & Erlichman,1975; Rangel-Aldao & Rosen,1976), the majority
of ^2p is incorporated into the R2 protein.
In hormone independent rat mammary tumours the inability of the
cAMP binding protein to translocate to the nucleus may be caused
by a defective association with the catalytic subunit which
prevents autophosphorylation and complex formation, events
necessary prior to translocation to the nucleus.
Ogreid et al. (1987) have further characterised the differences in
cAMP binding proteins between hormone dependent and independent
rat mammary tumours. They found that R2 from hormone dependent
tumours migrated as a doublet of apparent MWs 53K and 52K, whereas
R2 from hormone independent tumours appeared as a doublet of MW
54K and 52K. This electrophoretic pattern suggests that hormone
dependent and independent DMBA-induced tumours possess different
subclasses of isoenzyme with subtle but significant physiochemical
changes in R2 between the two groups. Differences in the migration
patterns of the R2 degradation products were also observed, as
well as a tendency for both R1 and R2 to form supramolecular
aggregates in the hormone independent tumours only. This may be
due to charge differences in the R subunits or to variable amounts
of complexing macromolecules in extracts from different tissues.
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Contrary to previous reports (Cho-Chung et al.,1977), no
difference was observed in temperature stability between binding
proteins from hormone dependent and hormone independent tumours.
It is possible that the tight association between binding proteins
and other intracellular proteins might in part explain the lack of
nuclear translocation observed in hormone unresponsive tumours.
It must be emphasised that these mechanisms have been elucidated
in experimental animals and in vitro studies, and the
corresponding depth of information in human breast tumours is not
available. However, studies on the MCF-7 cell line which is
derived from human breast cancer have shown that growth arrest is
preceded by an increase in cAMP-dependent protein kinase both in
the cytoplasm and nucleus of the cells (Cho-Chung et al.,1981).
Further experiments using antibodies directed against purified
cAMP receptor proteins from bovine tissues, and immunofluorescence
techniques (Kapoor and Cho-Chung,1983), showed that on regression
of MCF-7 tumours in nude mice following hormone withdrawal, the
intensity of immunofluoresence of R2, but not R1, increased
dramatically in the nuclei (Kapoor et al.,1984). In growing
tumours, the R2 cAMP receptor proteins were found only in the
cytosol and not in the nucleus. Hormone withdrawal, therefore,
resulted in specific transfer of the intact R2 cAMP receptor
protein from the cytoplasm to the nucleus. These experiments make
it probable that similar processes to those studied in more detail
in rodent mammary cancers exist in human breast cancer cells in
vivo. However, this remains to be determined.
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Finally, it is of interest that the mechanism of cAMP action at
the nuclear level, as demonstrated by the nuclear translocation of
the cAMP receptor complex, is remarkably similar to that of
steroid hormone action at the nuclear level. Thus an
inter-relationship between the action of cAMP and a steroid
hormone in the expression of genetic information is plausible. It
has been shown that during growth and regression of hormone
dependent tumours, oestrogen and cAMP exert opposing actions,
probably mediated via their respective receptor proteins.
Identification of the nuclear acceptor sites for these receptors
would assist further investigation into the interaction of cAMP
and oestrogen in the growth control of hormone dependent mammary
tumours.
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1:4 Cyclic AMP Binding and Endocrine Responsiveness in Advanced
Breast Cancer
The first indication that an antagonistic relationship might exist
between oestrogen and cAMP in the regulation of mammary tumour
growth was provided by the observation that either oophorectomy or
dbcAMP treatment can cause regression of hormone dependent tumours
(Cho-Chung and Redler,1977).
Results suggest that the growth regulation of DMBA-induced mammary
tumours may depend on a balance between oestrogen and cAMP
(Cho-Chung,1978) and a role for the specific cytoplasmic receptor
proteins for cAMP and oestrogen has been implicated (Cho-Chung et
al.,1978a). During growth, hormone dependent tumours have high
oestrogen binding but low cAMP binding. Within one day of
oophorectomy or dBcAMP treatment, a fall in oestrogen binding and
an increase in cAMP binding was observed (Bodwin et al.,1978).
These changes which occured within 6 hours of treatment, preceded
any physical or histological signs of tumour regression and are
unlikely, therefore, to be a consequence of regression. An
association with cell death in general is also unlikely since
treatment with the cytotoxic drug cyclophosphamide arrested tumour
growth but did not induce a rise in cAMP binding.
The decrease in oestrogen receptor (ER) activity was shown to be
due to a decrease in total binding sites without any modification
of either binding affinity or sedimentation characteristics
(Bodwin et al.,1978). These effects were reversed by injection of
oestrogen or cessation of dBcAMP treatment both of which renew
tumour growth.
Tumours whose growth was unaffected by these manipulations
exhibited no change in cAMP binding or oestrogen receptor
activity. These tumours had significantly lower basal ER levels
and significantly higher mean cAMP binding activity when compared
to their hormone dependent counterparts, although there was a
considerable overlap between the groups.
It is of interest that in rat mammary tumours the inverse
relationship observed between cAMP binding and oestrogen receptor
activities was found to be closely related to hormone dependency
(Cho-Chung,1978). A better assessment of hormone dependency was
achieved by using the ratio of ER to cAMP binding (CR) compared
with either parameter alone. In a study of 70 rat mammary tumours,
95% of hormone dependent tumours had an ER/CR ratio of less than
0.035 (Bodwin et al.,1980). When ER alone was measured, hormone
dependency could only be predicted in 60% of tumours. Thus, the
relative concentrations of ER/CR reflect the hormone dependency of
rat mammary tumours more accurately than ER alone.
In human breast cancer the presence or absence of the oestrogen
receptor is well established as an index for predicting response
to endocrine therapy (section 1.1). However, the mere presence of
tumour ER is not a reliable criterion for responsiveness.
The potential value of this combination of ER and CR in predicting
endocrine responsiveness has now been investigated in a limited
number of primary human breast tumours (Kvinnsland et al.,1983).
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Patients with advanced, evaluable breast cancer were biopsied
before the start of endocrine treatment and ER and CR measurements
performed. 16 of 30 patients (53%) had an objective response to
endocrine treatment. When ER and CR were expressed as a ratio and
this ratio was related to treatment response, it was found that
all objective responders had ratio values above 0.0025. 9 of 14
nonresponders had ER/CR ratios below this value. Thus a threshold
limit of 0.0025 correctly predicted the response to endocrine
treatment in 25 of 30 patients (83%). These results suggest that
cAMP receptor measurements may be a means of achieving better
selection of patients for endocrine therapy.
It remains to be determined whether the data can be consolidated
in a larger series of patients.
1:5 Expression of the Harvey Ras Oncogene Product. P21. in Mammary
Cancer
a) Genomic Regulation in Mammary Tumour Regression
As previously discussed in section l:3(b), regression of hormone
dependent rat mammary tumours by both dBcAMP and oophorectomy
appears to have a common mechanism of action. Both procedures
produce, as an early biochemical change, a marked increase in
cellular cAMP and cAMP binding proteins (Cho-Chung et al.,1978a).
Amongst the molecular forms of these binding proteins, it is a
species of molecular weight, 56K (R2), which increases in the
cytosol of hormone dependent tumours following endocrine
manipulation (Cho-Chung,1980a,b). This change is associated with
translocation of the kinase to the nucleus where it causes
increased phosphorylation of non-histone proteins and initiates
events which have been suggested to lead to cellular regression.
Investigations have now been carried out to elucidate these
genetic events.
RNAs isolated from growing and regressing DMBA tumours have been
translated in cell-free protein synthesising systems (Huang and
Cho-Chung,1982). The translation products were then analysed by
SDS-polyacrylamide gel electrophoresis. It was found that within 6
hours of dBcAMP treatment, the concentration of one protein band
(MW 20.5K) increased and those of two protein bands (MW 21K and
35K) decreased in the regressing tumours as compared to the
growing tumours. These events occured well in advance of any
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physical or histological signs of regression. Strikingly, the
translated protein patterns of the regressing tumours were
identical whether regression was induced by oophorectomy or dBcAMP
treatment.
In contrast, autonomously growing tumours exhibited protein
patterns appreciably different from those of hormone dependent
tumours and the patterns did not alter after oophorectomy or dBcAMP
treatment.
It appears,therefore, that loss of transcriptional control may
contribute to hormone independence. Moreover, the changing levels
of transcription in regressing tumours did not appear to be
associated with incipient cell death in general, since treatment
with the cytotoxic chemotherapeutic agent cyclophosphamide
arrested the growth of DMBA tumours but had no effect on the
translation products.
Of individual proteins exhibiting these changes, one with a
molecular weight of 21-22K is of particular interest (Huang and
Cho-Chung,1984). The significance of this protein is that it
appears to represent the product, p21, of the cellular
proto-oncogene ras (c-ras), which is homologous to the
transforming gene of Harvey Sarcoma virus (v-ras). Ras proteins
are implicated in cellular proliferation and may function in
signal transduction pathways.
To date, there has been little investigation into the role of cAMP
and oestrogen in the regulation of ras in human breast cancer,
and it is not yet known whether analogous mechanisms exist.
b) Expression of Ras Genes in Hormone Dependent Mammary Tumours
It is now known that the normal eukaryotic genome may contain
restriction fragments homologous to the genes of oncogenic
viruses. These potentially oncogenic sequences of DNA are known as
proto-oncogenes and may provide a link between transforming genes
of viruses and neoplastic disease.
The cellular oncogene appears to be the evolutionary progenitor of
the viral oncogene in that viral acquisition of oncogenes is
believed to have occured by recombinational events between the
genome of the infecting retrovirus and that of the host cell
(Bishop,1983).
The structural similarity between c-onc genes and their viral
homologs suggests that the former may also possess oncogenic
potential. "Normal" proto-oncogenes with dormant oncogenic
potential may be activated, either quantitatively to abnormal
levels of expression, or qualitatively by mutation, changing some
aspect of their function. They then produce transforming or
"activated" protein products.
Many of the protein products of cellular oncogenes have been shown
to be similar to substances normally involved in control of cell
division, e.g.(l) growth factors,(2)growth factor receptors, which
are usually located on the plasma membrane (3)nuclear DNA-binding
substances and, in the case of the ras protein (4) modulators of
the transduction of exogenous signals across the cell membrane.
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Cellular oncogenes are now regarded as playing vital roles in the
normal control of mitosis and cell differentiation. Like all other
genes, when mutated, their effects change, promoting disorders in
cell division and potentially contributing to the pathogenesis of
cancer.
Over a dozen oncogenes have now been implicated in human cancers
(Barbacid, 1985). Among these, the most frequently identified are
members of the ras family. This acronym is derived from the words
rat sarcoma because ras genes were originally identified as being
responsible for the transforming ability of certain acute
transforming viruses, the Harvey and Kirsten strains of rat
sarcoma viruses (Ellis et al.,1982).
Three different members of the ras gene family have been
identified in vertebrates ; c-rasH which is located on chromosome
11 .c-rasK (on chromosome 12) and c-ras" (on chromosome 1) (Der
et al.,1982).
These genes have highly related but distinct nucleotide sequences
(Defeo et al.,1981; Fasano et al.,1983; Shimizu et al.,1983 and
Tsuchida et al.,1982). C-rasH and c-rasK derive their names from
the homologous oncogenes (v-rasH and v-rasK) in Harvey sarcoma
virus and Kirsten sarcoma virus, respectively. C-rasN was
identified as a dominant transforming gene of a human
neuroblastoma cell line and appears to have no viral counterpart
(Taparowsky et al.,1983).The c-rasH gene product has been most
extensively studied.
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Ras genes encode proteins of approximately 21,000 daltons (and
188 or 189 amino acids) which are designated p21 (Ellis et
al.,1981; Langbeheim et al.,1980; Shih et al.,1979).
Identification of p21 as the protein which dramatically decreases
in regressing hormone dependent rat mammary tumours (Cho-Chung and
Huang,1984) initially involved analysing [35S] methionine-labelled
in vitro translation products from growing DMBA tumours by
immunoprecipitation with a rat monoclonal antibody directed
against Harvey sarcoma virus-encoded p21 (Furth et al.,1982). A
substantial amount of the 21K protein was specifically
immunoprecipitated by the antibody and the immunoprecipitated band
comigrated with purified p21 on SDS-polyacrylamide gel
electrophoresis. Furthermore, the antibody detected no significant
amounts of p21 in regressing tumours. Quantitation by densitometry
showed that levels of p21 in regressing tumours at 3 days
post-dBcAMP treatment were only 21% of those found in growing
tumours. Injection of oestradiol into the ovariectomised host or
cessation of dBcAMP treatment renewed tumour growth and the
tumours resumed p21 production. These results suggest that
enhanced expression of the cellular ras oncogene may be associated
with hormone dependent growth of mammary cancers in vivo and that
cAMP may play a role to suppress this oncogene. It is possible
that changes in p21 production may be due to quantitative
modulation of the c-ras gene at a regulatory locus. As both
oestrogen withdrawal and dBcAMP treatment appear to result in
suppression of ras gene expression it could be postulated that
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the antagonistic interaction between oestrogen and cAMP may exert
itself at such a locus. Several studies now appear to consolidate
this hypothesis.
An interesting study by Tagliaferri et al.(1985), examined the
effect of cAMP on p21 expression in ras transformed 13 -3B-4
cells (a clone of NIH-3T3 cells). Treatment of the cells with cAMP
analogs inhibited p21 synthesis while increasing levels of the 56K
R2 receptor protein. These results suggest a possible role for
both cAMP and its receptor protein in the regulation of ras
oncogene expression.
A study by Hiwasa and Sakiyama (1986) also suggests an inter¬
relationship between ras expression and cAMP-dependent protein
kinase activity. CAMP-dependent protein kinase activity was lower
in both v-ras" transformed and activated c-rasH transformed
NIH-3T3 cells compared to normal NIH-3T3 cells.
A subsequent report (Najam et al.,1986) appeared to confirm that
an increase of intracellular cAMP can modulate the expression of
the ras gene. This group used the clone 433 of NIH-3T3 cells
which is a stable carrier of a chimeric molecular construction
consisting of the mouse mammary tumour virus long terminal repeat
(MMTV-LTR), which contains one or more DNA sequences known to bind
glucocorticoid-receptor complex, fused to the ras gene of Harvey
Sarcoma virus (v-ras). Expression of this v-rasH is dependent
upon a promoter sequence(s) within the MMTV-LTR, which requires
physiological concentrations of glucocorticoid hormones for
efficient transcription. In the presence of dexamethasone (a
synthetic glucocorticoid) these transfected cells exhibit an
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induced level of p21 transforming protein and phenotypic
transformation, i.e. the cells become round and refractile and
float away from the substratum. However, it was observed that
dBcAMP antagonises the transforming effect of dexamethasone in a
time and concentration dependent manner. The cells exhibited flat,
contact inhibited monolayers and p21 levels, as detected by
Western Blotting analysis, showed a marked decrease. Therefore,
p21 was induced by dexamethasone and dBcAMP blocked this p21
production.
On the basis of these results and previous data on mammary cancer
in vivo, it has been postulated that cAMP may be an intracellular
suppressor acting at a regulatory locus of both cellular and viral
ras genes. The role of cAMP and its receptor protein at the
nuclear level appears to be essential in the cAMP-induced
regression of mammary tumours. Understanding the ultimate
mechanism by which cAMP modulates ras gene expression would
provide an insight into the intracellular mechanism that controls
cellular proliferation and neoplastic transformation.
c) Possible Functions of P21
Members of the ras gene family have been found in lower
eukaryotes such as yeast, as well as in humans and other higher
eukaryotes. Ras genes are widely conserved in evolution
(Barbacid, 1985) which suggests that they may play a fundamental
role in cellular proliferation.
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The only known biological functions of p21 are to non-covalently
bind and hydrolyse guanine nucleotides (Scolnick et al.,1979;
Furth et al.,1982; McGrath et al.,1984; Gibbs et al.,1984; Manne
et al.,1985). These properties may be closely related to the
transforming ability of ras proteins.
P21 can also catalyse its own phosphorylation (if threonine
replaces alanine at codon 59) using GTP as the P donor (Shih et
al.,1980). Threonine 59 is an activating mutation but the possible
contribution of this phosphorylation to the biological activity of
the protein is unknown.
It has been shown that transforming ras genes, whether of viral
or cellular origin, differ from their normal homologues by the
presence of missense mutations at a limited number of positions.
Mutations at amino acid positions 12,13,59,61,and 63 are
sufficient to confer a transforming phenotype (Fasano et
al.,1984). Two particular 'hot spots' for activation of ras have
been revealed: codon 12, located in the first exon and codon 61,
in the second exon. A single point mutation which substitutes a
different amino acid for glycine (12) and for glutamine (61) can
be responsible for the transforming properties of ras genes in
NIH-3T3 cells (Fasano et al.,1984).
A precursor form of p21 (pro-p21) is translated from mRNA on free
polysomes. The majority of intracellular p21 appears, by electron
microscopic immunocytochemistry, to migrate to the inner surface
of the plasma membrane, where it is post-translationally modified
by acylation. This membrane association appears to be mediated via
the covalent attachment of palmitic acid to p21 (Sefton et
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al.,1982) at cysteine 186 near the C-terrainal region (Buss &
Sefton,1986). This suggests that the cell membrane may be a major
site of action of this protein (Willingham et al.,1980).
Membrane localisation appears to be essential for the oncogenic
activity of viral p21. A series of mutant v-rasH genes constructed
by Willumsen and coworkers (1984) demonstrated that mutants which
failed to bind lipid and encode soluble p21 proteins also lacked
transforming activity.
There is no evidence that ras is a transmembrane protein or that
it is secreted.
The known biochemical activities of p21 appear to be located
within the large N-terminal segment (the "catalytic domain") while
the extreme C-terminal is required for membrane localisation
(Willumsen et al.,1984) and is called the "membrane binding
domain". The region in between is largely heterogeneous between
species and its function remains undetermined.
It has been shown that the biochemical characteristics and amino
acid sequences of p21 resemble those of other GTP-binding
proteins, in particular the alpha subunit of the nucleotide
regulatory G proteins of adenylate cyclase. P21 is also partially
homologous to other G proteins e.g.elongation factors (EF)-C and
(EF)-Tu .which are proteins involved in the elongation of
polypeptide chains (Fasano et al.,1982), tubulin (Carlier &
Pantaloni,1982), and transducin, the alpha subunit of the visual
transducing system which regulates cGMP concentrations in the rods
of the eye by inactivating a phosphodiesterase inhibitor (Hurley
et al.,1984; Lochrie et al.,1985).
The G proteins function as intermediaries in transmembrane
signalling pathways that generally consist of three proteins;
receptors, G proteins, and effectors. G protein linked systems are
activated on binding of GTP. Hydrolysis of GTP initiates or is
responsible for deactivation. Dissociation of GDP is the rate
limiting step and is controlled by the receptor.
Both p21 and G proteins bind GTP and are associated with the cell
membrane. Both have GTPase activity and both are substrates for
phosphorylation.These similarities suggest that G proteins and
ras proteins may have analogous functions and have led workers to
speculate whether p21 may be implicated in the regulation of
adenylate cyclase activity.
In this respect, it has been shown (Toda et al.,1985) that in
yeast cells p21 does play a role in the modulation of adenylate
cyclase activity. Yeast cells lacking the ras gene have an almost
undetectable adenylate cyclase activity (Broeck et al.,1985;
Tatchell,1986) while yeast strains carrying mutated ras gene have
increased adenylate cyclase activity.
However, controversies have arisen over whether vertebrate p21 is
a regulatory G protein of adenylate cyclase. It has been shown
(Beckner et al.,1985) that one mammalian ras gene product, the
p21 Ha-ras protein, neither stimulates nor inhibits mammalian
adenylate cyclase.
However, Franks et al. (1987) have since reported a relationship
between Ki-ras p21 and mammalian adenylate cyclase. Bursts of
v-rasK gene transcription appeared to coincide with bursts of
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adenylate cyclase activity in early G1 phase of cultured rat
cells. It is still not clear whether this is a direct or indirect
effect.
It has also been reported (Tarpley et al.,1986; Gorman et
al.,1987) that both hormone stimulated adenylate cyclase and
Platelet-derived growth factor-stimulated phospholipase A2/C
activities were inhibited in NIH-3T3 cells expressing the EJ-ras
human bladder carcinoma oncogene. G proteins regulate both
adenylate cyclase and phospholipase activities. In both cases the
enzyme activity was reduced by mutated ras. Since expression of
high levels of c-ras also mildly inhibited both phospholipase and
adenylate cyclase activities, this group believe that there may be
an actual role for ras in the regulation of mammalian adenylate
cyclase.
However, these results are conflicting as one group reports
stimulation of adenylate cyclase in ras transfected cells while
another reports inhibition.
G proteins generally act to transduce signals from receptors that
have an immediate effect on cellular metabolism. It is possible
that the ras gene product may be part of a comparable information
processing system, albeit controlling a different regulatory
pathway. There is a growing body of data to suggest that p21
mediates signals that are essential in the regulation of cell
growth and cell division (Campisi et al.,1984),e.g. untransformed
NIH-3T3 cells fail to divide in response to stimulation by serum
in the presence of the anti-ras antibody, Y13-259 (Mulcahy et
al.,1985).
Furthermore, p21 appears to be an essential requirement for the
action of a variety of growth factors as no growth factor present
in serum could promote cell division in NIH-3T3 cells containing
anti-ras antibody (Mulcahy et al.,1985). The ras protein may,
therefore, represent a common element in the molecular sequence
initiated by numerous growth factors.
Recent studies of interest have shown that p21 is associated with
cell surface receptors involved in growth control e.g. the
insulin, EGF (Kamata & Feramisco, 1984) and possibly transferrin
receptors (Finkel et al.,1984).
GTP dependent phosphorylation of p21 has been shown to be
stimulated by both EGF and insulin (Kamata & Feramisco, 1984). It
is thought,therefore that the role of p21 may be in the control of
cell proliferation, possibly as a signal transducer for growth
factors.
Recently, there has been considerable interest in the possibility
that the ras species might act as the elusive G proteins of the
phosphatidylinositol-lipid signalling pathways (Michell,1984;
Berridge & Irvine,1984). However, ras overexpression was found to
amplify inositol phosphate production in some cell lines (Chiarugi
et al.,1986; Bar-Sagi & Feramisco,1986) while attenuating it in
others (Fleischman et al.,1986) and as with adenylate cyclase no
conclusive results have been forthcoming to date.
Therefore, the search for a function for p21 in mammalian cells
continues unresolved at present. Several hypothetical roles have
been proposed. For example, it has been suggested that the ras
protein may behave like the alpha subunit of G proteins in that it
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may cycle through alternative configurations as a result of its
association with receptors and guanine nucleotides, e.g.certain G
proteins, when complexed with GTP, stimulate adenylate cyclase
until the action is terminated by the hydrolysis of GTP. In the
absence of GTPase activity, adenylate cyclase remains permanently
in the activated configuration (Newbold,1984). If, by analogy,
p21, when bound to GTP, forms part of a signal system to promote
growth, by transducing signals from the extracellular environment
to the nucleus, permanent activation of ras could result in the
delivery of a continuous, as opposed to an intermittent,regulated
signal. Theoretically, this could occur via amplification of the
normal p21 product, or by the synthesis of mutant forms i.e., a
p21 deficient in GTPase activity (the p21 would then be kept in
its active GTP-bound state).
Evidence already exists for the latter possibilty, mutations at a
variety of sites significantly impairing p21-specific GTP
hydrolytic activity (McGrath et al.,1984; Newbold,1984).
Sweet et al.(1984) have investigated normal and mutant
transforming ras proteins in E.Coli (which show indistinguishable
biochemical properties from the same proteins in mammalian cells)
and observed no difference in localisation or GTP binding
activity. However, normal p21 had an intrinsic GTPase activity,
while activated p21 had reduced GTPase activity. It has been
suggested that this deficiency may be the cause of the
transforming phenotype of the activated protein as this represents
the first major biochemical difference between the products of a
normal and a mutant ras gene.
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Recently, the discovery of a further link to this chain of events
has been reported. A cytoplasmic protein, GTPase Activating
Protein (GAP) has been identified that interacts with the ras
proteins, dramatically increasing the GTPase activity of normal
p21 but not of mutated ras (Trahey & McCormick,1987). By
microinjecting mammalian ras proteins complexed with GTP into
oocytes, this group identified a cytoplasmic protein which appears
to interact with p21 at a site previously identified as the
"Effector" site (Sigal et al.,1986) strongly implicating GAP as
the biological target for regulation by p21. This protein appears
to maintain normal p21 in a biologically inactive state through
its effect on GTPase activity. Furthermore, it seems that the
major effect of certain mutations is to prevent this protein from
stimulating p21 GTPase activity, thereby allowing these mutants to
remain in the active GTP-bound state.
The difference between normal and mutated p21 might, therefore,
not be a lack of intrinsic GTPase activity in mutated p21, but
rather a lack of interaction with GAP, resulting in reduced GTPase
activity. This observation might explain apparent discrepancies
which have arisen in the literature, e.g. systematic mutation of a
mammalian ras gene at amino acid 61 resulted in transforming
activities that varied over three orders of magnitude whereas low
GTPase activity was reported for all these proteins (Der et
al.,1986). These results suggest that factors other than intrinsic
GTPase activity help determine whether ras genes are highly
transforming.
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A study by Lacal et al.(1986) also disputes the theory that
intrinsic GTPase activity is central to the biological function of
p21. This group substituted normal Ha-ras p21 with Threonine at
the 59 position and found that this mutant possessed high GTPase
activity while acquiring the ability to transform cells. This
argues that the acquisition of efficient transforming ability
involves more than an alteration in intrinsic GTPase activity.
This lack of a quantitative relationship between GTPase activity
and transforming potential (Lacal et al.,1986) could be because in
vitro measurements on cellular fractions do not accurately reflect
conditions in vivo using whole cells,so that estimates of GTPase
activities are misleading. The effect of mutations in p21 on
intrinsic GTPase activity may not, therefore, be biologically
significant but rather the interaction between p21 and GAP that
determines GTPase activity (Cales et al.,1988).
Until the exact biochemical cycles which the ras genes regulate
in mammalian cell are identified, the possibilty still remains
that p21 may cause transformation through some other process such
as by phosphorylation of proteins or other small molecules.
d) P21 in Human Breast Cancer
Only 10-20% of human tumours have been shown to possess point
mutated "activated" ras genes, by demonstrating the potential of
tumour DNA to transform NIH-3T3 cells (Santos et al.,1984). This
may be an overestimate since negative results are often not
reported.
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In human primary tumours, c-rasK has been the cellular oncogene
most commonly detected by transfection assay. Carcinomas from
colon, lung, bladder, gall bladder, and pancreas as well as
sarcomas such as fibro- and rhabdomyosarcoma have shown activation
of the c-rasK oncogene (McCoy et al.,1983; Der & Cooper,1983).
Activated c-rasH has been detected in bladder and urinary tract
tumours and c-ras" in haemopoetic malignancies and neuroblastomas
(Parada et al.,1982; Slamon et al.,1984).
However, breast cancers have not been shown to contain point
mutated forms of p21, with the exception of one study (Kraus et
al.,1984). This group were able to identify a position
12-activated ras oncogene in the HS578T human mammary
carcinosarcoma cell line derived from a very rare highly
aggressive tumour possessing characteristics of both epithelial
and mesodermal cells. Normal mammary cells from the same patient
did not contain the mutation. Among breast tumours this example
remains a unique case.
Therefore, it appears more likely that quantitative
over-expression of the normal c-ras gene may contribute to
carcinogenesis in breast cancer, rather than specific qualitative
changes affecting the protein product.
High level expression of normal c-rasH can also transform a cell,
as shown by transfection studies with murine c-rasH under the
influence of a promoter from a retroviral Long Terminal Repeat
(Chang et al.,1982).
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Amplification of c-rasK and c-ras" have been reported in murine
adrenocortical tumour cells and MCF-7 human breast cancer cells,
respectively (Schwab et al.,1983; Graham et al.,1985).
However, oncogene over-expression may occur by mechanisms other
than gene amplification. In fact the overall incidence of ras gene
amplification in human neoplasia is estimated to be not higher
than 1% (Pulciani et al.,1985). Inappropriate expression may
arise, for example, by mutations in the regulatory sequences of
the oncogene or by chromosome duplication. The exact mechanism of
enhanced gene expression in human breast cancer is not yet clearly
defined.
Raised values of p21 and ras mRNA have now been detected in
various tumours in man, including those of the breast and colon
(Hand et al.,1984; Spandidos & Agnantis,1984; Spandidos &
Kerr,1984).
Spandidos' group examined breast tumour tissue and adjacent normal
tissue for the expression of the c-rasH gene. In 12/12 tumours
there was an apparent 4- to 15-fold increase in c-rasH mRNA
compared with adjacent normal tissue as determined by dot blot
analysis.
Expression of p21 in breast cancer tissues, benign breast tumours
and normal mammary gland has also been investigated (DeBortoli et
al.,1985). Normal breast tissue and 3 fibroadenomas had very low
or undetectable levels of p21, whereas a percentage (68%) of
oestrogen and progesterone receptor positive tumours displayed
high levels of p21. Receptor negative tumours exhibited only low
activity. It is interesting that approximately the same proportion
of steroid receptor positive tumours which expressed high p21
levels should respond to endocrine therapy. A correlation may,
therefore, exist between hormone dependence and p21 levels.
Using the photoaffinity label, 8-N3-[32P]GTP, this group also
reported that tumours with low p21 exhibit GTP-labelling of a
protein of molecular weight 21K whereas tumour lysates containing
high levels of p21 show no GTP binding. Tumours with high p21 also
had high GTPase activity which would account for this difference.
Mixtures of lysates, containing high and low levels of p21
resulted in complete loss of the GTP-bound p21 band. The
implication is that p21 expressed in high levels is the "normal"
species, with functioning GTPase, whereas p21 present in low
amounts is "activated" and deficient in GTPase. These observations
remain unsubstantiated as there has been only one report of a
mutated ras gene in human mammary cancer and this was in a rare
carcinosarcoma cell line (Kraus et al.,1984). Further studies on
the significance of p21 expression in human breast cancer are
required.
A more comprehensive study of p21 expression in mammary tissues
(Ohuchi et al.,1986) demonstrated, using immunohistochemical
assays, that p21 expression is enhanced in invasive breast cancer
with generally decreasing expression in carcinoma in situ,
atypical hyperplasia and nonatypical hyperplasia, respectively.
Analysis of specimens available from 18 patients with 15 years
follow-up, revealed that those mammary hyperplasia patients who
subsequently developed cancer (5) had significantly higher levels
of p21 than those patients who did not develop cancer (13). The
authors concluded that p21 ras over-expression may contribute to
the establishment of a cancer, but probably was not essential for
its maintenance.
This work was supported by Whittaker et al.(1986) who examined
ras expression in various benign and malignant human breast
tissues and also found that ras expression was significantly
higher in breast cancers compared to benign tissue. However,
over-expression was also evident in some fibrocystic specimens
with prominent hyperplastic features which is the group of
patients that has been linked with an increased risk of developing
breast cancer (Roberts et al.,1984). Follow-up should determine
whether there is a correlation between elevated oncogene
expression and the subsequent development of breast cancer.
In addition to predicting future primary tumour development, it
has been shown immunohistochemically that p21 expression in breast
cancer correlates with the presence of lymph node metastases
(Lundy et al.,1986).
Higher levels of ras mRNA have also been found in breast tumours
from patients with metastases (Agnantis et al.,1986).
These results indicate that p21 may be a determinant of the
malignant potential of breast cancer cells. Overexpression may
confer growth advantages to cell clones and may predispose them to
metastatic variants. However, extensive investigation is required
before it can be concluded that ras overexpression represents a
reliable indicator of the metastatic potential of a primary
mammary tumour.
Not all workers agree that ras expression may be of prognostic
value in breast cancer. An immunohistochemical study by Candlish
et al.(1986) has shown widespread positive staining for p21 in a
series of benign and malignant breast specimens suggesting that
the presence of p21 is a normal feature of certain cell types.
The observation of significant levels of p21 immunoreactivity in
normal mammary lobules and basal layers of stratified epithelium
(Furth et al.,1987) also suggests that in many cases high levels
of ras expression may be a marker rather than a cause of the
active proliferation of neoplastic cells.
No clear picture, therefore, has emerged from these expression
studies and little is known at present of factors controlling
levels of p21 in mammary cancer.
An alternative experimental approach has been introduced in an
attempt to investigate the possible role of the ras oncogene in
mammary carcinogenesis; the transfer of cloned oncogenes and the
in vitro propagation of transfected mammary epithelial cells.
An important study suggesting a potential link between expression
of p21 and hormone dependence was performed in this way using the
MCF-7 human breast cancer cell line. These cells are
oestrogen-dependent, require oestrogen supplementation for
efficient in vitro growth, and are inhibited by anti-oestrogens.
On transfection with the v-rasH oncogene, the resulting cell line
(MCF-7ras) appeared hormone insensitive and was no longer
inhibited by anti-oestrogens (Kasid et al.,1985).
Transfection with an exogenous activated ras gene appears,
therefore, to bypass a hormonal mechanism that customarily
triggers cellular growth. The transfected cells' oestrogen
receptor content was no different from the parental cell line.
However, it appears that growth signals, as triggered by receptor
ligand interactions in MCF-7 cells are no longer recognised in
transfected cells.
It has been shown that MCF-7 cells secrete peptide growth factors
or mitogens in response to oestrogen stimulation (Kasid & Lippman,
1987). The MCF-7ras cells formed tumours in nude mice independent
of exogenous oestrogen and secreted elevated levels of these
growth factors including a factor related to tumour-derived growth
factor alpha, insulin-like growth factor-1, Platelet-derived
growth factor and others. Medium from MCF-7ras cells was able to
replace oestrogen in stimulating MCF-7 cell growth in vitro and in
vivo (Kasid & Lippman,1987; Dickson et al.,1987). Therefore, the
introduction of a single mutated oncogene resulted in growth
alterations which bypassed hormonal control of growth. The
relevance of c-ras gene activation to human breast cancer is not
yet understood. It is common for hormone responsive human breast
tumours to become unresponsive and develop more aggressive
behaviour. It is not yet established if ras activation or over-
expression is implicated in this alteration of the hormone
dependent phenotype. It is apparent, however, that changes in this
single gene may radically alter the growth regulatory behaviour of
a cell that already has malignant potential.
Although ras overexpression rather than activation appears to be
a feature of human breast tumours the possibility remains that
activation may occur early in tumour development and additional
secondary changes may be necessary to achieve the full malignant
phenotype.
A single dose of the carcinogen NMU is sufficient to induce
mammary tumours in rats, apparently by activating ras via a
specific point mutation (Zarbl et al.,1985). Furthermore, these
tumours are hormone dependent which implies that ras activation
does not always confer a hormone independent phenotype.
There is experimental evidence suggesting that ras oncogenes can
become activated after cells have acquired neoplastic properties
(Albino et al.,1984; Tainsky et al.,1984; Vousden & Marshall,
1984) . Ras oncogenes appear to be switched off and on at
different stages of tumour development and as yet no clear pattern
has emerged.
A question posed by the frequent identification of ras oncogenes
in human tumours is whether ras oncogenes participate in the
induction of neoplastic development or are a consequence of it.
Evidence now suggests that it may be an oversimplification to
assign such importance to a single oncogene. Many cancers have
been found to involve activation of at least two distinct
oncogenes, suggesting that different oncogenes may function at
different stages of neoplastic development. A key study by Land et
al.(1983) showed that transfection of embryo fibroblasts by a
human ras oncogene does not convert them into tumour cells unless
a second oncogene such as myc is introduced together with the ras
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gene. It may be that the ability of activated ras oncogenes to
influence tumour growth depends on which other genes are altered.
It is now recognised that carcinogenesis is a process involving
multiple, independent steps.
The state of the c-rasH gene in breast cancers has also been
examined with respect to genomic structure and allelic exclusion.
Southern analysis of DNA from over 100 breast cancers showed no
evidence of ras gene amplification or rearrangement (Lidereau et
al.,1986; Theillet et al.,1986). However, c-rasH gene
polymorphisms have been detected, with an increased incidence of
rare Ha-ras alleles in breast cancer patients. In addition, in
those patients who were heterozygous for the c-rasH gene, loss of
an allele in the breast cancer did not alter p21 expression but
did correlate with lack of hormone receptors, tumour
aggressiveness, i.e. occurence of distant metastases, and advanced
histological tumour grade (Theillet et al.,1986).
Much has been learned about c-rasH oncogene expression in breast
cancer but at present these data must be treated with caution. The
usefulness of studying altered expression of p21 in the diagnosis,
prognosis and monitoring of human breast disease has yet to be
determined.
In the present study p21 has been measured by Western Blotting
analysis and levels correlated with factors of established
prognostic value, as well as disease recurrence and patient
survival; this to determine if p21 has a role as a prognostic
parameter in early human breast cancer.
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1:6 Obiectives
The data discussed in this chapter have largely been accrued from
studies in experimental animals and in vitro culture systems and
the corresponding depth of information is not available in human
breast cancers. Therefore, the main objective of this thesis was
to develop assays for and measure, in human breast cancers;
1) the types and amounts of cAMP binding proteins
2) the ras oncogene product, p21.
In order to assess the value of these parameters in prognosis,
measurements were performed in tumours obtained from women with
early breast cancer and the results were related to parameters of
established prognostic value e.g. steroid receptors, lymph node
status, tumour histology, tumour grade as well as disease-free
interval and patient survival.
The possible interrelationships between cAMP, cAMP binding
proteins and p21 were also examined.
In patients with advanced breast cancer the ratio of cAMP binding
to oestrogen receptors was correlated with response to endocrine




The following materials were obtained as indicated.
Radiochemicals
From Amersham International pic,Bucks.,U.K.;
[5,8,- %]Adenosine 3',5'-Cyclic Phosphate.Ammonium salt (specific
activity 40-60Ci/mmol)
[14C] Methylated Protein mixture (radioactive concentration
5uCi/ml)
[a 32P] Guanosine 5'-triphosphate, tetra-triethylammonium salt
(specific activity 3000 Ci/mmol)
From ICN Radiochemicals,Irvine,California;
[32P] 8-Azidoadenosine-3',5'-cyclic monophosphate (specific
activity 40-60 Ci/mmol)
[1231] Protein A (specific activity 30-60 Ci/mmol)
Unlabelled cyclic nucleotides
Adenosine 3',5'-cyclic monophosphate,sodium salt and Guanosine




All reagents were of "Analar" Grade.
From Fisons,Leics.,U.K.;
Tris(2-amino-2-[hydroxy-methyl] propane-1,3-diol), EDTA (diamino-
ethanetetra-acetic acid disodium salt), MgCl26H20, CaCl22H20, KC1,
HCL, KHCO3, NaHC03, NaCl,
Perchloric Acid, sodium lauryl sulphate (SDS),and glycerol.
From BDH Ltd,Poole,Eng.;




From Biorad Laboratories Ltd..Herts.,U.K.;
Electrophoresis Purity Reagents; Tris,Glycine
Biochemicals
From Sigma Chemicals:
Bovine serum albumin (fraction V),Protein Standard (Total Protein
8g/dl).Rabbit anti-rat IgG.
Prestained MW Standards were purchased from Bethesda Research
Laboratories,MD..U.S.A.
Enzyme Inhibitors
Theophylline(1,3-Dimethylxanthine) and Phenyl methyl sulphonyl
fluoride were purchased from Sigma Chemicals.
Aprotinin was obtained from Bayer U.K. Ltd,Berks.,U.K.
Solvents
All solvents were of "Analar" grade.
BDH were the suppliers of ethanol, methanol, phosphoric
acid(85%[v\v]), and glacial acetic acid.
Other Reagents
Coomassie Brilliant Blue G-250 was from Sigma.
Acrylamide/Bisacrylamide(Electrophoresis Purity Reagent) and Temed
(N,N,N',N'-Tetramethylethylenediamine) were from Biorad.
Ammonium persulphate was from Fisons and Bromophenol Blue was
purchased from G.T. Gurr Ltd,London.
Kodak X-ray Developer and Fixer were supplied by Hamilton Tait,
Penicuik, Scotland.
Cell Culture
Dulbecco's Minimal Essential Medium, New Born Calf Serum and Heat
Inactivated Foetal Calf Serum were obtained from Gibco,Paisley,
Scotland.
Ham F12 was purchased from Flow Laboratories, Irvine, Scotland.
Penicillin and Streptomycin were from Glaxo Laboratories
Ltd..Middlesex, U.K.
Liquid Scintillator
NE-260 was obtained from Nuclear Enterprises,Scotland.
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Cyclic AMP Assay Kit
A kit containing reagents in freeze-dried form was purchased from
Amersham International pic.
Non-Chemical Materials
MF-Millipore (mixed esters of cellulose) Membrane filters of pore
size 0.45um and 25mm diameter, were purchased from Millipore U.K.
Ltd..Middlesex,U.K.
Kodak X-Omat-RP X ray film was purchased from Hamilton Tait,
Penicuik,Scotland.
Nitrocellulose membrane (0.45um) was obtained from Biorad
Laboratories.
Whatman No. 1 filter paper (18.5cm diameter) was obtained from
Whatman International Ltd., Maidstone, U.K.
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2:2 Buffers
All buffers were made up in distilled water (20°C).The following
buffers were used as described in the "Methods" section:-
Buffer A (pH 7.5)
20mM Tris, 0.25M sucrose, 2mM magnesium chloride, ImM calcium
chloride, lOmM potassium chloride, 16.26mM HC1
Buffer B (pH 6.5)
55mM potassium phosphate to which llmM theophylline was added
immediately before use
Buffer C (pH 6.5)





0. 1M NaCl, 5mM MgCl2, 1% Nonidet P-40, 0.5% Na Deoxycholate,
2KIU/ml bovine aprotinin, 20mM Tris-HCl,pH 7.5
Sample Buffer
3% SDS, 15% mercaptoethanol, 30mM Tris, 30% glycerol, 1%
bromophenol blue saturated solution
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Electrophoresis Tank Buffer
25mM Tris, 0.2M glycine, 3.5mM SDS
Transfer Buffer
25mM Tris, 0.2M glycine, 20% methanol
NTE-NP40 (pH7.5)
50mM Tris, 0.15M NaCl, 2mM EDTA, 0.1% NP40
Lvsis Buffer
25mM Tris-HCl,pH 8, 50mM NaCl, 0.5% NP40. Note- The half life of
PMSF in aqueous solution is about 30 minutes.For this reason, a
solution of PMSF in absolute ethanol (5 mg in 250 ul) was made up
on the day of the experiment and added in the appropriate amount
(1000 fold dilution) to the buffer immediately prior to its use.
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2:3 Breast Tumour Procurement and Storage
Tissues
These studies were carried out on breast tumour material from
patients attending the breast clinics of the University Department
of Clinical Surgery. In patients with early disease, tumour tissue
was obtained by mastectomy or local excision depending on the form
of primary treatment and the size of the lesion. Patients were
routinely investigated to determine whether free from clinically
evident metastatic disease. The histological status of excised
axillary lymph nodes was assessed at the time of primary surgery
by either total axillary clearance or lower axillary sampling with
subsequent histological examination.
Tumour was also obtained by biopsy from patients with large
locally advanced primary cancers or metastatic disease.
All material was transported on ice to a cold room and processed
immediately or snap-frozen in liquid nitrogen until assayed.
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2:4 Preparation of Subcellular Tissue Fractions
All procedures were performed at 0-4°C
Cvtosol
Tumour (approx. 200mg) was dissected from surrounding fat and
connective tissue, finely cut with scissors and homogenised in
Buffer A (w/v 1:10) using a Silverson homogeniser at maximum speed
for 20 seconds then 15 sec, with a one minute interval for
cooling. The homogenate was then dispensed into 10 ml poly¬
carbonate tubes which were loaded in an angled T 865.1 rotor and
centrifuged at 105,000g for 1 hour in an OTD-50 Ultracentrifuge
(Sorvall ARC-1, Du pont instruments, Herts.,U.K.).The supernatant
was harvested with a Pasteur pipette, care being taken to avoid
residual floating lipid substance.
Particulate Fraction
The high speed pellet obtained above was then scraped from the
bottom of the tube with a spatula and dispersed with 10 strokes of
a Teflon-glass homogeniser in 4 volumes of ice-cold Buffer 10. The
suspension was centrifuged at 750g for 20 min and this supernatant
was used as a cell lysate.
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2:5 Cell Lines
a) Maintenance of Cell Lines
The maintenance of cell lines was kindly performed by Mr W.N.Scott
as follows:
The mouse derived fibroblast cell line NIH/3T3, clone 13-3B-4,
transfected with Harvey murine sarcoma virus (Ha-MuSV) DNA,
(provided by Dr Y.S. Cho-Chung, N.I.H.) was routinely maintained
in monolayer culture at 37° C in Dulbecco's minimal essential
medium (DMEM) containing 10% heat inactivated foetal bovine serum
and sodium hydrogen carbonate (44mM) under an atmosphere of
air/C02 (95%/5%). The growth medium was also supplemented with
penicillin (100 I.U./ml) and streptomycin (lOOug/ml).
The Y13-259 hybridoma cell line (which was gifted by Merck,Sharpe
and Dohme) was maintained in a 1:1 mixture of DMEM and Ham F12
containing 10% heat inactivated foetal bovine serum and NaHC03
(44mM) in an atmosphere of air/C02 (95%/5%). The growth medium was
also supplemented with penicillin (100 I.U./ml) and streptomycin
(lOOug/ml).
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b) Preparation of Cell Proteins for Immunoblotting
Confluent flasks of 13-3B-4 cells, expressing p21, were harvested
as follows;
EDTA (0.02%, 15 to 20ml) was added to the cell culture bottles and
the cultures gently agitated until the monolayers became detached.
The cell suspension was then transferred to universal containers
and centrifuged at 1000 rpm for 10 minutes at 4°C. The
supernatant was discarded and the cells were washed with Phosphate
buffered saline (5 ml) and centrifuged as before. The cells were
then resuspended in Lysis Buffer (1ml) and refluxed vigorously
without frothing through a 21 gauge needle, followed by a 23 gauge
needle. This suspension was then spun at 10,000 rpm for 30 minutes
at 4°C. The supernatant was decanted off and aliquots stored at
-20°C for use as reference p21 standards in Western Blotting.
c) Preparation of Monoclonal Antibody, Y13-259 from Culture
Supernatants,
Logarithmically-growing Y13-259 hybridoma cells were spun down at
1500 rpm and washed once with serum free medium.
The cells were resuspended in 3-4 times the original volume, to
give 3xl05 cells/ ml, in serum free medium.On day 3 or 4 the
medium was harvested and spun at 7000 rpm (GSA rotor) for 10 to 15
minutes at 4°C. (Up to 80% cell death was allowable.) Ammonium
sulphate was then added to the supernatant (331g/l) and the
mixture was stirred at 4°C overnight. After centrifugation for 1
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hour at 7000rpm, the pellet was resuspended in 50% ammonium
sulphate in sterile distilled water to the same volume as the
original supernatant. This was recentrifuged at 7000 rpm for 1
hour. The pellet was then resuspended in the smallest volume in
which it would dissolve (about 10-20 ml/1 original supernatant).
Finally the suspension was dialysed against PBS overnight in a
cellodion bag. It was important to dialyse extensively as traces
of residual ammonium sulphate can denature the antibody during
freezing, and interfere with the binding affinity. The purified
antibody was then stored in 0.2 ml aliquots at -80°C.
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2:6 General Methods
The following standard assay conditions were adopted throughout
this thesis.
a) Cyclic AMP Binding Assay
The assay for cAMP binding was that of Miller et al.,(1985).
Breast tumour cytosol (prepared as described in section 2:4) was
incubated with 5',8'-[3H] cAMP (25nM to give a final concentration
in the assay system of lOnM),(lOOul), and Buffer B (lOOul)
containing radioinert cAMP (final concentration 0, 10, 20, 40, 80,
and 10,000nM). Each system was set up in duplicate and incubated
at room temperature for 3 hours. To separate protein bound cAMP
from free nucleotide, Buffer B (2ml) was added to each tube. The
contents were then mixed and filtered through a Millipore filter
(pore size 0.45um) at 5mm Hg negative pressure followed by Buffer
C (20ml) at 10mm Hg negative pressure. The filters were then
transferred to scintillation vials and dried under a stream of
air. Micellar fluor ( NE260, 5ml) was added to each vial. The
vials were then incubated at 37°C for 2h and radioactivity was
measured in a Tricarb liquid scintillation counter (Packard).
The counting efficiency (45%) was routinely checked using a
tritiated toluene standard of specified radioactivity and decay
rate. Using quench curves and counting 3H cAMP on filters a
correction was made for loss of efficiency caused by these
counting conditions which on average was 15%. With each assay run
the efficiency of counting was monitored by checking the channel
ratio for cpms. Since this was relatively consistent correction
for counting efficiency was not used in routine calculations.
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b) Photoaffinitv Labelling of cAMP Binding Proteins and
Polvacrvlamide gel Electrophoresis
Photoaffinitv Labelling
The method used to characterise individual cAMP binding proteins
by the photoactivated incorporation of 8-N3 -[32P]cAMP was adapted
from Pomerantz et al.(1975). Breast tumour cytosols were prepared
as described in section 2:4. The reaction mixtures (final volume
80ul) contained cytosol (50 ul, 20-50 ug protein), 4x10"7M 8-N3-
[32P]cAMP, and MES/MgCl2 Buffer (15ul) or 1000-fold excess
radioinert cAMP in MES/MgCl2 Buffer (15ul). The incubations were
carried out at 20° C for 60 minutes in 96-well pyrex immunoplates
in the dark. The reaction mixtures were then irradiated for 15
minutes at 254nm by placing a Mineralight UVS-11 hand lamp 8 cm
above the spot plate. The samples were then mixed with sample
buffer (40ul) and transferred to 75 x 12 mm tubes. The tubes were
sealed,heated at 80°C for 5 minutes, and centrifuged at 770g for 5
minutes. Aliquots of each sample (20ul,2-5ug protein) were then
subjected to 0.05% SDS-12% polyacrylamide gel electrophoresis as
described.
SDS-Polvacrvlamide gel electrophoresis
SDS-polyacrylamide gel electrophoresis was based on the system of
Laemmli (1970) . The apparatus used was a Biorad Model 220 Dual
Vertical Slab Gel Electrophoresis Cell connected to a Pharmacia
Electrophoresis Power Supply 500/400.
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Separating gel solution containing 12% acrylamide/bisacrylamide,
4.5% Tris (pH 8.8), and 0.05% SDS was mixed in a conical flask.
Immediately prior to pouring, the polymerizing agents, ammonium
persulphate (0.06%) and Temed (0.08%) were added. The separating
gel interface was formed by carefully layering distilled water in
the sandwich space. The separating gel was then allowed to
polymerize for 30-60 minutes.
Stacking gel solution contained 4% acrylamide/bisacrylamide, 1.5%
Tris (pH 6.8), 0.1% SDS, 0.05% ammonium persulphate, and 0.1%
Temed. A Teflon well-forming comb was inserted and the stacking
gel poured in using a Pasteur pipette. After polymerization, the
comb was removed and the sample slots rinsed with distilled water.
The electrophoresis cell was then placed in its tank and electro¬
phoresis buffer (section 2:2) added to both upper and lower
reservoirs. Samples were slowly expelled into the wells as
required. The gel was run at 35mA per gel for 2-3 hrs, or until
the tracking dye left the bottom of the gel. The apparatus was
then dismantled and the gel was soaked in Fix solution I (20%
acetic acid, 30% methanol) for 45 minutes or overnight. The gel
was then transfered to Fix solution II (10% acetic acid, 40%
ethanol) for 45 minutes with gentle shaking, followed by Fix
solution III (7% acetic acid) for 45 minutes. The gel was dried
using a Pharmacia Gel Slab Drier connected to a Pharmacia
Destainer Power Supply and a vacuum pump and exposed overnight to
Kodak X-Omat-RP X ray film.
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The autoradiographs were subsequently processed in Kodak X-ray
Developer and Fixer (diluted l:5[v/v] with distilled water) for 5
minutes consecutively at 20°C.
The molecular weights of the radiolabelled protein bands which
appeared were determined by comparison with [14 C] methylated
protein standards. (0.125uCi (25ul) was mixed with an equal volume
of Sample Buffer, heated for 5 minutes at 80°C and run in a single
lane on the gel).
Autoradiographs were scanned by densitometry and the peak areas of
the optical density tracings were used as a measure of the
relative amounts of the individual protein bands, or the
percentage distribution of incorporation of [32P]-8-N3 cAMP
between individual binding proteins. This ratio was then used to
calculate the absolute amounts of cAMP binding activity
attributable to each binding protein from the total cAMP binding
level in pmoles/mg cytosol protein (section 2:6(a)).
In some experiments radioactive bands were also carefully cut out
of dried gels, dissolved in hydrogen peroxide (70% v/v, 1ml) and
incorporation of 32P measured by liquid scintillation counting.
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c) Radioimmunoassay for Cyclic AMP
Tissue Extraction Procedure
Tissue deproteinization was performed using a method adapted from
Cooper et al.,(1972). All procedures were performed at 0-4°C.
Breast tumour tissue (200mg) was finely minced and homogenised in
perchloric acid (0.6N, 1ml).The homogenate was centrifuged for 10
min at 3000 rpm to remove the precipitated protein. The
supernatant (700ul) was then neutralised with saturated potassium
bicarbonate (300ul) and the precipitate removed by further
centrifugation. The supernatant was then dried under air and taken
up in a given volume of the assay buffer.
The procedure was further adapted in order to deproteinise breast
tumour cytosols (prepared as described previously, section 2.4),
rather than tumour tissue. This would enable a direct comparison
of cAMP levels and cAMP binding activity to be made in identical
cytosol fractions.
Cytosol (200ul,20mg tissue) was deproteinized with perchloric acid
(1.2N,200ul) and the precipitate removed by centrifugation. The
supernatant was then neutralised with saturated potassium
bicarbonate (170ul) and the precipitate removed by further
centrifugation. The supernatant was decanted off, dried down and
resuspended in assay buffer (50ul).
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Reconstitution of freeze dried reagents
The assay was performed using Amersham's Cyclic AMP assay kit
which includes the following reagents, all of which contain
Tris/EDTA buffer and are in freeze-dried form;
i) Tris/EDTA buffer
ii) Binding protein,purified from bovine muscle
iii) [8-3H] Adenosine 3',5'-cyclic phosphate,180 pmol containing
approximately 5 uCi
iv) Adenosine 3',5'-cyclic phosphate standard,1600 pmol
v) charcoal adsorbent
When reconstituted with the correct volume of distilled water the
assay buffer was 50 mM Tris/HCL, 4mM EDTA,pH7.5.
Preparation of Standards
Serial dilutions of the standard cyclic AMP solution were prepared
as follows;
Assay buffer (0.5ml) was added to five tubes.The reconstituted
cAMP standard (0.5ml) was added to the first tube and mixed
thoroughly. An aliquot of this diluted solution (0.5ml) was
transfared to the next tube and sequential dilutions with assay
buffer (0.5ml) performed. This produced a standard curve of 16, 8,
4, 2, 1, and 0.5 pmol (0.5ml) in each tube.
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Assay Procedure
Standard cAMP dilutions and unknowns (50ul) were incubated at 4°C
for 2 hours in duplicate with reconstituted radiolabelled cAMP
(50ul) and binding protein (lOOul). The reagent blank was
determined with Assay buffer (150ul).
To separate protein bound cAMP from the unbound nucleotide,
charcoal suspension (lOOul) was added and the tubes were
centrifuged for 5 minutes at 12,000g. Aliquots of the resulting
supernatant (200ul) were then removed, mixed with NE-260 Micellar
Fluor (5ml) and radioactivity measured by liquid scintillation
counting. The concentration of unlabelled cAMP in the samples was
then calculated from a linear standard curve.
d) Western Blotting for p21
Breast tumour cell lysates were prepared as described in section
2:4. Duplicate samples were diluted with Buffer 10 (final volume
lOOul) so that lOOug protein was applied to each gel lane. In
addition 14 C protein standards of known molecular weight were
prepared as described in section 2:5 (b) . Prestained MW standards
(lOul + 5ul Sample Buffer /gel lane) were included in order to
monitor the efficiency of the electrophoretic transfer.
To provide a reference p21, a cell lysate prepared from NIH-3T3
clone 13-3B-4 that had been transfected with Ha-MuSV DNA was
prepared as described in section 2.5 (e) and run on one track per
gel. Sample Buffer (50ul) was added to the diluted samples and the
solutions were heated at 80°C for 5 minutes. After centrifugation
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at 770g for 5 minutes, aliquots of each sample (lOOul) were
applied to a 0.05% SDS-12% polyacrylamide gel. Electophoresis was
carried out at 35mA/gel for 2-3 hours (as described in section 2.6
(b)). The stacking gel was then removed and the gel soaked in
Transfer Buffer for 10 minutes with gentle shaking.
Electrophoretic transfer was performed using a Biorad Trans-Blot
Cell onto nitrocellulose sheets. Transfer was conducted at 4°C,
60V with no current limit, for 2.5 hours or at 50V overnight.
The apparatus was then disassembled and the nitrocellulose filter
washed in NTE NP40 (section 2:2) for 10 minutes at room
temperature. In order to block non-specific binding sites, the
filter was incubated at 37°C for 3 hours in NTE NP40 containing 3%
bovine serum albumin.
The filter was then incubated for 16 hours at 4°C with a p21
monoclonal antiserum, Y13-259, directed against the
Ha-MuSV-encoded p21 (diluted 1:2000 v/v with NTE-NP40 + 3% BSA) .
After washing twice with NTE NP40 (30ml) for 10 minutes in an ice
cold water bath, the second antibody, rabbit anti-rat IgG (1:800
v/v in NTE NP40 + 3% BSA) , was added and the filter incubated in
an ice cold water bath with gentle shaking for 90 minutes. The
filter was again washed twice in NTE NP40 for 10 minutes each.
[125I] Protein A (5 x 105 cpm/ml in NTE NP40 + 3% BSA) was then
added and the filter incubated for 45 minutes in an iced water
bath. The filter was then washed as before and air dried. It was




Protein determination was by the method of Bradford (1976). In
principle, protein binds to the dye Coomassie Brilliant Blue. This
causes the dye's colour to change from brownish to bright blue and
its absorption of light to increase markedly at 595nm.
Reagent
Coomassie Blue G-250 (lOOmg) was dissolved in 95% ethanol in water
(v/v,50ml) by stirring for 20min. To this, phosphoric acid
(85%v/v, 100ml) was added and mixed for a further 20 min. The
solution was then made up to 1 litre with distilled water, mixed
and filtered once through a double thickness of Whatman 1 filter
paper to remove insoluble material.
Standards
Bovine serum albumin powder was dissolved in 0.15 M NaCl to yield
a stock solution containing Img/ml. From this stock solution,
working standards containing 10, 20, 40, 60, and 80 mg BSA/lOOml,
were prepared by diluting with 0.15 M NaCl.
Internal standards containing 40 and 80 mg protein/ 100ml were
also prepared using Sigma Protein Standard (Total Protein 8g/dl).
Samples




Coomassie blue reagent (5ml) was added to each test solution
(lOOul) in duplicate. After 10 to 20 minutes the absorbance of the
solutions was read at 595nm against a reagent blank taken through
the same procedure. A plot of Absorbance v. protein concentration
for the standards was a near linear curve, (Figure 1). The protein
concentration in each sample was read off a standard curve and
corrected for the dilution factor.
b) Oestrogen Receptor Assay
Oestrogen receptor measurements were based on a saturation
analysis assay and were performed by Dr R.A. Hawkins as described
(Hawkins et al.,1975) with one minor modification. All tissues
were homogenised (1:10 w/v)in buffer containing thiol activator
(lOmM Tris, 0.25M sucrose, ImM EDTA, pH 8.0 at 22° C, plus 1% v/v
monothioglycerol and 10% v/v glycerol) in place of Tris buffer.
Briefly, tumour extract was centrifuged at low speed (2040g) and
incubated overnight at 4° C with 0.031nM [2,4,6,7-3H]
oestradiol-17-beta and varying concentrations of competing, non-
-radioactive oestradiol-17-beta, (0.03, 0.09, 0.15, 0.21, 0.28,
0.31, 0.64, and 61.2nM). Free and bound steroid were separated by
the addition of dextran coated charcoal suspension and the radio¬
activity in the supernatant bound fraction was determined by
liquid scintillation counting. The concentration of receptor sites
and dissociation constant of binding were calculated by Scatchard
analysis (Scatchard,1949).
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Activities in excess of 5 fmoles/mg cytosol protein were
designated receptor positive.
c) Progesterone Receptor Assay
The same cytosol that was used for the oestrogen receptor assay
was incubated with a fixed concentration of [3H]0rganon-2058
(0.22nM) and varying concentrations of non-radioactive
Organon-2058 (0.22-11.1 nM) with overnight binding at 0°C.
Separation of free and bound was by charcoal adsorption.
Activities in excess of 10 fmoles/mg cytosol protein were
designated receptor positive.
d) Tumour Grade
Paraffin-embedded specimens were cut and histological sections
were stained with haematoxylin and eosin. These were scored for
tumour grade as described by Bloom and Richardson (1957), analyses
being performed retrospectively by a single person who was not
aware of the results of other estimations.
e) Statistics
The relationship of the parameters to each other, to established
prognostic factors and to disease status at 36 months was tested
by Wilcoxon Rank Tests or Spearman's Rank Correlation. Cox
Proportional Hazards Analysis was used to test whether time to
recurrence or death was significantly associated with individual
factors or combinations of them.
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Figure_l Protein Calibration Curve
Increasing amounts (10-80ug) of a BSA solution (l.Omg/ml) were















3:1 Characterisation of Cyclic AMP Binding Assay in Breast Tumour
Cvtosols
Basic characterisation of the method for measuring cAMP binding
proteins in cytosols of human breast cancers has been described
previously (Miller et al.,1985). The following additional
characterisation studies were performed, all of which involved
modifications of the standard assay described in section 2:6(a).
a) Scatchard Analysis
The effect of increasing concentration of radioinert cAMP on the
binding of [3H]cAMP in a representative breast tumour cytosol is
shown in Figure l:l(a). Low concentrations of radioinert cAMP were
able to compete with [3H]cAMP for binding, and there remained only
a low level of non-specific binding in the presence of a thousand
fold excess of competitor.
A plot of the data according to Scatchard (1949) showed that the
dissociation constant of binding was 2.7x10"8 M and that the
maximum concentration of binding sites within the assay system was
about 2.0nM (Figure l:l(b)).
Similar results were also obtained by using an assay system in
which cytosols were incubated with increasing concentrations of
radio-labelled ligand and non-specific binding was assessed by
including a 100 fold excess of cold competitor at each of these
concentrations (data not shown).
7 3
Figure 1:1
The effect of radioinert cyclic AMP on the binding of [3H]cAMP to
a cytosol of human breast cancer. Assay conditions were as
described in section 2:6(a). Data plotted as (a) radioactivity
bound, (b) according to Scatchard (1949).
bound/free
radioactivitybound(cpm)
b) Effect of Cvtosol Protein Concentration
Cytosols were diluted in Buffer A at 1:10, 1:20, 1:40, and 1:80
(v/v) and assayed as described. The results plotted as a function
of protein concentration are shown in Figure 1:2.
The amount of cAMP binding was linear with respect to increasing
cytosol protein concentration up to at least 3.0 mg/ml.
c) Effect of Storage of Breast Tumour Tissue in Liquid Nitrogen
on Cyclic AMP Binding
Ten large breast cancers were each finely minced and divided into
six aliquots of approximately 200mg. One portion of each tumour
was assayed for cAMP binding activity immediately (day 0) and the
remaining portions were stored in separate vials in liquid N2 for
2 weeks, 1 month, 3 months, 6 months and 1 year before assay.
Results are shown in Figure 1:3. There appeared to be no
observable decline in the level of cAMP binding activity with
storage. Considering measurements within the same tumour as
replicate estimates, the interassay coefficients of variation were
as shown in Table 1:1.
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Figure 1:2
The effect of cytosol concentration on the binding of [3H] cyclic
AMP. Cytosols of 2 different breast carcinomas were prepared as
described in section 2:4 and serially diluted to give the protein
concentrations indicated. The diluted cytosols were incubated for
3h at 20°C with increasing concentrations of radioinert cAMP. The
data were analysed by Scatchard plot and each point represents the




The effect of storage in liquid nitrogen on reproducibility of
cyclic AMP binding protein levels in human breast cancers. Results






Interassay coefficient of variation for cyclic AMP binding assay.
10 tumours were aliquoted as described in section 3:1 (c) and
assayed over 1 year. Storage in liquid nitrogen was shown to have






1 1642 ± 275 16-7
2 2781 ± 589 21 • 1
3 1659 t 289 17- 4
4 2999 - 178 5-9
5 2634 ± 378 14-4
6 2138 ± 272 12- 7
7 2408 t 336 13' 9
8 882 ± 79 00 CD
9 2941 ± 276 20-2
10 3338 - 301 CO CD
d) Specificity Studies
To determine the specificity of the binding proteins for cAMP in
breast tumour cytosols, cyclic GMP was substituted at varying
concentrations (0,10,40,80nM) for cAMP as the radioinert
competitor in the standard assay. At these concentrations cGMP did
not displace cAMP (present at lOnM). Figure 1:4 represents a
typical plot of the displacement of cAMP by both cAMP and cGMP
in a breast tumour cytosol. Displacement of 50% of total binding
was obtained with a 15nM solution of cAMP whereas a 2000nM
solution of cGMP was required for an equivalent response.
e) Effect of the Enzyme Inhibitors Aprotinin and Sodium Molvbdate
on Cyclic AMP Binding
The possibility of high levels of endogenous proteases in breast
tumours, plus a report that sodium molybdate improved androgen
receptor assays (Trachtenberg et al.,1981; Smith et al.,1983)
prompted an investigation of the effects of the protease inhibitor
aprotinin (Trasylol) and sodium molybdate, a phosphatase
inhibitor.
Cytosols were incubated for 3 hours in Buffer B containing i)
sodium molybdate (lOmM) and ii) aprotinin (2KIU/ml or 100mg/l).
The results are presented in Table 1:2. Cyclic AMP binding was not
significantly enhanced by the presence of these enzyme blockers.
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Figure 1:4
Specificity of -^H cyclic AMP binding in breast tumour cytosols.
Breast tumour cytosol was incubated under standard assay
conditions with cAMP alone (lOnM) or in the presence of a)
radioinert cAMP (10, 20, 40, 80,nM) and b) radioinert cGMP (1250,
2500, 5000, 7500nM). Displacement was assessed as a percentage of
the total binding.
Results are expressed as mean values of 3 experiments (+ S.D.).
amountofcompetitor(nM)
Table 2:2
The effect of enzyme inhibitors on cyclic AMP binding in breast
tumour cytosols. Cytosol incubated for 3 hours in Buffer B
containing i) aprotinin (2KIU/ml) and ii) sodium molybdate (lOmM)
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3:2 Cyclic AMP Binding Proteins in Human Breast Cancer
Cyclic AMP binding activity has been assayed in tumour cytosols
from 245 women with early breast carcinomas i.e. with no evidence
of distant metastatic disease on routine staging (section 2:3).
The cases were selected on the basis that sufficient tumour was
available for assay of cAMP binding proteins after material had
been taken for histopathological diagnosis and oestrogen receptor
measurement. In all cases the lesion was a primary tumour.
a) Range of Cyclic AMP Binding Activity in Breast Tumour Cvtosols
The range of levels and dissociation constants obtained is
presented in Table 2:1, and the concentration of binding sites in
individual tumours is plotted in Figure 2:1. All cytosols
possessed cAMP binding but levels varied greatly between
individual tumours, from 0.77 to 15.05 pmol/mg cytosol protein
(median 3.85).
Dissociation constants ranged from 0.5 to 5.2 (M x 10"8) with a
median value of 1.70.
A selection of control tissues consisting of normal breast tissue
from a reduction mammoplasty (2), uninvolved breast tissue
adjacent to carcinoma, uninvolved axillary lymph node (2), normal
breast adjacent to fibroadenoma, and a fibroadenoma (2) were also
assayed. The range of levels obtained is shown in Figure 2:1 and




Levels and dissociation constants of cyclic AMP binding proteins














Levels of cyclic AMP binding proteins in cytosols of 245 primary
breast cancers (.) and 8 control tissues (o) . Horizontal line
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In order to determine factors which might be responsible for the
wide range of values in breast tumour cytosols, levels of cAMP
binding proteins have been related to the following parameters;
patients' menopausal status, tumour steroid receptors, tumour
grade, clinical stage, and lymph node involvement.
b)Tumour Cyclic AMP Binding and Menopausal Status of the Patients
Of 245 patients, 67 were pre-menopausal (regular menstrual
periods), 12 were peri-menopausal (within 3 years of the last
menstrual period) and 163 were post-menopausal (at least 3 years
beyond their last menstrual period). The remaining 3 patients had
undergone an hysterectomy and their menopausal status was
uncertain.
Level of tumour cAMP binding protein subdivided according to the
menopausal status of the patients is shown in Figure 2:2. Although
the median value for cAMP binding decreased progressively from pre
to postmenopausal patients no significant difference in cAMP
binding activity was observed between the groups.
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Figure 2:2
Levels of cAMP binding in 242 tumours from 67 pre, 12 peri and 163
postmenopausal patients. Horizontal lines represent median values.
No significant differences between individual groups by Wilcoxon




















c) Cyclic AMP Binding and Oestrogen Receptor Status
Oestrogen receptor measurements were performed on 238 breast
cancers. Oestrogen receptor activity (>5 fmoles/mg cytosol
protein) was detected in 171 tumours (72%) . The relationship
between the presence of receptors and cAMP binding activity is
shown in Figure 2:3. The median value for cAMP binding was higher
in tumours without oestrogen receptors as compared to those with
ER, but this difference failed to reach statistical significance.
The relationship between the level of cAMP binding and the
concentration of oestrogen receptor activity was also investigated
in receptor positive tumours (Figure 2:4). No significant
correlation between amounts of cAMP binding proteins and oestrogen
receptors was observed by Spearman's Rank Correlation.
d)Cyclic AMP Binding Proteins and Progesterone Receptor Status
Progesterone receptor measurements were performed in 128 breast
tumours as decribed in section 2:7 (c) and receptor activity was
detected in 49 tumours (38%) . Tumours were designated positive if
the receptor level was greater then 10 fmoles/mg cytosol protein.
The relationship between the presence or absence of receptors and
cAMP binding activity is shown in Figure 2:5. There was no




Levels of cyclic AMP binding proteins in 171 oestrogen receptor
positive (+) and 67 negative (-) breast tumours.
Horizontal lines represent median values. No significant






























Relationship between levels of cAMP binding proteins and oestrogen
receptor concentration in 171 oestrogen receptor positive breast









>-V* •*\mm •C-•*.K •• .x.V ••
,(
1001000
oestrogenr ceptor(fm l/gcyt solpr t in)
Figure 2:5
Levels of cyclic AMP binding proteins in 49 progesterone receptor
positive (+ve) and 79 progesterone receptor negative (-ve) breast
tumours. Horizontal lines represent median values. No significant
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A comparison of levels of cAMP binding proteins and amounts of
progesterone receptor also revealed no significant correlation
between the two parameters by Spearman's Rank Correlation (Figure
2:6).
Cyclic AMP binding activity has also been compared in groups of
tumours subdivided according to the combination of oestrogen and
progesterone receptor status. Of 128 tumours assayed for the two
receptors, 46 were both oestrogen and progesterone receptor
positive, 49 were oestrogen receptor positive and progesterone
receptor negative, 3 were oestrogen receptor negative and
progesterone receptor positive and 30 were both oestrogen and
progesterone receptor negative. The levels of cAMP binding protein
in these groups is compared in Figure 2:7. No significant
difference in levels between these groups was observed.
e) Cyclic AMP Binding and Tumour Grade
Tumour grade was assessed as described in section 2:7 (d) . The
number of tumours graded 1, 2 and 3 was respectively 31, 123, and
91. There was no significant difference in cAMP binding levels
between tumours of different histological grade (Figure 2:8).
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Figure 2:6
Relationship between levels of cyclic AMP binding proteins and
progesterone receptor concentration in 49 progesterone receptor
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Figure 2:7
Levels of tumour cAMP binding proteins grouped according to both
oestrogen (ER) and progesterone receptor (PgR) status. 128 breast
cancers were divided into 46 ER+ve PgR+ve, 49 ER+ve PgR-ve, 3 ER-
ve PgR+ve, and 30 ER-ve PgR-ve tumours. No significant difference
between individual groups by Wilcoxon Rank Test or trend between

























Levels of cyclic AMP binding proteins in 31 grade 1, 123 grade 2,
and 91 grade 3 breast tumours. Lines represent median values. No
significant difference between individual groups by Wilcoxon Rank


























f) Cyclic AMP Binding and Clinical Stage
The T stage (assessed according to UICC TNM classification) or
tumour size was known in 232 patients. The number of patients
staged To to T4 was respectively, 6, 24, 164, 27, and 11. There
was no significant difference in levels between these groups
(Figure 2:9).
g) Cyclic AMP Binding and Lvmnh Node Status
Lymph nodes were obtained for histological examination in 216
patients. 116 patients (54%) had histologically involved lymph
nodes. There was, however, no significant difference in cAMP




Levels of cyclic AMP binding proteins grouped according to T stage
: To, no palpable lesion; T1, tumour size <2cm; T2, 2 to 5cm; T3,
>5cm; T4, tumour on chest wall invading skin.
Lines represent median values. No significant difference between
individual groups by Wilcoxon Rank Test or trend between the

















Levels of cyclic AMP binding proteins in 116 lymph node positive
(+ve) and 100 negative (-ve) tumours. Lines represent median























h) Cyclic AMP Binding and Disease Recurrence
In 196 of 245 patients with early breast cancer studied, at least
36 months had elapsed since removal of their primary tumour.
Within this period, 59 patients presented with recurrent disease
whilst the remaining 137 patients appeared disease-free. The
relationship between cAMP binding protein levels and recurrence at
36 months is shown in Figure 2:11. Although there was a
considerble overlap in the ranges of tumour cAMP binding activity
between these two subgroups of patients, the median cAMP binding
level was significantly higher in the group which developed
recurrent disease within 36 months of primary treatment (p<0.001,
by Wilcoxon Rank Test).
In order to determine the value of tumour cAMP binding which gave
the maximum discrimination between tumours associated with early
and non-recurrence, the data were retrospectively analysed by
checking misclassification rates for a range of possible cut-off
values. This showed that a value of 8 pmoles/mg cytosol protein
would misclassify only 14% of patients. This value was
subsequently used in a Cox analysis of disease-free interval and
survival data using the total follow-up available on ,?36 patients
(rather than performing analysis at 36 months).
Data on disease-free interval is shown in Figure 2:12 and
indicates that patients with tumours having cAMP binding proteins
greater than 8 pmoles/mg cytosol protein had a significantly
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increased chance of developing recurrent disease than patients
with a lower cAMP binding. This difference was evident up to five
years of follow-up.
i) Cyclic AMP Binding and Patient Survival
Of 196 patients with at least 36 months follow-up, 31 had died of
their disease within this period. 165 patients survived this
period.
The relationship between cAMP binding levels and patient survival
is shown in Figure 2:13. Despite the large overlap in values
between the groups the median cAMP binding was significantly
higher in tumours from patients who had died within 36 months of
primary treatment compared to those surviving this period
(p<0.001).
Survival curves with death from cancer as an end point are shown
in Figure 2:14. The cut-off value of 8 pmoles/mg cytosol protein
was obtained as described in the previous section. Results
indicate a similar trend for tumours with high cAMP binding to be
significantly associated with poorer survival.
These analyses on both disease-free interval and survival have
been performed by univariate tests and despite the lack of a
correlation with other parameters it was decided to subject the
data to multivariate analysis. Included in the model were clinical
stage, lymph node involvement, tumour grade, oestrogen receptor
status and adjuvant therapy. The results are shown in Table 2:2
and indicate that in this group of patients tumour grade, lymph
9 9
node status and ER status were also significantly related to
recurrence and survival, both alone and when adjusted for the
effect of cyclic AMP binding. Clinical stage and adjuvant therapy




Levels of cyclic AMP binding proteins in 137 tumours which did not
recur within 36 months of initial treatment (NR) and in 59 tumours
which recurred within this time (R) . Lines represent median
results. (p<0.001 by Wilcoxon Rank Test).
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recurrence at 36 months
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Figure 2:12
Overall disease free interval in patients with tumour cyclic AMP
binding levels >8 and <8 pmoles/mg cytosol protein. Significant
difference (p<0.001) between the curves by Cox Analysis.
>8pmol/mg protein n = 26
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Figure 2:13
Levels of cyclic AMP binding proteins in 31 tumours from patients
who had died within 36 months of initial treatment (D) and in 165
tumours from patients who had survived this period (ND).Lines
represent median values.(p<0.001 by Wilcoxon Rank Test).
cAMP
binding
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Figure 2:14
Survival curves for patients with tumour cyclic AMP binding >8,
and <8 pmoles/mg cytosol protein. Significant difference between
the curves by Cox Analysis (p<0.001).
>8pmol/mg protein n = 26














Significance of prognosis for recurrence and death for other
factors. p-values are shown for the significance from Cox
Analysis for each factor when entered alone and also when adjusted
for the effect of cyclic AMP binding.
Recurrence
cAMPbinding clinicalstage lymphnodestatus grade ERstatus Adjuvantther py
aloneadjustedforcAMP binding <0.001 0.0617 <0.0010.0 2 0.043 0.0043 0.9537
Death
aloneadjustedforcAMP binding
<0.001 0.19.41 0.0042 0.05. 0.001. 02 0.43.10
3:3 Tumour Cyclic AMP Binding Proteins and Endocrine
Responsiveness in Patients with Inoperable Breast Cancer
Thirty-one women with oestrogen receptor positive advanced breast
cancer were studied. Premenopausal patients with regular menstrual
periods (4 women) were treated by oophorectomy. The remaining 27
postmenopausal patients (more than 3 years since their last
menstrual period) received tamoxifen (20mg/day) and/or
aminoglutethimide (lg/day) plus hydrocortisone (40mg/day) as
primary endocrine treatment (except for one patient who had
previously received tamoxifen and one woman who had undergone a
previous oophorectomy).
Response to treatment was classified according to UICC criteria by
an independent objective assessment of clinical records and
without knowledge of the results of the biochemical analyses.
The biopsy material, which was obtained prior to endocrine
treatment, consisted of 26 primary tumours, 4 invaded lymph nodes,
and one mastectomy scar recurrence.
Of 31 patients, 2 had a complete remission (CR), 12 a partial
remission (PR), 2 a static response (NC) and 15 progressive
disease (PD). This represented an overall response rate of 45%
(CR+PR).
The level of ER in tumours, subdivided according to response to
endocrine therapy, is shown in Figure 3:1. Concentrations of ER
were significantly higher in tumours from responding patients as
compared with those from the non-responding group (p<10~\ by
Wilcoxon Rank Test) and all responders had an ER level above 100
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fmoles/mg cytosol protein. However, one third of the patients
whose tumour contained ER in excess of 100 fmoles/mg cytosol
protein did not respond to endocrine treatment. Therefore, whilst
a statistical difference in ER levels exists between responding
and non-responding groups, this does not provide discrimination
for individual patients.
Cyclic AMP binding (cAMP BP) was detected in all tumours, with
concentrations from 0.99 to 13.45 pmoles/mg cytosol protein.
Levels of CAMP BP, subdivided into two groups according to
endocrine responsiveness, are shown in Figure 3:1. No significant
difference was observed between tumour cAMP BP levels in
responding and non-responding patients.
The ratio of ER to cAMP BP for each tumour within the response
groups is also presented in Figure 3:1. There was a highly
significant difference (p< 10"7) between the two groups of
patients. This difference was significantly greater than that
obtained by using ER alone, and it was possible to discriminate
totally between the patient groups. All subjects responding to
therapy had tumour ER:cAMP BP ratios greater than 45 x 10"3
compared with non-responding patients in whom values were less
than this discriminatory level.
The presence of progesterone receptors (PgR) in ER positive
tumours has been reported to improve the prediction of endocrine
responsiveness (Knight et al.,1980) but in the present series of
patients PgR did not enhance prediction. Of the 22 patients in
which PgR was measured 5/8 PgR-positive tumours and 6 of 14
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PgR-negative tumours responded to treatment. The presence of




Levels of oestrogen receptors (ER), cyclic AMP binding proteins
(cAMP BP) and the ratio of ER to cAMP BP in endocrine responsive
(R) and non-responsive (NR) tumours.
Horizontal bars represent median values. Significance values are
derived from Wilcoxon Rank Test.
Oestrogenreceptors
CyclicAMPbinding






















3:4 Characterisation of a Technique for the Photoaffinitv Labelling
of Cyclic AMP Binding Proteins
The method used for the photoaffinity labelling of cAMP binding
proteins in breast tumour cytosols was adapted from that of
Pomerantz et al.(1975) with several modifications.
Preliminary studies were performed in order to optimise the
standard assay conditions and characterise the binding described
in section 2:6 (b).
a)Competitive Inhibition of f—PI 8-N3-cAMP binding by cyclic AMP
Binding of [32P]-8-N3-cAMP (0.4 uM) to breast tumour cytosol
(50ul,40 ug total protein) was investigated by incubation in the
absence and presence of varying concentrations of radioinert cAMP
(final concentration 0.050, 0.175, 0.350, 0.500 and 400 uM ) in
duplicate for 1 hour at 20°C. (The reaction mixture final volume
was 80 ul.)
At the end of this incubation, samples were diluted with Buffer B,
filtered as described in section 2:6 (a), and analysed for 32P
counts bound to the filters.
The effect of incubating in the presence of radioinert cAMP on the
binding of [32P]- 8-N3-cAMP is shown in Figure 4:1(a).Low
concentrations of radioinert cAMP were able to compete with
[32P]-8-N3-cAMP for binding, and only a low level of non-specific
binding remained in the presence of a 1000-fold excess of
competitor. This concentration of cAMP (0.4mM) was therefore used
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in the standard assay system as a measure of non-specific binding.
The data plotted according to Scatchard (1949), showed that the
dissociation constant (Kd) of binding was 2.5 x 10"8M and that the
maximum concentration of binding sites within the assay system was
about 10.65nM.
Thus, the Kd value obtained for [32P]-8-N3-cAMP (2.5xl0"8M) was
similar to the median Kd for [3H]cAMP (1.7xlO"8M, section 3:2
(a)). These results suggest that the 8-azido derivative binds
specifically and reversibly with cAMP binding proteins and has an
affinity very similar to that of cAMP.
b)Effect of Varying the Pre-photolvtic Incubation Time and
Temperature
In order to monitor the time course required for reversible cyclic
nucleotide binding to reach equilibrium, pre-photolytic
incubations were carried out for 30 minutes, 1 hour, 3 hours, and
6 hours either at 0°C or 20°C. Samples were filtered and 32P
counts bound measured.
A typical result is presented in Figure 4:2. Maximum binding at
20°C was achieved by 1 hour. Binding at 0°C was lower than at 20°C
at each time point studied. Overnight incubation at either 0°C or
20°C produced reduced binding (data not shown). For routine assays
it was decided to incubate at 20°C for 1 hour.
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Figure 4:1
The effect of radioinert cyclic AMP on the binding of [32P]-8-N3-
cAMP to a cytosol of human breast cancer. Data plotted as (a)
radioactivity bound (b) according to Scatchard (1949).
coneD fcoldompetitor(^M)b undM
Figure 4:2
The effect of time of pre-photolytic incubation on the
incorporation of [32P]-8-N3-cAMP (0.4uM) into a cytosol of breast
tumour (40ug protein) either at 20°C (.) or 0°C (o).
Each point represents the amount of [32P]-8-N3-cAMP bound in the













c'iEffect of Irradiation Time Course
Following the pre-photolytic incubation, the pyrex spot plate was
subjected to irradiation at 254 nM with a UV hand lamp supported
at a distance of 8 cm. Samples (80ul) were removed after periods
of irradiation ranging from 0-60 minutes and were immediately
mixed with Sample buffer (40ul). The samples were then analysed
for covalent incorporation of [32P]- 8-N3-cAMP as described in
section 2 : 6(b).
Figures 4:3 (a) and (b) show the results of the irradiation time
course experiment described above.
An autoradiograph (a) shows the incorporation of [32P]-8-N3-cAMP
into replicate aliquots of a breast tumour cytosol after
irradiation for 0, 1, 5, 15 and 30 minutes. (Incorporation of
radioactivity is eliminated by the presence in the incubation
mixture of nonradioactive cAMP at a 1000-fold molar excess (+)).
Only a trace of radioactivity was incorporated when the photolytic
incubation mixture was not irradiated (time 0).
Photoactivated incorporation into the binding proteins is seen to
increase with time of irradiation and to be essentially complete
after a 15-minute period of photolysis (Figure 4:3(b)). This was
assessed by comparing the optical density profiles of each channel
of the exposed film by densitometry. The peak areas of the
densitometric tracings are proportional to the incorporation of
radioactivity into the bands. Results were expressed as a
percentage of the maximum bound. For routine assays the spot plate
was therefore irradiated for 15 minutes.
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Figure 4:3
Effect of irradiation time course.
(a) Autoradiograph showing irradiation time course of the
photoaffinity labelling of breast tumour cytosols. [32P]-8-N3-cAMP
(0.4uM) in the absence (-) and presence (+) of 0.4mM radioinert
cAMP in the standard assay mixture was photolysed at 254nM for the
indicated periods of time, according to the method described in
the text.
Lane 7 contains 14C markers of known molecular weight.
(b) Plot of irradiation time course. Incorporation of
[32P]-8-N3-cAMP is expressed as a percentage of the maximum bound
as described in the text.
a)
3:5 Types of Cyclic AMP Binding Proteins in Human Breast Cancer
a) Identification of Types of cAMP Binding Proteins in Breast
Tumour Cytosols
The molecular species of cAMP binding proteins present in human
breast cancer cytosols were identified by the use of the
photoaffinity label, [32P]-8-N3-cAMP, as described in section 2:6
(b). A typical autoradiograph of an SDS-polyacrylamide gel showing
results from the incubation of [32P]-8-N3-cAMP with breast tumour
cytosols is presented in Figure 5:1. The molecular weights of
individual binding proteins were calculated by comparing their
mobility relative to 14C labelled protein standards of known
molecular weight.
Studies of 154 early breast cancers revealed that 4 major types of
cAMP binding protein with apparent molecular weights of 52K, 48K,
43K, and 39K could be identified in most tumour cytosols. The 39K
and 52K bands sometimes appeared as doublets but were counted as
one band in quantitation studies. In addition a labelled band with
a molecular weight of 67,000 which was not displaced by 0.4uM cAMP
was often found. This may be serum albumin, which is known to bind
cAMP non-specifically.
In order to characterise the binding, breast tumour cytosols were
run on SDS-polyacrylamide gels in parallel with cAMP-dependent
protein kinase Types 1 and 2 purified from rabbit skeletal muscle
and bovine heart, respectively (Figure 5:2). The 52K protein
comigrated with Type 2 while the 48K comigrated with the Type 1
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receptor protein. The 48K and 52K bands could, therefore, be Rl
and R2, the monomeric regulatory subunits of cAMP-dependent
Protein Kinase Types 1 and 2, respectively. It has been suggested
that the lower molecular weight proteins (43K and 39K) are
proteolytic products of these larger proteins (Corbin et al.,1975;
Weber et al.,1981).
In an attempt to confirm that the lower molecular weight cAMP
binding proteins (43K and 39K) in cytosolic extracts of breast
tumours are the result of proteolysis during preparation, a fresh
breast tumour was finely minced and divided into 2 equal
fractions. One cytosol was prepared under standard assay
conditions (section 2:4) while the other was prepared in buffer
containing the protease inhibitor, aprotinin (60KIU/ml). The two
samples were then run in parallel on SDS-polyacrylamide gels,
subjected to autoradiography and the intensity of the bands
determined by densitometry. No significant difference was observed
in the overall incorporation of 32 P or in the proportions of the
binding proteins (Figure 5:3).
These results, therefore, suggest that these lower molecular
weight proteins are not artefacts created by proteolysis during




Autoradiograph showing the photoactivated incorporation of
[32P]-8-N3-cAMP (0.4um) into 4 cytosols of human breast tumours
(20ug protein/lane). cAMP was absent (-) or present (+) at a
concentration of 0.4mM in the reaction mixture.
14C, 14C-labelled molecular weight standards.
MW
Figure 5:2
Autoradiograph showing photoaffinity labelling of purified
cAMP-'dependent protein kinase Types 1 and 2 (2ug
protein/lane)(lanes 1 and 2) and breast tumour cytosols (20ug
protein/lane) (3-14).





























Autoradiograph showing photoaffinity labelling of a breast tumour
cytosol prepared in the absence (-) and presence (+) of Aprotinin
(60KIU/ml Buffer A) (20ug protein/lane)
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b) Quantitation of Types of Cyclic AMP Binding Proteins
Autoradiographs were scanned by densitometry and the peak areas of
the optical density tracings were used as a measure of the
relative amounts of the individual protein bands as described in
section 2:6 (b). As a comparison in some preliminary experiments,
radioactive bands were cut out of dried gels, dissolved in
hydrogen peroxide and measured by liquid scintillation counting to
determine absolute amounts of radioactive phosphate incorporated
(section 2:6(b)).
Figure 5:4 demonstrates a typical result comparing the two methods
of analysing [32P]-N3-cAMP incorporation which consisted of (a)
scanning the autoradiograph of a gel by densitometry and (b)
liquid scintillation counting of slices cut from the gel. In all
instances the peak heights of the scans were proportional to the
radioactivity of the corresponding peaks estimated by liquid
scintillation counting. It was,therefore, decided to use
densitometry routinely as this is a less laborious and less costly
method of quantitation.
Densitometry provides a measure of the % distribution of 32P
between individual binding proteins. This ratio was used to
calculate the absolute amounts of cAMP binding activity
attributable to each binding protein from the total cAMP binding




A, densitometric tracing obtained from an autoradiograph (C)
showing the photoactivated incorporation of [32P]-8-N3-cAMP into
protein bands of a breast tumour cytosol. B, scintillation
counting of the gel channel corresponding to the densitometric






























c) Distribution and Range of Levels of Cyclic AMP Binding Protein
Types
Types of cAMP binding proteins were identified and quantitated in
154 early breast cancers by photoaffinity labelling as described
in section 2:6 (b). The results are presented in Table 5:1.
The 52K (Type 2 or R2) protein was detected in 115 tumours (75%).
The 48K (Type 1 or Rl) protein was detected in 154 tumours (100%),
the 43K protein in 68 tumours (44%) and the 39K protein in 141
tumours (92%). In terms of quantitation, the predominant band was
the 52K protein in 18 tumours (12%), the 48K protein in 110
tumours (71%) , the 43K protein in 3 tumours (2%) and the 39K
protein in 23 tumours (15%).
Levels of individual binding proteins varied greatly between
tumours (Table 5:2(a), Figure 5:5). Levels of the 52K protein
ranged from 0 to 5.450 pmoles/mg cytosol protein (median 0.559).
The 48K protein ranged from 0.105 to 7.912 pmol/mg cytosol protein
(median 1.922), the 43 K protein from 0 to 2.445 (median 0) and
the 39K from 0 to 7.345 pmoles/mg cytosol protein (median 0.742).
Relative amounts of binding proteins are shown in Table 5:2(b).
The ratio of 48K:52K (R1:R2) in the tumours ranged from 0 to
16.380 (median 1.245). The ratio of the intact binding proteins
(52K + 48K) versus the "degradation products" (43K + 39K) ranged
from 0 to 6485 (median 2.610).
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Table 5:1
Incidence and predominance of cyclic AMP binding protein types in








Incidence (%) Predominant band (%)
(no./total) (no./total)
115/154 75 18/154 12
154/154 100 110/154 71
68/154 44 3/154
141/154 92 23/154 15
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Table 5:2
(a) Levels of and (b) relative amounts of cAMP binding protein
types in cytosols of 154 early breast tumours
(a)
52K




Range 0-5.450 0.105-7.912 0-2.445
0-7.345
Median 0.559 1.922 0.742







Levels of types of cyclic AMP binding proteins in 154 early breast


































In an analogous study to that for total cAMP binding activity in
breast cancers (section 3:2), levels and ratios of individual
binding proteins in breast tumours were then correlated with
established prognostic parameters.
d) Tumour Cyclic AMP Binding Protein Types and Menopausal Status of
the Patients
Of 154 patients with early breast cancer studied, 52 were
pre-menopausal, 4 were peri-menopausal, and 95 were
post-menopausal. The remaining 3 patients had undergone an
hysterectomy and their menopausal status was uncertain.
The range of levels and median values of individual cAMP binding
proteins and their ratios, subdivided according to the menopausal
status of the patients is shown in Table 5:3. There was no
significant difference in the level of the 52K, 48K, 43K or 39K
protein between tumours from women of different menopausal status.
There was also no significant difference in the ratio of R1:R2 or
in the relative amounts of 52K +48K versus 43K +39K cAMP binding
proteins between the subgroups.
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Table 5:3
Median values and range of levels (pmoles/rag cytosol protein) of
the 52K, 48K, 43K, and 39K cAMP binding proteins, plus the ratios,
48K:52K and 52K+48K:43K+39K, in 151 breast tumours from 52 pre, 4
peri and 95 post-menopausal patients. No significant difference
between the groups by Wilcoxon Rank Test or trend by Spearman's
Rank Correlation.
pre(n=52)
52K0.490( -5.45 ) 48K1.900(0-5.124) 43K0( -2.445) 39K0.600( -7.3^5) 48K:52K1.49(0-16.38) 48K+52K:43K+39K2.8(0.43-6061)
MenopausalStat s perl(n=4) 0.353(0-0.690) 1.730(0.990-2.440) 0.181( -0.875) 0.480(0.25 -1.869) 3.04(0-3.96) 1.93(0.59-18.48)
post(n=95) 0.595(0-4.888) 1.964(0.105-7.912) 0(0-1.651) 0.854(0-4.875) 1.29(0-13.46) 2.69(0.47- 485)
e) Cyclic AMP Binding Protein Types and Oestrogen Receptor Status
Oestrogen receptor measurements were performed on 147 breast
cancers and receptor activity was detected in 100 tumours (68%).
The relationship between the presence of receptors and individual
cAMP binding proteins and their ratios is shown in Table 5:4. The
median values for the 52K, 48K and 39K binding proteins were
slightly higher in oestrogen receptor positive tumours but the
difference did not reach statistical significance. There was also
no significant difference in the values of the ratios between the
subgroups.
The relationship between the levels of the cAMP binding proteins
and the concentration of oestrogen receptor activity in the 100
receptor positive tumours was also investigated but no significant
correlations were observed (data not shown).
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Table 5:4
Median values and range of levels (pmoles/mg cytosol protein) of
the 52K, 48K, 43K, and 39K cyclic AMP binding proteins, plus the
ratios, 48K:52K and 52K+48K:43K+39K, in 100 oestrogen receptor
positive (+ve) and 47 receptor negative (-ve) breast tumours.
No significant difference in binding protein levels between the
groups by Wilcoxon Rank Test.
52K 48K 43K 39K 48K:52K 48+52K:43+39K
OestrogenR ceptorSta us
+ve(n=100) 0.620( -5.450) 1.954(0.505-7.536) 0( -1.777) 0.788( -4.875) 1.50(0-10.19) 2.69(0.51- 485)
-ve(n=47) 0.285( -3.000) 1.922(0.105-7.912) 0(0-2.445) 0.715(0-7.345) 1.05(0-16.38) 1.95(0.43-6151)
f) Cyclic AMP Binding Protein Types and Progesterone Receptor
Status
Progesterone receptor measurements were performed in 56 breast
tumours and receptor activity was detected in 17 tumours (30%).
The relationship between the presence or absence of receptors and
the levels of cAMP binding protein types as well as their ratios
is presented in Table 5:5. There were no significant differences
in the levels of individual binding proteins or their ratios
between receptor positive and negative groups. A comparison of
levels of binding proteins and amounts of progesterone receptor in
the 17 receptor positive tumours also revealed no significant
correlations (data not shown).
g) Cyclic AMP Binding Protein Types and Tumour Grade
The number of tumours graded 1, 2 and 3 was respectively 20, 72
and 68. The levels of the individual binding proteins and their
ratios at the different tumour grades are shown in Table 5:6.
There was no significant difference in binding activity between
tumours of different histological grade. There was also no
significant difference in the R1:R2 ratio or the ratio of intact
versus degraded binding proteins between the groups.
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Table 5:5
Median values and range of levels (pmoles/mg cytosol protein) of
the 52K, 48K, 43K and 39K cyclic AMP binding proteins plus the
ratios, 48K:52K and 52K+48K:43K+39K in 17 progesterone receptor
positive (+ve) and 39 progesterone receptor negative (-ve) breast
tumours. No significant difference between the groups by Wilcoxon
Rank Test.
52K 48K 43K 39K 48K:52K 48+52K:43+39K
ProgesteroneRec pt rStatus
+ve(n=17) 0.301( -5.450) 2.343(0.620-5.124) 0(0-1.239) 1.100(0.245-2.550) 1.20(0-5.05) 2.80(0.51-6.55)
-ve(n=39) 0.468( -4.105) 1.925(0.689-7.536) 0(0-1.949) 0.738(0-4.875) 1.09(0-13.46) 2.62(0.46- 151)
Table 5:6
Median values and range of levels (pmoles/mg cytosol protein) of
the 52K, 48K, 43K, and 39K cyclic AMP binding proteins plus the
ratios, 48K:52K and 52K+48K:43K+39K in tumours of different
histological grade. No significant difference between the groups
by Wilcoxon Rank Test or trend between the groups by Spearman's
Rank Correlation.
1(n=20)
52K0.238( -3.031) 48K1. 28(0-5.120) 43K0.049( -1.651) 39K0.726( -4.875) 48K:52K1.00(O-I6.38) 48K+52K:43K+39K1.85(0-11.28)
TumourGrade 2(n=72) 0.553( -5.4 0) 1.525(0-7. 36) 0(0-1.777) 0.692( -2.692) 1.38(0-10.19) 2.87(0-6485)
3(n=68) 0.496(0-4.888) 2.012(0-7.91 ) 0(0-2.445) 0.734(0-7.345) 1.07(0-13.46) 2.50(0-6061)
h) Cyclic AMP Binding Protein Types and Clinical Stage
The T stage or tumour size was known in 139 patients. The number
of patients staged To to T4 was respectively 3, 17, 97, 12, and
10. The levels of the individual binding protein types at the
different T stages are shown in Table 5:7. There was no
significant difference in binding activity between tumours of
different size. There was also no significant difference in the
R1:R2 ratio or the ratio of intact versus degraded binding
proteins between the groups.
i) Cyclic AMP Binding Protein Types and Lvmph Node Status
Lymph nodes were obtained for histological examination in 129
patients. 65 patients (50%) were shown to have nodes
histologically involved with tumour. There was no significant
difference in the levels of any individual tumour cAMP binding
protein or ratio of binding proteins between patients with lymph
node metastases and those without (Table 5:8).
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Table 5:7
Median values and range of levels (pmoles/mg cytosol protein) of
the 52K, 48K, 43K, and 39K cyclic AMP binding proteins plus the
ratios, 48K:52K and 52K+48K:43K+39K in tumours of different T
stage. No significant difference between the groups by Wilcoxon
Rank Test or trend by Spearman's Rank Correlation.
n
T0(n=3)
52K 48K 43K 39K 48K:52K 48+52K:43+39K
0.475(0-0.950) 2.211(1.208-2.730) 0( -0.584) 0.935(0.521-1.139) 0( -0.85) 2.880(1.94-5.24)
ClinicalStage
T1(n=17)2(n=97)3(n=12)(n=10) 0.455(0-3.024)0.595(0-5.450)0.143(0-3.87 )0.535(0-1.695) 1.727(0.250-4.395)1.985(0.559-7.912)1.945(0.836-7. 36)1.566( . 0 -2.445) 0(0-1.012)(0-2.445)0.2 8(0-1.345)(0-1. 7) 0.598(0-1.988)0.854(0-7.345)0.9 3(0.173-1.680)0.957( -2.590) 1.000(0-4.98)1.73 (0-1 .19)0.945(0-13.46)1.730(0-6.21) 3.650(0.65-5554)2.620( .43-6485)2.915(0.68-11.95)1.40(0-3852)
Table 5:8
Median values and range of levels (pmoles/mg cytosol protein) of
the 52K, 48K, 43K and 39K cyclic AMP binding proteins plus the
ratios, 48K:52K and 52K+48K:43K+39K in 65 lymph node positive
(+ve) and 64 node negative (-ve) breast tumours. No significant
difference between the groups by Wilcoxon Rank Test.
52K 48K 43K 39K 48K:52 48+52K:3 39
LymphNodeStatus +ve(n=65) 0.559( - .450) 2.203(0-7.5 6) 0( -1.949) 1.081(0-7.345) 1.27(0-8.600) 2.160(0-5554)
-ve(n=64) 0.590( -4.888) 1.848(0-7.912) 0( -2.445) 0.648( -3.792) 1.62(0-13.460) 2.870(0.59-6151)
j) Cyclic AMP Binding Protein Types and Disease Recurrence
In 107 of 154 patients with early breast cancer studied, at least
36 months had elapsed since removal of their primary tumour.
Within this period, 35 patients presented with recurrent disease
whilst the remaining 72 patients appeared disease-free. The
relationship between levels of the different cAMP binding protein
types and recurrence at 36 months is shown in Figure 5:6.
The median 52K binding level was higher in the early recurrence
group but there was a considerable overlap in the ranges of the
binding protein between these two subgroups of patients, and the
difference did not reach statistical significance (p<0.07 by
Wilcoxon Rank Test). However, the median 48K binding protein level
was significantly higher in the group which developed recurrent
disease (p<0.01 by Wilcoxon Rank Test). No statistically
significant difference in levels of either the 43K protein or the
39K protein were observed between the two groups.
These investigations were then repeated, using tumours with
detectable levels of binding protein types only, i.e. omitting the
zero values. The relationship between the 52K protein and
recurrence at 36 months is presented in Figure 5:7(a). The median
52K protein level was significantly higher in the early recurrence
group (p<0.001 by Wilcoxon Rank Test). Therefore, the 52K protein
appears to be of prognostic significance only in tumours with
detectable levels of the binding protein. In order to determine
whether this correlation between high levels of the 52K binding
protein and poor prognosis was a reflection of total tumour cAMP
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binding activity, cAMP binding levels were related to recurrence
in this group of tumours (Figure 5:7(b)). The median cAMP binding
level was also significantly higher in the early recurrence group
(p<0.01 by Wilcoxon Rank Test), but the level of statistical
significance attained was lower than that for the 52K protein
(p<0.001 by Wilcoxon Rank Test). Thus, in this subpopulation of
early breast cancers, measurement of the 52K protein improves the
prognostic value of total cAMP binding measurements.
The 48K protein, which was detectable in all tumours, was
significantly higher in the early recurrence group (p<0.01 by
Wilcoxon Rank Test) but this was probably a reflection of total
cyclic AMP binding activity as this was also significantly higher
in this group at the same level of statistical significance
(p<0.01).
Correlations between levels of the degradation products (43K and
39K) and recurrence at 36 months, in tumours with detectable
levels of each protein, did not reach statistical significance.
The ratio of the level of the 48K protein:52K protein (R1:R2) was
also examined with respect to disease recurrence (Figure 5:8).
There was no significant difference in the R1:R2 ratio between
breast tumours which recurred early and those which remained
disease-free. Omitting zero values did not alter this result.
There was also no significant difference in the ratio
52K+48K:43K+39K between these groups (Figure 5:9).
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Figure 5:6
Levels of 52K, 48K, 43K, and 39K cyclic AMP binding proteins in 72
tumours which did not recur within 36 months of initial treatment
(NR) and in 35 tumours which recurred within this time (R). Lines
represent median values. Significant difference in level of 48K
protein between the groups (p<0.01 by Wilcoxon Rank Test). No






































(a) Levels of detectable tumour 52K binding protein in 52 patients
who had not developed recurrent disease within 36 months (NR) and
24 patients who had recurred within this interval (R) . Lines
represent median values. Significant difference between the groups
(p<0.001 by Wilcoxon Rank Test).
(b) Total tumour cyclic AMP binding activity in patients as
defined in (a). Significant difference between the groups (p<0.01


















Ratio of levels of 52K to 48K protein (R1:R2) in 72 patients who
had not developed recurrent disease (NR) within 36 months of
primary treatment and 35 patients who had recurred within this
interval (R). Lines represent median values. No significant

















Ratio of tumour levels of 52K + 48K : 43K + 39K in 72 patients who
had not developed recurrent disease within 36 months of primary
treatment (NR) and 35 patients who had recurred within this
interval (R). Lines represent median values. No significant
difference between the groups.
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k) Cyclic AMP Binding Protein Types and Patient Survival
Of 107 patients with at least 36 months follow-up since primary
treatment, 22 patients had died of their disease within this
period whilst 85 patients had survived. The relationship between
levels of individual cAMP binding protein types and patient
survival is shown in Figure 5:10. Although the median levels of
all four cAMP binding proteins were higher in tumours from
patients who had died within 36 months of primary treatment this
difference did not reach statistical significance for any
individual binding protein. Omitting tumours with undetectable
levels of binding proteins did not alter this result.
There was also no significant difference in either the tumour
R1:R2 ratio (Figure 5:11) or 52K+48K:43K+39K ratio (Figure 5:12)




Levels of 52K, 48K, 43K, and 39K cyclic AMP binding proteins in 22
tumours from patients who had died within 36 months of initial
treatment (D) and in 85 tumours from patients who had survived
this period (ND). Lines represent median values. No significant







































Ratio of levels of 52K to 48K protein (R1:R2) in 85 patients who
had not died (ND) within 36 months of primary treatment and 22
patients who had died within this interval (D) . Lines represent
median values. No significant difference between the groups.
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survival at 36 months
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Figure 5:12
Ratio of tumour levels of 52K +48K : 43K +39K in 85 patients who
had not died within 36 months of primary treatment (ND) and 22
patients who had died within this interval (D) . Lines represent
median values. No significant difference between the groups.
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3:6 Cyclic AMP Levels in Human Breast Cancer
Of the group of 245 early breast cancers investigated for cAMP
binding activity (section 3:2), 160 tumours were also analysed for
cyclic AMP levels as described in section 2:6(c). Results
contained in this section concern this subgroup.
a) Range of Cyclic AMP Levels in Breast Cancer Cytosols
The range of levels of cAMP obtained is presented in Table 6:1,
and the concentration of the cyclic nucleotide in individual
tumours is plotted in Figure 6:1. All cytosols contained
measureable amounts of cAMP and levels varied from 43 to 861
pmoles/g wet weight (median 258) . The range of levels of 8 control
tissues (section 3:2(a)) is also shown in Figure 6:1 and varied
from 25 to 46 pmoles/g wet weight (median 34) which is
significantly lower than the range for tumours with an overlap of
only one point. The strong correlation between cAMP measurements
based either on a wet weight or cytosol protein basis (Fig 6:x)
meant that the following relationships were similar irrespective
of the units employed.
b) Relationship between Cyclic AMP Level and Cyclic AMP Binding
Activity in Breast Tumour Cytosols
The relationship between the level of cAMP and cAMP binding
activity in breast tumour cytosols is presented in Figure 6:2.
There was a highly significant correlation between the two
parameters (p<0.001 by Spearman's Rank Correlation).
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Table 6:1
Levels of cAMP in cytosols of 160 early breast cancers









Levels of cAMP in cytosols of 160 primary breast cancers (.) and 8



















Relationship between cyclic AMP measurements expressed either as
pmol/g wet weight or pmol/g cytosol protein. Significant






















Relationship between cyclic AMP binding activity and cyclic AMP
levels in 160 early breast cancers. Significant correlation














c) Cyclic AMP and Menopausal Status in Breast Tumours
Of 160 patients, 52 were pre-menopausal, 4 were peri-menopausal
and 101 were post-menopausal. The remaining 3 patients had
undergone an hysterectomy and their status was unclear.
The level of cAMP subdivided according to the menopausal staus of
the patients is shown in Figure 6:3. No significant difference in
cAMP level was observed between the groups.
d) Cyclic AMP and Oestrogen Receptor Status
Oestrogen receptor measurements were performed on 153 breast
carcinomas. Activity was detected in 104 tumours (68%). The
relationship between the presence or absence of receptors and cAMP
levels is shown in Figure 6:4. The median value for cAMP was
higher in the receptor negative group compared to the receptor
positive tumours but the difference failed to reach statistical
significance by the Wilcoxon Rank Test.
The relationship between the level of cAMP and the concentration
of oestrogen receptors in the 104 receptor positive tumours is
also shown in Figure 6:5. No significant correlation between




Levels of cAMP in 157 tumours from 52 pre, 4 peri and 101
postmenopausal patients. Horizontal lines represent median values.
No significant difference between individual groups by Wilcoxon


















Level of cAMP in 104 oestrogen receptor positive (+ve) and 49
negative (-ve) breast tumours.
Horizontal lines represent median values. No significant















Relationship between levels of cAMP and oestrogen receptor
concentration in 104 oestrogen receptor positive breast tumours.




















e) Cyclic AMP and Progesterone Receptor Status
Progesterone receptor measurements were performed in 56 breast
tumours and were positive in 17 tumours (30%).
The relationship between the presence or absence of receptors and
cAMP level is shown in Figure 6:6. There was no significant
difference in cAMP levels between the two groups.
A comparison of cAMP levels and amounts of progesterone receptor
in the small number of progesterone receptor positive tumours also
revealed no significant trend between the two parameters (Figure
6:7).
Cyclic AMP levels have been compared in tumours with the different
possible combinations of oestrogen and progesterone receptors. Of
56 tumours assayed for both receptors, 15 were positive for both
oestrogen and progesterone receptors; 24 were oestrogen receptor
positive and progesterone receptor negative; 2 were oestrogen
receptor negative and progesterone receptor positive and 15 were
both oestrogen and progesterone receptor negative. The level of
cAMP in these tumour groups is compared in Figure 6:8. No




Levels of cAMP in 17 progesterone receptor positive (+ve) and 39
progesterone receptor negative (-ve) breast tumours. Horizontal
lines represent median values. No significant difference between










Relationship between levels of cAMP and progesterone receptor
concentration in 17 progesterone receptor positive breast tumours.
No significant correlation by Spearman's Rank Correlation.
1000 cAMP pmol/g
100 10
101 0 Progestogenr ceptor(fmol/mg.cytosolpr ein)
Figure 6:8
Levels of cAMP grouped according to both oestrogen receptor (ER)
and progesterone receptor (PgR) status. 56 breast tumours were
divided into 15 ER+ve PgR+ve, 24 ER+vePgR-ve, 2 ER-ve PgR+ve, and
15 ER-ve PgR-ve cancers. No significant difference between
individual groups by Wilcoxon Rank Test or trend between the
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f) Cyclic AMP and Tumour Grade
Tumour grade was assessed as described in section 2:7(d). The
number of tumours graded 1, 2 and 3 was respectively 20, 72 and
68. There was no significant difference in cAMP levels between
tumours of different histological grade (Figure 6:9).
g) Cyclic AMP and Clinical Stage
The T stage or tumour size was documented in 145 patients. The
number of patients staged To to T4 was respectively, 4, 17, 102,
12, and 10. There was no significant difference in levels between
these groups (Figure 6:10).
h) Cyclic AMP and Lymph Node Status
Lymph nodes were obtained for histological examination in 133
patients. 67 patients (50%) had histologically involved nodes.
There was however no significant difference in cAMP level between
the lymph node positive and negative groups (Figure 6:11).
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Figure 6:9
Levels of cyclic AMP in 20 grade 1, 72 grade 2 and 68 grade 3
breast tumours. Horizontal lines represent median values. No
significant difference between individual groups by Wilcoxon Rank
















Levels of cAMP grouped according to T stage (To - T4) . Lines
represent median values. No significant difference between
individual groups by Wilcoxon Rank Test or trend between the














Levels of cAMP in 67 lymph node positive (+ve) and 66 node
negative (-ve) tumours. Lines represent median values. No




















i) Cyclic AMP Level and Disease Recurrence
In 111 patients with early breast cancer studied, at least 36
months had elapsed since their primary treatment. During this
period, 37 patients presented with recurrent disease while the
remaining 74 patients appeared disease-free. The relationship
between cAMP levels and recurrence at 36 months is shown in Figure
6:12. There was a complete overlap in the ranges of tumour cAMP
between these two subgroups. However the median cAMP level was
significantly higher in the group which developed recurrent
disease (p<0.04, by Wilcoxon Rank Test).
It has already been shown (section 3:2 (h)) in 245 early breast
cancers that tumour cAMP binding activity is significantly higher
in patients whose disease recurred early (p<0.001 by Wilcoxon Rank
Test). Cyclic AMP binding protein levels were also investigated in
this subgroup of 111 patients and the difference remained
statistically significant (p<0.01 by Wilcoxon Rank Test) (data not
shown).
Cox Analysis of the data using the total follow-up available was
then performed. Tumours were divided according to quartiles of
cAMP (Group A = 0-150; B - 151-250; C = 251-350; D = 351+ pmoles/g
wet weight). The resulting curves are shown in Figure 6:13. There
was a significant tendency for tumours with increasing cAMP levels
to develop a recurrence (p<0.001).
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Figure 6:12
Levels of cAMP in 74 breast tumours which did not recur within 36
months of initial treatment (NR) and in 37 tumours which recurred


















Recurrence at 36 months
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Figure 6:13
Overall disease free interval in patients with tumour cAMP levels
(pmoles/g wet weight) divided by quartiles.
A = 0-150 n = 29
B = 151-250 n = 43
C - 251-350 n = 35
D = 351+ n = 4 5
Significant trend by Cox Analysis (p<0.001).
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j) Cyclic AMP Level and Patient Survival
Of 111 patients with at least 36 months follow-up, 24 had died of
their disease within this period and 87 patients survived.
The relationship between cAMP and patient survival is shown in
Figure 6:14. Although the median tumour cAMP level was higher in
the patients who had died within 36 months compared to those
surviving, this difference did not reach statistical significance.
A comparison of tumour cAMP binding protein levels in these groups
showed a significantly higher median cAMP binding activity in
patients who had died within 36 months (p<0.03 by Wilcoxon Rank
Test).
Cox Analysis of the cAMP data sub-divided into quartiles revealed
a significant trend (p<0.001) for increasing cAMP levels to be
associated with decreased probability of survival (Figure 6:15).
1 6 6
Figure 6:14
Levels of cAMP in 24 tumours from patients who had died within 36
months of initial treatment (D) and in 87 tumours from patients
who had survived this period (ND).Lines represent median values.
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Figure 6:15
Overall survival in patients with tumour cAMP levels (pmoles/g wet
weight) divided by quartiles.
A = 0-150 n = 2 9
B = 151-250 n =43
C - 251-350 n = 35
D = 351+ n =45




3:7 Characterisation of Western Blotting Technique for p21
a") Preparation of Cell Lysates
Two different methods of preparing tumour extracts for p21
estimation were compared using the same breast tumour specimens.
The first method (Debortoli et al.,1985) comprised pulverising
breast tumour tissue (100-200 mg) in liquid nitrogen. The powder
obtained was then dispersed with a Teflon-glass homogeniser in
Buffer 10 (l-2ml).The suspension was centrifuged at 750g for 20
minutes and the supernatant used as a cell lysate.
Method 2 (described fully in section 2:4) involved homogenising
breast tumour (1:10 w/v in Buffer A) and centrifuging at 100,OOOg
for 1 hour. The pellet was then scraped from the centrifuge tube,
dispersed and centrifuged as above.
Figure 7:1 shows a Western blotting analysis for p21 in 5 human
breast cancers comparing cell lysates prepared according to Method
1 (lanes 1-5) and Method 2 (lanes 6-10).
Radiolabelled doublet bands, comigrating with p21 from fibroblasts
expressing p21 (STD) were detected. Similar results were obtained
with the same relative intensities between different tumours using
either of the two tissue preparations.
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Figure 7:1
A comparison of methods for the preparation of p21 containing cell
lysates.
The cell lysates were prepared from frozen pulverised specimens
(lanes 1-5) or from microsomal pellets (lanes 6-10) as described
in the text. The cellular proteins were separated by SDS-PAGE,
transferred to nitrocellulose, immunoblotted with monoclonal
antibody Y13-259, and then exposed to an X-ray film (section 2:6
(d)). Each lane was loaded with lOOug protein.
STD, a reference p21 from the FH05T1 fibroblast cell line
expressing mutated human ras H p21 in Chinese Hamsters.
14C, labelled MW markers.
STD 1 2 3 U 5 6 7 8 9 10 UG








The advantage of the latter technique was that breast tumour
cytosols could be prepared by standard methods prior to preparing
membrane extracts. This enabled estimates for cAMP, cAMP binding
proteins and p21 to be performed on the same breast tumour
specimen, thus minimising variations associated with tissue
heterogeneity.lt was, therefore, decided to adopt the latter
technique for routine measurements.
b)Effect of Storage of Particulate Fractions
In order to determine the effects of freezing microsomal
preparations on p21 levels, microsomal pellets prepared as above
were assayed directly or after storage at -80°C for 3 months.
The results are shown in Figure 7:2. Storage of microsomal pellets
at -80°C adversely affected the detection of p21 by Western
blotting. Thus in 3 of 4 tumours, p21 bands and those of other
nonspecific immunoglobulins were present at greatly reduced
intensity as compared with freshly prepared cell lysates.




The effect of freezing microsomal pellets on the detection of p21
by Western blotting analysis in 4 breast tumours, comparing
freshly prepared cell lysates (lanes 1-4) and frozen cell lysates
(lanes 5-8). lOOug protein was added to each lane.
*
12 3 it 5 6 7 8
172
c) Effect of Electroblotting Time on Detection of p21
Efficiency of transfer of separated proteins from
SDS-polyacrylamide gels to nitrocellulose was compared using
replicate gels subject either to 60V for 2.5 hours or 50V
overnight.
No significant difference was observed (Figure 7:3).
1 7 3
Figure 7:3
The effect of electroblotting time on the detection of p21.
Replicate breast cancer preparations were electrotransferred for A
2.5h at 60V and B overnight at 50V.
STD, reference p21 from the FH05T1 fibroblast cell line expressing
mutated human ras H p21 in Chinese hamsters.
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3:8 Expression of p21 in Human Breast Cancer
a) Western Blotting Analysis of p21
p21 was identified in 160 early primary breast carcinomas by
Western Blotting analysis as described in section 2:6(d). A
typical autoradiograph is shown in Figure 8:1. Radiolabelled
doublet bands, which varied in intensity among the tumour extracts
(lanes 1-9), comigrated with p21 from 13-3B-4 cells (STD) (section
2:5 (a)). 13-3B-4 cells were observed to exhibit both upper and
lower bands of p21, whereas human breast tumours showed only the
lower band of p21 protein. This is consistent with reports that
13-3B-4 cells contain the viral rasH gene which encodes both
phosphorylated (upper band) and unphosphorylated (lower band)
forms of p21 (Shih et al.,1979; Langebeheim et al.,1980)., whereas
human breast tumours contain the cellular rasH gene which encodes
only the unphosphorylated form of p21 (Slamon et al.,1984;
Spandidos and Agnantis, 1984).
b) Quantification of p21 Levels in Breast Cancers
The level of p21 protein in human breast cancers was estimated
semi-quantitatively by measuring the incorporation of 1251 into
p21 bands in the nitrocellulose filters. This was achieved by
superimposing the nitrocellulose sheet on the autoradiograph. The
bands corresponding to p21 were cut out and counted in a gamma
counter. The levels of p21 were then expressed in arbitrary units
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where 1 arbitrary unit was set equal to the average p21 level of
normal breast tissue. Units 2, 3, 4, and 5 were equivalent to 2-3,
3-5, 5-7 and 7-10 times, respectively, that of unit 1. Thus in
Figure 8:1, the intensity of p21 bands in lane 4 was set equal to
1, lane 2 was unit 2, lanes 1 and 9 were unit 3, lanes 6, 7, and 8
were unit 4 and lanes 3 and 5 were unit 5.
The band intensity of given aliquots of p21 extracted from 13-3B-4
cells served as an internal standard, compensating for interassay
variation between autoradiographs. As an additional control of p21
quantification, several tumours and normal breast specimens were
repeatedly analysed for p21 on different occasions using different
portions of the tumours. Typical results are presented in Table
8:1. P21 units determined for individual tumours were found to be
reproducible and specific for each tumour. The control tissues
were uninvolved breast tissue adjacent to a carcinoma, normal
breast tissue adjacent to a fibroadenoma and normal breast tissue
from a reduction mammoplasty. These tissues exhibited variations
in p21 levels less than 2-fold as quantified by counting the
incorporation of 1251 into the bands. Thus, high levels of p21
were frequently found in primary breast cancers compared to normal
breast tissue.
Table 8:2 shows levels of p21 in the 160 early breast cancers
studied expressed in the arbitrary units described. 19 of 160
tumours (12%) were classified as unit 1, 45 tumours (28%) were
unit 2, 44 tumours (27.5%) unit 3, 40 tumours (25%) unit 4 and 12
1 76
tumours (7.5%) were unit 5. Thus, 141 of 160 breast cancers (88%)
with no evidence of metastases contained elevated p21 levels
compared with normal breast tissue.
1 77
Figure 8:1
Western Blotting analysis of p21 in human breast carcinomas.
STD, 13-3B-4 cells; lanes 1 to 9, breast tumours; 14C,








p21 levels (arbitrary units 1-5) in 5 breast tumours and 3 control
tissues assayed on three separate occasions using different
portions of the same tumour.
p21 level (arbitrary units 1-5)
Breast Tumour Assay 1 Assay 2 Assay 3
12 2 2
2 4 4 4
3 5 5 5
4 111







Levels of p21 in 160 early breast cancers expressed in arbitrary
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c) Relationship between p21 Level and Cyclic AMP Binding Activity
Levels of p21 and cAMP binding were then compared in this group of
breast cancers. The results are presented in Figure 8:2. There was
a progressive and significant increase in the median cAMP binding
level with increasing expression of p21 (p<0.001 by Spearman's
Rank Correlation). Furthermore, there was an almost complete
discrimination between the range of cAMP binding activity in
tumours with a p21 level of 1 (0.765 - 5.750, median 2.077) and
tumours with a p21 level of 5 (5.555 - 12.278, median 8.000). This
difference was highly significant (p< 0.00001 by Wilcoxon Rank
Test).
d) Relationship between p21 Level and Cyclic AMP
There was also a significant positive trend between the level of
expression of p21 and the amount of cAMP in this group of 160
early breast tumours (Figure 8:3) (p<0.001 by Spearman's Rank
Correlation).There was also a highly significant difference, with
an almost complete discrimination, in cAMP level between p21 units
1 and 5 (p<0.00001 by Wilcoxon Rank Test).
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Figure8:2
Cyclic AMP binding activity grouped according to p21 level in 160
early breast cancers. Horizontal lines represent median values.
Significant trend between the groups by Spearman's Rank
Correlation (p<0.001) and significant difference in cAMP binding
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Figure 8:3
Level of cyclic AMP grouped according to p21 expression in 160
early breast cancers. Lines represent median values. Significant
positive trend between the groups by Spearman's Rank Correlation
(p<0.001) and significant difference between groups 1 and 5 by
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e) Relationship between Tumour p21 Level and Menopausal Status of
the Patient
The relationship between the tumour level of p21 and the
menopausal status of the patient is presented in Table 8:3. Of the
160 patients studied, 52 were premenopausal, 4 were perimenopausal
and 101 were postmenopausal. 3 had undergone previous
hysterectomies and their menopausal status was not assessable.
There was no significant trend in the percentage of pre-, peri- or
post-menopausal patients whose breast tumours expressed different
levels of p21 protein.
f) p21 Level and Oestrogen Receptors
The relationship between p21 protein enhancement and the presence
of oestrogen receptors is shown in Table 8:4. Of the 160 early
breast cancers studied oestrogen receptor measurements were
performed on 153 tumours, 104 of which were ER-positive (68%) and
49 ER-negative (32%).
It can be seen that although the percentage of ER-positive tumours
in the p21 unit 1 group (50%) was lower than in other groups (unit
2, 76%; unit 3, 68%; unit 4, 68%; and unit 5, 67%) there was no
significant overall difference in the percentage of ER-positive
cases in the breast cancers subdivided according to p21 level.
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Table8:3
Relationship between semi-quantitative assessment of tumour p21
and menopausal status in 52 pre-, 4 peri- and 101 post-menopausal

































Relationship between semi-quantitative assessment of p21 and
oestrogen receptor (ER) status. No significant difference between
the groups by Spearman's Rank Correlation.
p 21 level ER +ve / total (%) ER - ve / total (%)
1 9/18 50 9/18 50
2 22/12 76 10/42 24
3 28/41 68 13/41 32
4 27/40 68 13/40 32
5 8/ 12 6 7 4/12 33
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The relationship between the level of p21 and the concentration of
oestrogen receptor activity was also examined in receptor positive
tumours (Figure 8:4). The median oestrogen receptor level was not
significantly different in tumours expressing increasing units of
P21 •
g) p21 Level and Progesterone Receptors
Progesterone receptor measurements were performed in 56 of the 160
early breast cancers studied and receptor activity was detected in
17 tumours (30%).
The relationship between the level of p21 and the presence of
progesterone receptors is shown in Table 8:5. No significant
difference in the percentage of PgR-positive cases subdivided
according to p21 level was detected.
The relationship between the level of p21 and the concentration of
progesterone receptor activity was also investigated in the 17
receptor positive tumours (Figure 8:5). Numbers were too small for
meaningful statistical analysis, but no obvious trend between
amounts of p21 and progesterone receptor was apparent.
p21 levels were also compared in groups of tumours subdivided
according to the combination of oestrogen and progesterone
receptor status. Of 56 tumours assayed for the two receptors, 15
were both oestrogen and progesterone receptor positive, 24 were
oestrogen receptor positive and progesterone receptor negative, 2
were oestrogen receptor negative and progesterone receptor
positive, and 15 were both oestrogen and progesterone receptor
1 87
negative. These groups were then subdivided according to p21 level
(Table 8:6). Numbers were too small for statistical analysis but
no overall difference in the percentage of cancers in each
subgroup was apparent.
h) p21 Level and Tumour Grade
The relationship between p21 level and tumour grade is presented
in Table 8:7. No significant trend was observed.
18 8
Figure 8:4
Relationship between level of p21 and oestrogen receptor
concentration in 104 oestrogen receptor positive breast tumours.
No significant correlation by Spearman's Rank Correlation or
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Table8:5
Relationship between semi-quantitative assessment of p21 and
progesterone receptor (PgR) status. No significant difference
between the groups by Spearman's Rank Correlation.
p 21 level PgR +ve / total ( % ) PgR-ve / total (%)
1 2 / 6 33 4/6 67
2 3 / 12 25 9/12 75
3 7/20 35 13/20 65
4 2/10 20 8/10 80
5 3/8 38 5/8 62
1 9 0
Fieure8:5
Relationship between level of p21 and progesterone receptor
concentration in 17 progesterone receptor positive breast tumours.
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Table 8:6
Levels of tumour p21 grouped according to both oestrogen (ER) and
progesterone receptor (PgR) status.56 breast cancers were divided
into 15 ER+ve PgR+ve, 24 ER+ve PgR-ve, 2 ER-ve PgR+ve and 15 ER-ve

































































Relationship between semi-quantitative assessment of p21 and
tumour grade. Results are expressed as the number of tumours at
each grade per total number of tumours containing each p21 level.
No significant trend by Spearman's Rank Correlation.







1 1 / 19 5 8 /19 42 10/19 53
2 8/45 18 24 /45 53 13/45 29
3 3/44 7 21 / 44 48 20/44 45
4 6/40 14 17/40 43 17/40 43
5 2 /12 16 2/12 16 8/12 68
1 93
i) p21 Level and Clinical Stage
The T stage or tumour size was known in 145 patients. The
relationship between p21 level and T stage is presented in Table
8:8. In T1 tumours, the greatest proportion (31%) was found to
contain the lowest level of p21 (unit 1) , whereas in T4 tumours
there was a trend for increasing populations at higher p21 levels
(units 3 and 4). Although progression of T stage was positively
related to increasing p21 level this did not reach statistical
significance.
j) p21 Level and Lymph Node Involvement
Lymph nodes were obtained for histological examination in 133
patients. 67 patients (50%) had involved nodes. The relationship
between lymph node involvement and p21 level is shown in Table
8:9. There was a significant increase in the percentage of node




Relationship between serai-quantitative assessment of p21 and T
stage. Results are expressed as the number of tumours at each T
stage per total number of tumours containing each p21 level. No










































































Relationship between semi-quantitative assessment of p21 and lymph
node involvement. Results are expressed as the number of tumours
with and without lymph node involvement per total number of
tumours containing each p21 level. Significant increase in
percentage of lymph node +ve tumours with increasing p21 level
(p<0.05, by Spearman's Rank Correlation).
p 21 level node +ve / total % node -ve/ total %
1 4 1 16 25 12 / 16 75
2 17 / 36 47 19 / 36 53
3 14 / 32 44 18/ 32 56
4 28 / 38 74 10/38 26
5 4/11 36 7/ 11 64
1 9 6
k) p21 Level and Recurrence of Breast Cancer
In 111 of the 160 patients with early breast cancer studied, at
least 36 months had elapsed since their primary treatment. During
this period, 37 patients presented with recurrent disease while
the remaining 74 patients remained disease free. The relationship
between p21 levels and recurrence at 36 months is shown in Table
8:10. There is a significant increase in the percentage of
patients who developed recurrent disease with increasing p21 level
(p<0.001, by Spearman's Rank Correlation).
Subsequent Cox analysis of overall disease free interval for these
tumours grouped according to p21 level (units 1 and 2 were counted
as one group) is shown in Figure 8:6. Results show that there is a
significantly increased chance of developing a recurrence with
increasing p21 level (p<0.001).
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Table 8:10
Semi-quantitative assessment of p21 in 74 breast tumours which did
not recur within 36 months of initial treatment (NR) and in 37
tumours which recurred within this time (R). p<0.001, by
Spearman's Rank Correlation
a
p 21 level NR
no / total %
R
no / total %
1 10 / 12 83 2 / 12 1 7
2 24 1 28 86 4 / 28 1 4
3 24 / 34 71 10/ 34 29
4 15/28 54 13/ 28 46
5 1 / 9 1 1 8/9 89
1 98
Figure 8:6
Overall disease free interval in patients grouped according to p21
level.
A = p21 units 1+2 n=60
B - p21 unit 3 n = 4 2
C = p21 unit 4 n = 3 9
D = p21 unit 5 n = 11





1) p21 Level and Survival in Breast Cancer
Of 111 patients with at least 36 months follow-up, 24 had died of
their disease and 87 patients survived this period.
The relationship between p21 level and patient survival is shown
in Table 8:11. A significant positive correlation was observed
between tumour p21 level and the percentage of patients dying
within 36 months of primary treatment (p< 0.001, by Spearman's
Rank Correlation).
Survival curves using death from breast cancer as an end point are
shown in Figure 8:7, and indicate that tumours with high p21
levels are significantly associated with poorer survival (p<0.001,
by Cox Analysis).
m) Multivariate Analysis of Prognostic Criteria
Results have shown that levels of cAMP, cAMP binding and p21 are
of prognostic value by univariate analysis in early breast cancer.
The three parameters are interrelated. In order to determine the
relative importance of the individual factors a multivariate
analysis was performed. The results are shown in Table 8:12 and
indicate that when the effect of cAMP binding is taken into
account the prognostic significance of cAMP disappears, while that
for p21 becomes marginal.
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Table8:11
Semi-quantitative assessment of p21 levels in 24 tumours from
patients who had died within 36 months of initial treatment (D)
and in 87 tumours from patients who had survived this period (ND).


































Survival curves for patients grouped according to tumour
level.
A = p21 units 1+2 n = 60
B - p21 unit 3 n = 4 2
C - p21 unit 4 n — 3 9
D - p21 unit 5 n = 11
Significant trend by Cox Analysis (pCO.OOl).
1.0
Proportion0.8 surviving
0.6 0.4 0.2 0.0
1II 364860728496 Time/onths
Table 8:12
Significance of prognosis for recurrence and death for cAMP
binding, cAMP and p21. p-values are shown for the significance
from Cox Analysis for each factor when entered alone and also when
adjusted for the effect of cAMP binding.
Univariate Multivariate
recurrence survival recurrence survival
cAMP binding <0.001 <0.001
cAMP <0.001 <0.01 0.41 0.56




4:1 Cyclic AMP Binding Proteins irt Human Breast Cancer
Measurements of cyclic AMP binding proteins in experimental animal
tumours have yielded useful information regarding the state of
autonomy of the cancers (Cho-Chung et al.,1977; Bodwin et
al1978,1980,1981). The corresponding information in human breast
cancers has yet to be documented. In order to determine whether
cAMP binding proteins have the same relevance in human tumours an
assay has been developed which can be used routinely to measure
total binding sites for cAMP in cytosols of breast cancers (Miller
et al.,1985). In this thesis, additional characteristics of this
method were described.
The cyclic AMP binding assay, as developed, uses relatively simple
methodology, allowing several tumours to be assayed in one day.
The method has the considerable advantage of requiring the
provision of only small amounts of tumour material which means
that measurements can be performed in parallel with other
biochemical and histopathological assessments on the same
specimen.
Results showed that the assay is quantitative and reproducible.
Furthermore, the cAMP binding capacity is not affected by storage
of tumours in liquid nitrogen up to 1 year. This means that assays
may be performed on frozen breast tumour specimens.
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The absence of an effect of either sodium molybdate or aprotinin
on cAMP binding activity also indicates that the binding protein
is not subject to degradation by phosphatases or proteases during
the assay.
The receptor protein was shown to bind cAMP with a median
dissociation constant of 2 x 10"8M similar to that observed in rat
mammary tumours (Cho-Chung et al.,1978a). Results also showed that
the binding protein is highly specific for cAMP as approximately
100 times as much of the closely related cyclic nucleotide, cGMP,
as cAMP, was required to displace an equivalent amount of
radiolabelled cAMP. Furthermore, cGMP is unlikely to interfere
significantly in the assay as endogenous levels of this
nucleotide, found in breast tumour cytosols, are low compared with
amounts necessary to displace cAMP (Israeli et al.,1985).
Using this method, cAMP binding was detected in all breast tumours
assayed but there was a wide variation in levels between cancers.
Levels were similar to those reported by others in human breast
cancer cytosols (Eppenberger et al.,1980; Kvinnsland et al.,1983),
and were also comparable to those found in rat mammary tumours
(Cho-Chung et al.,1977; Cho-Chung, 1978; Cho-Chung et al.,1978a;
Bodwin et al.,1978).
Levels of cAMP binding proteins were also observed to be
significantly higher in breast cancers than in normal tissue or
benign tumours, as previously reported (Eppenberger et al.,1980;
Kvinnsland, 1986).
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In an effort to determine the factors influencing this wide
variation in binding, levels were compared with established
prognostic parameters as well as disease-free recurrence and
survival.
Definitive evidence was provided that patients with high tumour
cAMP binding were significantly more likely to present with a
recurrence or die from their disease within 36 months of primary
treatment than those with tumours having low binding.
Retrospective analysis of the data showed that a value of 8pmoles/
mg cytosol protein gave optimal discrimination between patients
recurring and those remaining disease - free. Although 36 months
represents a relatively short follow-up in the natural history of
breast cancer, it should be noted that Cox analyses of the total
follow-up data showed that patients with high cAMP binding protein
(>8pmoles/mg cytosol protein) had a significantly increased rate
of recurrence and a significantly decreased chance of survival,
even after 5 years of follow-up. This would suggest that tumour
cAMP binding protein is not merely a marker of extremely short
disease-free intervals and survival times but discriminates at
longer time points.
No statistically significant correlations were detected between
levels of cAMP binding proteins and other factors previously
suggested to be of prognostic value, viz steroid receptor status,
lymph node involvement, tumour stage, and histological grade.
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Therefore, the overall inference from the above studies is that
cAMP binding proteins are independent of established predictive
markers in breast cancer. That this is so was confirmed by
multivariate analysis of the data which examined the relative
importance of the different prognostic criteria. Results showed
that tumour grade, lymph node metastases and oestrogen receptor
status were also of prognostic significance for recurrence and
survival, both by univariate analysis and when adjusted for the
effect of cAMP binding.
Therefore, the established prognostic parameters investigated were
related to disease outcome as expected from previous studies
(Stewart et al 1982, Pari et al 1984). Thus, the data base
examined appears to be unbiased and representative.
Cyclic AMP binding proteins were also found to be predictive of
early recurrence irrespective of whether systemic adjuvant
treatment, either of a hormonal or chemotherapeutic modality was
administered.
It remains to be determined whether levels of cAMP binding
proteins are simply markers of poor prognosis e.g. as markers of
cell proliferation rate, or are causally involved in aggressive
tumour behaviour. In this respect it would be interesting to
compare cAMP binding protein levels with a known index of cellular
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proliferation such as DNA thymidine labelling, to determine
whether a simple correlation exists with the rate of cell
division.
However, there is evidence supporting a causal role for cAMP
binding in breast cancer. In order to postulate why cAMP binding
protein levels tend to be higher in poor prognosis tumours,
analogies were drawn with studies in vitro and in animal models,
as data in human breast cancer are not available.
In DMBA-induced hormone dependent rat mammary tumours it has been
demonstrated that during growth, levels of cAMP binding proteins
are low. However, on regression, induced by either oophorectomy or
dBcAMP administration, levels of the binding protein increase
dramatically (Cho-Chung et al.,1978b; Bodwin et al.,1978).
Conversely, hormone independent rat mammary tumours do not regress
following such treatment and continue to grow autonomously. These
tumours have been shown to contain significantly elevated cAMP
binding activity compared to their growing hormone dependent
counterparts and no change in this binding activity was apparent
on oestrogen ablation.
It has been hypothesised that the high levels of cAMP binding
detected in hormone independent rat mammary tumours are associated
with an abnormality in the receptor protein (Cho-Chung et
al.,1980a,b). This aberration may have several consequences. It
may prevent interaction with the catalytic subunit and inhibit
autophosphorylation of the binding protein. This is thought to be
necessary for translocation of the receptor complex to the nucleus
and the initiation of processes involved in tumour regression.
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It is tempting to speculate that the high levels of cAMP binding
observed in human breast tumours with a poor prognosis may be
analogous to the increased levels of binding detected in
autonomously growing hormone independent rat mammary tumours.
While it is not possible to equate hormone unresponsiveness in
animal tumours with poor prognosis in breast cancer, the two
groups are similar in that they tend to encompass the more
aggressive types of tumour. It is relevant that results from this
study and others (Kvinnsland et al. , 1983) have also shown that
cAMP binding may, in combination with oestrogen receptors, be
helpful in predicting response to endocrine therapy in patients
with advanced breast cancer. Breast cancers which did not respond
to endocrine therapy tended to have higher cAMP binding levels
which would lend further support to this analogy with the rat
tumour model.
It is now apparent, in the light of these observations, that
qualitative as well as quantitative studies on the physicochemical
nature of the binding proteins may be of value in detecting
similar aberrations in human breast cancer. Binding proteins which
fail to translocate to the nucleus and accumulate in the cytosol
have been shown to possess different electrophoretic mobilty from
those of hormone dependent rat mammary tumours (Cho-Chung et
al.,1977; Ogreid et al.,1987). Similar studies in human breast
cancer have yet to be performed. However, studies on the MCF-7
breast cancer cell line (Cho-Chung et al., 1981) indicate that the
mechanism of action of cAMP in human breast cancer is analogous to
that in animal models.
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Should such an aberrant species of binding protein be detected in
human breast cancer then cAMP binding proteins would appear to
reflect not only cell proliferation rate but also their degree of
autonomy.
Measurements of cAMP binding proteins may therefore be useful in
the management of patients with early breast cancer in terms of
distinguishing those biologically aggressive tumours which would
benefit from early intervention with adjuvant therapy from those
which will offer prolonged survival, even with minimal therapy.
Lastly it should be emphasised that the present study has been
based on retrospective analysis of a relatively small number of
patients with comparatively short follow-up. However, the
discriminating power of tumour cAMP binding proteins shows
sufficient promise to merit a prospective investigation of this
factor in patients with early breast cancer.
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4:2 Tumour Cyclic AMP Binding Proteins and Endocrine Responsiveness
in Patients with Inoperable Breast Cancer
In addition to identifying a role for cAMP binding proteins as a
new independent prognostic factor in early breast cancer, a pilot
study investigating a potential role for the binding protein in
predicting endocrine responsiveness in advanced disease was
performed.
Results showed, as have others (Edwards et al.,1979; Leclercq &
Heuson,1979), that patients with tumours having a high
concentration of oestrogen receptor (ER) were more likely to
respond to endocrine therapy than those with ER-poor tumours.
However, whilst a statistical difference in ER levels existed,
there was a considerable overlap in the ranges between responding
and non-responding groups so that ER did not provide
discrimination for individual patients.
The presence of progesterone receptors (PgR) in ER positive
tumours has been reported to improve the prediction of endocrine
responsiveness (Knight et al.,1980). This would be expected if PgR
synthesis is regulated by oestrogens and the presence of the PgR
indicates the likelihood that the tumour has maintained its
sensitivity to the influence of oestrogens (Clark & McGuire,
1983). In the series of patients studied, PgR did not enhance
prediction. (Of the 22 patients in which PgR was measured, 5/8
PgR-positive tumours and 6 of 14 PgR-negative tumours responded to
treatment.) Additional discriminating factors are clearly
required.
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Evidence that cyclic AMP binding proteins may represent such a
parameter has come from studies in which regression of hormone
dependent rat mammary tumours followed either oophorectomy or
administration of dibutyryl cAMP (Cho-Chung & Redler,1977). Tumour
regression was preceded by an increase in the cAMP binding protein
and a decrease in oestrogen receptor activity, changes which were
reversed on resumption of tumour growth following withdrawal of
dBcAMP or oestrogen replacement. (Bodwin et al.,1978; Cho-Chung et
al1978a,b). These changes did not occur when tumours failed to
regress after hormone ablation or dBcAMP treatment. Therefore,
these studies present evidence of an inverse relationship between
cAMP binding and oestrogen receptor activites in the growth
control of hormone dependent rat mammary tumours. This suggests
that a combination of these two parameters might provide a more
reliable assessment of hormone dependency than the oestrogen
receptor alone. In order to investigate this possibility Bodwin et
al.(1980) used the ratio of ER to cAMP binding and were able to
discriminate by 95% between hormone dependent and independent rat
mammary tumours as compared with a value of 60% using ER alone.
Studies on hormone dependent breast cancer cells in vitro
(Cho-Chung et al.,1981) suggest that a similar antagonistic
relationship between cAMP binding proteins and ER may exist in
breast tumours in vivo. Indeed a preliminary report by Kvinnsland
et al.(1983) suggested that cAMP binding may also be of value in
predicting endocrine responsive human breast cancers.
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Results from the present study support this contention. Levels of
cAMP binding proteins alone were found to be higher in
non-responsive tumours, although this tendency did not reach
statistical significance. However, the ratio of ER to cAMP BP
completely discriminated between responders and non-responders in
patients with ER-positive tumours. The cut-off point between the
two groups was 45 x 10"3 which is different from that used by
Kvinnsland et al. (1983) but similar to that found in rat mammary
tumours (Bodwin et al.1980). However, the methodology employed to
measure cAMP BP by Kvinnsland's group was different and is likely
to account for the dissimilar ranges of values reported.
It is necessary to emphasise that in both studies patient numbers
were small and discriminatory levels have been decided
retrospectively. These observations require to be extended in a
prospective study using a predetermined cut-off point so that the
usefulness of the ER to cAMP BP ratio in predicting endocrine
responsiveness can be confirmed.
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4:3 Types of Cyclic AMP Binding Proteins in Human Breast Cancer
The studies discussed to date have concerned total cyclic AMP
binding activity in breast tumour cytosols. However, it is well
established that there are two major types of cAMP binding
protein, designated R1 and R2, which correspond to the regulatory
subunits of cAMP-dependent protein kinase Types 1 and 2,
respectively (Kuo & Greengard, 1969; Corbin et al.,1975).
The roles of R1 and R2 in human breast cancer are unknown.
Numerous studies suggest that R2 is implicated in cellular
differentiation and regression whereas R1 is related to cell
proliferation (Costa et al.,1976; Gharret et al.,1976; Lee et
al.,1976; Fossberg et al.,1978; Handschin & Eppenberger, 1979;
Pawelek, 1979; Cho-Chung, 1980a; McClung & Kletzien,1981).
Studies of total cAMP binding activity in breast tumour cytosols
have shown sufficient promise to merit an investigation of the
relative contribution of individual cAMP binding protein types.
While a similar technique has been used previously to analyse cAMP
binding protein types in breast tumours (Weber et al.,1981;
Handschin et al.,1983) this is the first study to investigate
individual binding proteins in a substantial data-base of tumours
from patients with several years follow-up.
This study is also novel in that levels of binding protein types
were quantitative, expressed in pmoles/mg cytosol protein.
Handschin et al. (1983) expressed levels on an arbitrary scale,
based on relative peak heights of densitometer scans. In the
present study these peak heights were then used to calculate the
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proportion of total binding activity, assayed on the same
specimen, attributable to each type. This method of quantitation
is more precise as it corrects to some extent for tissue
cellularity and heterogeneity by expressing results on a protein
basis.
It was hoped that such studies might provide additional
information and perhaps improve the prognostic value of the total
binding measurements.
The photoaffinity labelling technique used to measure cAMP binding
protein types in human breast cancer was adapted from that of
Pomerantz et al.(1975) with several modifications (section
2 : 6(b)).
Characterisation of the method showed that the binding of the
photoaffinity label was specific and reversible and exhibits a
dissociation constant similar to that of cAMP. It, therefore, is
probable that this photoaffinity label binds to the same protein
as cAMP.
The characteristics of the assay were found to be consistent with
those of other groups using this technique in different systems,
e.g. photoactivated incorporation was seen to be complete after a
few minutes irradiation which is in keeping with Pomerantz et
al.(1975). This contrasts with observations of Antonoff and
Ferguson (1974) that photoactivated incorporation was linear with
irradiation time over several hours. However, the present study is
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more in accord with the proposed mechanism of photoaffinity
labelling in which the ligand is photolysed to yield a short
lived, but highly reactive intermediate.
Thus, characterisation studies confirmed several criteria for true
photoaffinity labelling; the affinity of the photoreactive ligand
for the binding proteins was similar to that of cAMP, its
selectivity was high in a heterogeneous protein mixture, and
covalent incorporation was rapid on irradiation.
Using this technique, analysis of cAMP binding protein types in
human breast cancer cytosols revealed 4 main bands on
SDS-polyacrylamide electrophoresis with molecular weights of 52K,
48K, 43K and 39K.
The types of binding protein were not definitively identified in
the present study but were assumed to represent certain species on
the basis of several criteria; 1) their molecular weight, 2)
comigration with purified R subunits on gels, and 3) comparisons
with other reports in breast cancer cytosols which have
investigated, in addition, elution profiles on DEAE-cellulose
chromatography (Handschin et al.,1983), and the use of specific
antibodies to R1 and R2 (Weber et al.,1981).
For example, the 48K and 52K binding proteins were assumed to be
R1 and R2 respectively, as the 48K protein comigrated with
purified R1 from rabbit skeletal muscle (MW 48K) while the 52K
protein migrated slightly ahead of purified R2 from bovine heart
(MW 54K).
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This finding is similar to that of other groups investigating
human breast cancer cytosols, e.g. Weber et al. (1981) who
identified proteins of molecular weight 52K (R2), 49K (Rl), 37K
and 34K and Handschin et al. (1983) who identified proteins of
molecular weight 52K, 49K, 45K, 39K and 37K.
In general, Rl characterised in mammalian species tends to have a
molecular weight of 47-49K whereas R2 exhibits greater
"microheterogeneity" (Nimmo & Cohen, 1977; Doskeland & Ogreid,
1981) and forms of molecular weight 50K, 52K, 54K and 56K have
been reported in various tissues (Weber et al.,1981).
The slight differences detected in the molecular weights of
binding proteins in breast cancer cytosols between groups may
reflect variations in gel separation techniques and difficulties
in accurately defining proteins with very similar molecular
weights.
The smaller species of cAMP binding proteins were assumed to
correspond to frequently observed proteolytic fragments of intact
regulatory subunits (Corbin et al.,1975; Imashuku et al.,1979;
Malkinson & Butley,1981; Potter & Taylor, 1979; Weber & Hilz,
1979) and have been confirmed as such in human mammary tumours
(Weber et al.,1981).
In an effort to determine the factors influencing the amounts of
individual binding proteins, levels were compared with established
prognostic parameters as well as disease-free interval and
survival.
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As there have been reports (Handschin et al.,1983) that it is the
relative amounts of the binding proteins, rather than actual
levels that are important in the regulation of tumour growth,
their ratios were also investigated.
In the present study levels of the 52K (R2) binding protein were
not significantly related to established prognostic parameters,
disease-free interval or survival. However, if only the tumours in
which R2 was expressed were examined, the median R2 level was
significantly higher in the early recurrence group. Furthermore,
this difference was more significant than the difference between
total cAMP binding activity in the same tumours. This relationship
may, however, be artefactual. A larger series of tumours
expressing the 52K protein should be investigated to determine
whether the correlation holds.
Alternatively, it may be postulated that tumours which express the
52K protein are different biologically from tumours which do not
contain this protein, and the two populations may be treated as
separate subgroups. If this is the case,it would appear that in
the subgroup of tumours in which the 52K protein is expressed,
high levels of the protein appear to be a poor prognostic sign.
Further studies are required before it can be proposed that
measurements of levels of this binding protein are of greater
prognostic value than total binding measurements.
There have been no other reports investigating the relationship
between the 52K protein and prognosis in human breast cancer which
might corroborate these findings.
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However, there is now evidence from studies in vitro and in animal
tumour models that qualitative rather than quantitative
differences in R2 may be of importance. For example, it has been
shown that growing hormone dependent rat mammary tumours contain
low levels of R2 which increase appreciably in the cytosol and
nucleus following oophorectomy or dBcAMP treatment (Cho Chung,
1980a,b). In contrast, autonomously growing mammary tumours which
do not regress following hormone treatment show no increase of
this receptor in either cytosol or nucleus following treatment.
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It has been postulated that this inability to penetrate the
nucleus and thereby initiate tumour regression is due to a
structural alteration of the protein. In fact, the R2 receptor
protein of hormone independent tumours was found to have a charge
alteration as compared to the receptor of hormone dependent
tumours (Cho-Chung et al.,1977). Thus, on 2-dimensional gel
electrophoresis the R2 protein of autonomously growing tumours
migrated as a doublet with a shift to a more acidic charge than
that of hormone dependent tumours. This charge alteration did not
effect cAMP binding but decreased the ability of the regulatory
subunit to interact with, and be phosphorylated by, its own
catalytic subunit.
In certain clones of Walker 251 rat mammary carcinoma cells,
abnormal R2 binding proteins are also associated with unrestrained
tumour growth (Cho-Chung et al.,1977).
Furthermore, a separate group (Ogried et al.,1987), characterised
the difference in cAMP binding proteins between hormone dependent
and independent rat mammary tumours and detected subtle but
significant physiochemical changes in R2 between the groups.
However no differences in quantitative levels of R2 were detected.
There have also been several reports of aberrant binding proteins
effecting the behaviour of other neoplasms in vivo and in vitro.
In lymphoma cells both quantitative and qualitative differences in
cAMP binding proteins have been reported in dBcAMP resistant and
responsive cells (Daniel et al.,1973; Steinberg et al., 1977).
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Abnormalities have been reported in R2 in lung neoplasms but it is
not known whether these changes affect the aggressiveness of the
tumour (Malkinson & Butley, 1981; Butley et al.,1984).
Yet another aberrant binding protein has been isolated from
adrenocortical carcinomas (Shanker et al.,1979).
Perhaps future studies in breast cancer should focus on physical
properties rather than amounts of binding protein types as this
area has not been previously investigated. A search for potential
aberrancies in cAMP binding protein types may prove to be of value
in predicting both endocrine reponsiveness and the prognosis of
the disease.
Investigations into the possible significance of the 48K (Rl)
binding protein in mammary tumour growth are less well documented.
In the present study Rl was detected in all breast cancers assayed
and was the predominant binding protein type in the majority of
breast tumours. These results agree with previous reports in
breast tumour cytosols (Weber et al.1981; Handschin et al.,1983).
However, the significance of these findings in human breast cancer
has yet to be determined.
In rat mammary tumours, Rl was a minor binding protein and was
often not detected (Cho-Chung, 1980a). This suggests that Rl may
have a biological significance in human breast cancer that is less
important or absent in rat mammary cancer.
It has been suggested that Rl may be an index of cell
proliferation rate (Costa et al.,1976) and as such may be of value
as a biological marker for breast cancer. However, immuno-
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fluoresence studies in MCF-7 human breast cancer cells, using
specific antibodies to R1 (Kapoor & Cho-Chung, 1983; Kapoor et
al.,1984) have not revealed any significant trend between
expression of R1 and cell growth rate.
Against this background, the role of R1 in breast cancer remains
an enigma. The main finding of the present study was that levels
of R1 were significantly higher in tumours which recurred early.
However, levels of total cAMP binding proteins were also higher in
the same group of tumours, at the same level of statistical
significance. Therefore, it has yet to be determined whether
differences in R1 are a reflection of total binding activity or
whether total cAMP binding measurements are only of prognostic
value because these tumours contain the highest amount of Rl.
At the moment, however, measurement of Rl does not seem to add to
the prognostic value of measuring total binding sites. As the
latter measurements are less time consuming, more cost effective,
and are required so that quantitation of binding types may be
achieved, routine measurements of Rl do not appear to be
warranted.
The ratios of both R1:R2 and of intact versus proteolysed binding
proteins were found to be greater than one, which is in accordance
with a previous report in breast tumour cytosols (Handschin et
al.,1983). However, the ratio was not significantly related to
either established prognostic parameters or to disease-free
interval or survival. Measurement of relative amounts of binding
proteins, therefore, does not appear to offer additional
prognostic value.
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Levels of the putative degradation products 43K and 39K were also
not found to be of any additional prognostic value. A single
report by Handschin et al.(1983) has reported a reciprocal
relationship between proteolysed cAMP binding proteins, expressed
in arbitrary units, and the oestrogen receptor, in a limited
number of human breast cancer cytosols. However, although this
inverse trend was emphasised, it did not reach statistical
significance.
The question remains whether these smaller entities are functional
in human breast tumour growth or are just proteolytic breakdown
products.
In rat mammary tumours it has been shown that proteolytic
fragments exhibit cAMP binding but have decreased functional
activity such as the ability to be phosphorylated by the catalytic
subunit and translocate to the nucleus (Cho-Chung, 1980a,b).
Preliminary studies in breast tumour cytosols (data not shown)
also suggest that these lower molecular weight binding proteins
lack the ability to autophosphorylate, suggesting that the
findings in rat mammary tumours may be extrapolated to human
breast cancer.
However, the present study has substantiated reports (Weber et
al.,1981; Handschin et al.,1983) that these lower MW proteins are
not merely artefacts created by the release of proteases during
experimental manipulations. The proteins were detected prior to
tissue homogenisation and may have some, as yet undetermined,
biological significance.
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The possibilty that the extent of proteolysis could be a function
of the time interval between surgery and storage in liquid N2
remains. However, all the tumours were routinely collected from
the same operating theatre and were subject to similar transport
procedures. The problem of variations in handling time due to the
constraints of clinical and pathological demands have thus been
minimised although not eliminated.
It has been postulated that levels of proteolysed cAMP binding
proteins may also be of value, not in themselves, but as a measure
of certain proteolytic enzymes which are thought to be involved in
tumour invasion (Strauli et al.,1980; Handschin et al.,1983) and
tumour promotion (Troll et al.,1975; Handschin et al.,1983). In
particular some protease activities have been shown to be markedly
increased in malignant as compared to normal human breast tissue
(Poole et al.,1980 ;Handschin et al.,1983).
However, the present data did not detect an increase in
proteolysed binding proteins in tumours which recurred early.
In conclusion, while this study has been disappointing in that it
has not been possible to augment the prognostic value of total
cAMP binding assays by measurement of any individual species, it
has provided useful information, previously not available in
breast cancer, and raised several questions for future research.
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4:4 Cyclic AMP in Human Breast Cancer
Measurement of cyclic AMP binding proteins in breast tumour
cytosols proved to be of sufficient prognostic importance to
justify extending the investigation of the cAMP system to include
measurements of cAMP itself.
Using radioimmunoassay, cAMP was detected in extracts of all
breast tumours assayed. Levels were higher than those in normal or
benign breast tissue and tumour tissues exhibited a wide range of
cAMP levels. These results are in concordance with reports by
others investigating breast tumour cytosols (Minton et al.,1974;
Guerinot et al.,1977; Israeli et al.,1985).
In an attempt to determine the factors influencing this wide
variation in cAMP levels, amounts were correlated with established
prognostic parameters, including cAMP binding activity, as well as
disease free interval and survival.
In this respect, cyclic AMP levels were not related to established
prognostic parameters such as steroid receptors, lymph node
involvement, tumour grade, and tumour size. This agrees with a
study by Israeli et al. (1985) reporting no correlation between
cAMP levels and mitotic index, nuclear grade, tumour size or lymph
node involvement in breast cancers.
However, levels of cAMP were found to be significantly related to
levels of cAMP binding proteins in the same breast tumour
cytosols. This correlation is perhaps not suprising as there is
evidence that cAMP and its binding protein are functionally
inter-dependent in the regulation of mammary tumour growth. It has
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been postulated (Cho-Chung, 1981) that an increase of cAMP,
whether endogenously generated or exogenously administered,
triggers a rise in the level of cAMP binding proteins, probably by
induction of protein synthesis. This hypothesis was derived from
numerous studies in experimental animals and in vitro studies. For
example, administration of dBcAMP induced a rise in both cAMP and
its binding protein, leading to growth inhibition in hormone
dependent rat mammary tumours (Cho-Chung et al.,1978b).
Experiments on Chinese hamster ovary cells (Costa, 1977) and rat
fibroblasts (Haddox et al., 1980) have also demonstrated that a
rise in the level of cAMP induces a burst in synthesis of
cAMP-dependent protein kinase.
Furthermore, there is evidence that as cAMP levels are reduced by
the enzyme phosphodiesterase, synthesis of protein kinase is
inhibited and levels of both cAMP and its binding protein return
to basal (Rosen & Erlichman, 1975) .
Thus, the cellular concentration of cAMP appears to be critical in
regulating levels of cAMP binding proteins, which may explain the
positive correlation between cAMP and its binding protein detected
in breast tumours.
In the present study, cAMP levels were also found to be
significantly associated with disease recurrence, although levels
of significance were lower than those for cAMP binding proteins in
the same tumours. That the prognostic significance of cAMP was a
reflection of the greater predictive value of cAMP binding
proteins to which it is closely related was demonstrated by
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multivariate analysis of the data.
Assay of cAMP binding proteins, therefore, remains the measurement
of choice in terms of clinical prognostic value in early breast
cancer.
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4:5 Expression of p21 in Human Breast Cancer
Interest in the present study was stimulated by evidence,in rat
mammary tumours, of a potential link between the expression of
p21, the protein product of the ras oncogene, and the mechanism
of action of cyclic AMP (Huang & Cho-Chung, 1982), as well as
frequent reports of elevated levels of p21 in human breast
cancers.
The relationship between the cAMP system and ras oncogene
expression in human breast cancer has not previously been
investigated. Furthermore, while there have been numerous reports
correlating p21 levels with established prognostic factors, there
have been suprisingly few attempts to relate tumour p21 expression
to disease-free interval and survival in patients with breast
cancer.
In order to address these issues a method was established and
characterised for the identification and semi-quantitative
assessment of p21 protein in primary breast tumours by Western
blotting analysis. P21 was measured in microsomal pellets from the
same tissue specimens as cytosol was derived for cAMP binding
assays. Whilst variations in these parameters between different
areas of the same tumour have been shown to be small this
minimised any underlying differences associated with tissue
heterogeneity. This also proved economical in the use of tumour
tissue as different estimations could be performed using only
200mg of tumour tissue.
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Storage of breast tumour tissue in liquid nitrogen was found to
have a negligible effect on p21 levels but storage of microsomal
pellets at -80°C did have an adverse affect on the detection of
p21. This was possibly caused by the release of proteolytic
enzymes during tissue homogenisation. This means that it is
acceptable to assay frozen tumour tissue for p21 but not frozen
microsomal pellets.
The standard Western blotting technique used, revealed that breast
tumour lysates contained radiolabelled bands which varied in
intensity between extracts and comigrated with p21 from cells
transfected with v-rasH. Such cells exhibited both an upper and
lower band of p21, whereas human breast tumours contained a
doublet comigrating with the lower band of p21. The difference in
molecular weights of the upper and lower p21 bands was greater
than that of the p21 bands in the doublet. This is consistent with
reports that cells transfected with the viral rasH gene encode
both phosphorylated (upper band) and unphosphorylated (lower band)
forms of p21 (Shih et al.,1979; Langbeheim et al.,1980), whereas
human breast tumours contain the cellular ras gene which encodes
only the unphosphorylated form of p21 (Slamon et al.,1984;
Spandidos & Agnantis, 1984).
There are several possible explanations for the presence of the
doublet p21 band in breast cancers. The monoclonal antibody used
does not distinguish between species of p21 either in terms of
activated and non-mutated, or Ha, Ki, and N-ras. However, the
doublet is unlikely to represent point mutated and non-mutated
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forms of p21 as it is now widely accepted that human breast
cancers do not contain mutated ras genes (Gelmann & Lippman,
1987). Only one cell line, derived from a rare human mammary
carcinosarcoma has been shown to have a point mutation in p21 at
amino acid 12 (Kraus et al.,1984).
It also seems improbable that this doublet represented Ha and Ki
strains of p21. Recent molecular studies have provided evidence
that the Ha-ras proto-oncogene is the ras family member most
often associated with human breast cancer (Theillet et al.,1986).
This study showed that 70% of breast cancers contained elevated
levels of Ha-ras mRNA. In contrast, no Ki or N-ras RNA was
detected. However, the possibilty cannot be ruled out that that
the doublet represents the gene products of two separate, although
as yet unidentified, endogenous ras genes.
The most likely explanation for the presence of this doublet seems
to be that it represents a difference in post-translational
processing of the same p21 protein. The occurence of unpredicted
forms of p21, manifested by slight differences in electrophoretic
mobility has been reported in a variety of cells (Langbeheim et
al.,1980; Fuhrer et al.,1986). p21 proteins are known to be
synthesised on soluble microsomes as pro-p21 which is subsequently
modified via acylation by the covalent attachment of palmitic acid
(Sefton et al.,1982; Chen et al.,1985) and becomes incorporated
into the cytoplasmic face of the plasma membrane (Papageorge et
al.,1982; Shih et al.,1982). There are two reasons why the doublet
in human breast tumour lysates is unlikley to represent pro-p21
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and p21. Firstly, pro-p21 is known to have a half-life of less
than 30 minutes (Weeks et al.,1987) and would not be detected
under the present experimental conditions.
Secondly, experiments incorporating [35S]-methionine into newly
synthesised proteins have shown that cytosolic pro-p21 is observed
as a more slowly migrating species on SDS-polyacrylamide gel
electrophoresis (Chen et al.,1985; Buss & Sefton, 1986; Fujiyama &
Tamanoi, 1986). However, p21 detected in the cytoplasm of breast
tumour lysates (data not shown) and other cell types (Weeks et
al.,1987) consisted mainly of the more rapidly migrating species
of the doublet. Furthermore, the small difference in molecular
weights between the two species of the doublet was more
characteristic of the cleavage of a very small peptide fragment,
potentially causing dissociation of the protein from the membrane.
The reason why p21 should migrate more rapidly after the addition
of palmitate, which anchors it to the plasma membrane, is unclear.
There is evidence that acylation is only one of several
post-translational modifications. In yeast ras proteins are
converted to forms with faster electrophoretic mobility before the
attachment of palmitic acid (Fujiyama & Tamanoi, 1986), and
studies with mammalian p21 indicate that removal of lipids does
not restore the mobilty of the mature protein to that of the
precursor form (Chen et al.,1985). The p21 detected in breast
tumour lysates is, therefore, assumed to represent
unphosphorylated, non-mutated, Harvey-p21. Some protein may have
lost a peptide fragment so that a doublet may be manifest.
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Alternatively, loss of a fragment may result in p21 becoming
detached from the plasma membrane. Cytoplasmic contamination may
then account for the presence of this doublet in membrane
preparations.
Having endeavoured to identify the species of p21 present in
breast tumours, the next step was to quantitate the amounts of
this protein expressed.
The intensity of radiolabelling of the p21 doublet was found to
vary considerably between breast tumours. A disadvantage of the
Western Blotting technique used was that it was only possible to
estimate p21 levels semi-quantitatively. This was based on
measuring the incorporation of 125I-labelled Protein A into p21
bands. Appropriate controls were included to account for
interassay variation and p21 levels in the same breast tumours
were found to be reproducible. The present method of quantitation
of p21 levels, while similar to that of Clair et al. (1987), has
several points which commend it. Clair's group employed
densitometry to measure the relative intensities of radiolabelled
bands, whereas in the present study the incorporation of 1251
Protein A into individual bands was assessed by gamma-counting.
Hence, an arbitrary scale of only 1-3 was used by Clair's group,
whereas this study is based on a wider and more accurate scale of
1-5, where unit 1 is equivalent to the average p21 level of normal
breast tissue.
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Using this method of quantitation, the majority of breast cancers
were found to contain markedly elevated levels of p21 compared
with normal control tissue. This is consistent with reports by
other groups, also using Western Blotting techniques (DeBortoli et
al.,1985; Tanaka et al.,1986; Clair et al.,1987).
Other methods commonly used in oncogene expression studies confirm
that expression of ras is often increased in breast tumour
relative to normal tissue. Analysis of ras RNA transcripts,
rather than levels of p21 protein, also showed a significant
elevation of mRNA in malignant as compared to normal breast tissue
(Spandidos & Agnantis, 1984). However, it cannot always be assumed
that levels of mRNA transcripts reflect actual levels of protein
expression.
A radioimmunoassay developed to measure p21 quantitatively (Hand
et al.,1987) also detected enhanced expression of p21 in breast
cancers compared to non-malignant tissue.
The expression of p21 has also been studied by immunohistochemical
techniques. This has the advantage of allowing the evaluation of
p21 expression in individual cells. The majority of these studies
have reported increased levels of p21 in cells of mammary cancers
compared to those in corresponding benign lesions or normal tissue
(Hand et al.,1984; Thor et al.,1984; Ohuchi et al.,1986; Whittaker
et al.,1986). Others, however, have failed to detect any
significant difference (Ghosh et al.,1986; Candlish et al.,1986)
showing widespread positive staining for p21 in both benign and
malignant breast specimens.
2 3 3
Two different monoclonal antibodies have largely been used in
immunohistochemical studies; Y13-259 (Furth et al.,1982) and RAP-5
(Hand et al.,1984). However, it is now thought that RAP-5 may also
recognise a cytoplasmic cellular component distinct from p21
(Ghosh et al.,1986). Such problems with nonspecific staining are
common in fixed tissue samples and may result in false positives
complicating interpretation of the results.
Nevertheless, the majority of studies support the present data in
detecting elevated levels of p21 in mammary cancers compared with
benign or normal tissue.
In order to determine which parameter might account for the wide
variation in expression of p21 observed in breast cancers, levels
were related to prognostic factors, including cAMP and its binding
protein as well as disease-free interval and survival.
In the present study, no significant correlation between p21
levels and either oestrogen or progesterone receptor status was
observed. This is consistent with reports by other groups (Clair
et al.,1987; Lundy et al.,1986; Ohuchi et al.,1986; Querzoli et
al.,1988) .
A tendency for tumour p21 levels to be positively associated with
histological grade was observed but did not reach statistical
significance. In Clair's study (1987), on a limited number of
patients, such a correlation was not apparent.
No trend between p21 levels and tumour size was detected in the
present study. This agrees with a report by Agnantis et al.(1986),
who found no correlation between Ha-ras mRNA transcripts and T
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stage. In contrast it has been reported that progression of T
stage correlated significantly with an increase in p21 levels
(Clair et al.,1987; Lundy et al.,1986).
Investigations of p21 level in relation to lymph node involvement
revealed a significant trend between increasing p21 level and the
presence of lymph node metastases.
Other groups have also reported a significant correlation between
lymph node involvement and high expression of p21 or its related
mRNA (Lundy et al.,1986; Agnantis et al.,1986; Clair et al.,1987;
Querzoli et al.,1988). It is apparent from the studies to date
that, despite specific differences, there is a general tendency
for high p21 levels to be associated with poor prognostic indices.
Results from the present study represent the first evidence,in
human breast cancer, that enhanced expression of p21 accompanies
an augmentation of the cAMP system.
Furthermore, a highly significant correlation between increased
expression of p21 and both early disease recurrence and reduced
survival was observed. This confirms a smaller study by Clair et
al. (1987) also suggesting a trend between high p21 levels and
poor prognosis.
Thus, p21 and the cAMP system appear to be related to each other
and to prognosis in breast cancer. However, the prognostic
significance of p21 was only marginal when results were adjusted
for the predictive effect of cAMP binding by multivariate
analysis. Therefore, the prognostic value of p21 appears to be a
reflection of its close relationship with cAMP binding activity.
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Whether high levels of cAMP binding and p21 are the cause of the
poor prognosis of certain breast cancers or are merely markers of
tumour aggressiveness or cell proliferation rate can only be
postulated at this stage.
It could be postulated that high levels of cAMP and its binding
protein stimulate expression of p21 which switches on growth
signals. Alternatively, there is evidence that regression of
hormone dependent rat mammary tumours is accomanied by a marked
increase in both cAMP and its binding protein (Cho-Chung et
al.,1978a), as well as a dramatic decline in p21 (Huang &
Cho-Chung, 1982). This led to the hypothesis (Huang & Cho-Chung,
1982) that p21 production may be controlled by the cAMP system
exerting an effect at a regulatory locus of the c-ras gene. This
has been further substantiated in vitro as treatment of a ras
transformed cell line with cAMP analogs resulted in a decrease of
p21 synthesis (Tagliaferri et al.,1985).
However, as has been discussed previously, in autonomously growing
hormone independent rat mammary tumours there appear to be high
levels of aberrant cAMP binding proteins which fail to translocate
to the nucleus (Cho-Chung, 1980a). It could be postulated that
these defective binding proteins would not be capable of
inhibiting p21 production.
The observation that p21 levels did not decrease on administration
of dBcAMP in hormone independent rat mammary tumours would support
this contention (Huang & Cho-Chung, 1983). Therefore, in rat
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mammary tumours, uncontrolled production of p21 coupled with high
levels of an abnormal cAMP binding protein appear to be a feature
of autonomous growth.
It is tempting to speculate that human breast cancer could be
analogous to this tumour model as high levels of both p21 and cAMP
binding proteins are detected in cancers of poor prognosis.
However, it should be noted that data on hormone responsiveness of
breast tumours was not available in the present study and it is
speculation that the biology of hormone independent rat mammary
tumours can be extrapolated to aggressively growing human breast
cancers. It is also not known whether an abnormal cAMP binding
protein, incapable of penetrating the nucleus, exists in human
breast cancer.
Studies on human breast cancer cells in vitro, however, suggest
that such analogies between rat and human mammary cancer may be
justified.
A study by Kasid et al. (1985) showed that on transfection of
oestrogen dependent breast cancer cells with v-rasH they became
hormone insensitive. There is evidence that overexpression of
normal ras can have a similar effect (Gelmann & Lippman,1987).
Therefore, high levels of p21 in human breast cancer cells may be
a feature of hormone independency.
To summarise, a group of breast cancers has been identified with a
reduced disease-free interval and survival, expressing high levels
of both cAMP binding and p21, which appears to share several
features with autonomously growing hormone independent mammary
cancer models.
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An interesting parallel between the cAMP system and expression of
ras which might help to explain the relevance of these
observations should be discussed. Investigations of the possible
functions of p21 have shown that the biochemical characteristics
and amino acid sequence of p21 resemble those of the G proteins of
adenylate cyclase. Both p21 and G proteins bind GTP, are
associated with the cell membrane, have GTPase activity and are
substrates for phosphorylation. These similarities suggest that G
proteins and p21 may have analogous functions and have led workers
to speculate whether p21 may be implicated in the regulation of
adenylate cyclase and hence in the control of the production of
cAMP.
While it has been shown in yeast (Broeck et al.,1985; Toda et
al.,1985; Tatchell, 1986) that p21 does modulate adenylate cyclase
activity, results are conflicting in vertebrates.
Both positive (Franks et al.,1987) and negative (Tarpley et
al.,1986; Gorman et al.,1987) effects of p21 on adenylate cyclase
activity have been reported. It has also been shown (Beckner et
al.,1985) that p21 has no effect on adenylate cyclase. Therefore,
whether there is a role for ras in the regulation of mammalian
adenylate cyclase remains controversial.
Given the structural and biochemical similarities between p21 and
G proteins it seems probable that p21 is implicated in an
analogous signal transduction pathway. The localisation of p21 at
the plasma membrane appears to be essential for its function since
mutant mammalian ras genes encoding proteins which do not attach
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to the membrane are incapable of inducing transformation
(Willumsen et al.,1984). It is likely that p21 transmits a growth
signal from the environment to an intracellular target located at
the plasma membrane, leading to the synthesis of a second
messenger which mediates the physiological response to the growth
signal.
The function of p21 is well conserved in evolution (Campisi et
al.,1984), and appears to be vital in the control of cell growth,
as demonstrated by the observation that microinjection of p21
antibody into resting fibroblasts blocked their response to
stimulation by serum or growth factors (Mulcahy et al.,1985).
The search for an exact function for p21 in mammalian cells
continues unresolved at present. Several hypothetical models have
been proposed. For example, it has been suggested that p21 may
behave like G proteins in that it may cycle through alternative
configurations, existing in equilibrium between an active and an
inactive state. G proteins, when complexed with GTP, stimulate
adenylate cyclase until the action is terminated by the hydrolysis
of GTP. In the absence of GTPase activity, adenylate cyclase
remains permanently in the activated configuration (Newbold,1984).
If, by analogy, p21, when bound to GTP, forms part of a signal
system to promote growth, by transducing signals from the
extracellular environment to a putative effector molecule,
permanent activation of ras could result in the delivery of a
continuous, as opposed to an intermittent, mitogenic signal
resulting in unrestrained growth. Theoretically, this could occur
via overexpression of the normal p21 product, or by the synthesis
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of mutant forms i.e., a p21 deficient in GTPase activity. Whlie
evidence exists for the latter possibilty, mutations at a variety
of sites significantly impairing p21-specific GTP hydrolytic
activity (McGrath et al.,1984; Newbold,1984; Sweet et al.,1984;
Gibbs et al.,1984; Der et al., 1986), it has been confirmed that
breast cancers do not contain mutated ras. rather they express
elevated levels of normal p21 (Gelmann & Lippman, 1987).
Therefore, if p21 in breast cancer cytosols is " switched off and
on" like G proteins, it may be postulated that overexpression of
p21 may produce enough molecules in their active GTP-bound state
to result in a permanent positive signal for cell proliferation.
The present study has given additional credence to this hypothesis
by the observation that breast tumours which expressed high levels
of p21 were significantly more aggressive in their natural history
than cancers with low p21 levels.
Thus the present study substantiates the importance of ras
oncogene expression in the behaviour of breast cancers,
identifying p21 as a new predictive parameter in breast cancer.
While the mode of action of p21 in the biological behaviour of
mammary tumours is not yet resolved, it is postulated that
overexpression of p21 may permanently activate a signal for tumour
growth. This may have important clinical implications in
predicting which patients should have more aggressive therapy.
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4:6 General Discussion
It has been shown that a positive relationship exists between the
cAMP system and p21 in the primary tumour from patients with non-
metastatic breast cancer. Furthermore, cAMP, total cAMP binding
activity and expression of p21 are all increased in tumours from
poor prognosis patients. Moreover, multivariate analysis has shown
that cAMP binding is the greatest predictive factor. The
prognostic value of cAMP and p21 is a reflection of the
relationship with the binding protein.
In order to explain these observations a hypothetical model, based
largely on studies in experimental animals and in vitro models,
may be postulated. This is represented diagramatically in Figure
2.
There is good evidence to support the concept that cAMP is a
negative controller of tumour growth and that cAMP levels are
inversely related to cell proliferation rate (Cho-Chung & Gullino,
1974; Cho-Chung et al.,1981, Cho-Chung et al.,1983).
During the controlled growth of hormone dependent mammary tumours
levels of cAMP appear to be low (Figure 2a).
However, a rise in the level of cAMP, caused either by
administration of cAMP derivatives or cAMP-elevating agents
inhibits mammary tumour growth. Studies in rat mammary tumours and
human breast cancer cells in vitro (Cho-Chung 1980 a,b) suggest
that the mode of action of cAMP depends on successful
translocation of a complex consisting of cAMP and its binding
protein to the nucleus. There processes involved in tumour
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regression are initiated, including the suppression of p21
expression (Huang & Cho-Chung, 1984).
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However, the present study in human breast tumours has shown that
high levels of both cAMP and its binding protein are associated
with poor prognosis. A possible explanation for this (Figure 2b)
is derived from the observation that autonomously growing hormone
independent rat mammary tumours contain elevated levels of
cytosolic cAMP binding proteins compared to their hormone
dependent counterparts (Cho-Chung et al., 1977). There is some
evidence that these binding proteins are non-functional and fail
to translocate to the nucleus, resulting in uninhibited expression
of p21 and unrestrained tumour growth.
Aberrant cAMP binding proteins exist in several tumour systems but
this has not yet been investigated in human breast cancer.
Whether the above observations can be extrapolated to human breast
cancers remains to be determined. Data on hormone - responsiveness
was not available in this study of early breast tumours. It,
therefore, remains speculative whether the biology of hormone
independent rat mammary tumours can be extended to aggressively
growing human breast cancers. However, some evidence in support of
this was provided. In a small group of patients with ER-positive,
inoperable breast cancers, it was shown that cAMP binding activity
was related to tumour endocrine responsiveness. A tendency for
cAMP binding activity to be higher in non-responsive tumours was
evident, and the ratio of ER:cAMP BP discriminated completely
between hormone dependent and independent tumours.
Therefore, several analogies exist between poor prognosis breast
tumours and hormone independent rat mammary tumours.
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Despite the relative importance of cAMP binding measurments in
prognosis, quantitative studies of individual cAMP binding protein
types did not identify any one species as being responsible. Value
may be gained in the future from investigations of functional
abnormalities in cAMP binding proteins.
If such abnormal binding proteins are present in poor prognosis
breast tumours this might explain why cAMP levels alone were of
less value in predicting disease outcome than cAMP binding levels.
Presumably, cAMP induces both normal and abnormal binding
proteins. The growth of tumour cells synthesising normal binding
proteins would be controlled, while growth of cells producing
aberrant binding proteins would be unrestrained. As cAMP cannot
discriminate between the two forms this may explain why the
nucleotide is less significant as a prognostic factor than the
binding protein.
It has been postulated that cAMP binding proteins control tumour
growth by switching off expression of p21 at a regulatory locus of
the ras gene. In tumours with non-functional binding proteins
p21 production remains uninhibited. However, the predictive value
of p21 appears to be largely dependent on its relationship with
cAMP binding activity and not vice versa. This would suggest that
the mode of action of cAMP binding protein is complex. The binding
proteins may control tumour growth by interaction with several
nuclear binding sites, of which the ras locus may only be one.
Several other grey areas remain in this hypothetical model. For
example, it might be postulated that in tumours with low cAMP
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binding activity, expression of p21 would not be inhibited. Such a
group of tumours with low cAMP binding and high p21 levels has not
been identified. It is possible that endogenous levels of cAMP
binding appear low as a result of continuous translocation to the
nucleus, where suppression of p21 occurs.
However, if this were the case, two distinct subgroups of breast
cancers, i.e a group of tumours with high p21, and high cAMP
binding and a group with low p21 and low cAMP binding should
exist. Rather there is a continuous gradation between the two
extremes. Heterogeneity of breast tumour tissue may account for
this; within a single tumour there may exist a mixture of
different clones of cells expressing either normal or aberrant
binding proteins.
A second possible explanation for the results found must be
considered. It could be postulated that in poor prognosis breast
tumours, high levels of cAMP induce high levels of cAMP binding
proteins which then translocate to the nucleus stimulating
overexpression of p21 and promoting tumour growth. However,
experimental evidence supporting this concept is lacking. In
yeast, where p21 is known to regulate adenylate cyclase
(Tatchell,1986), cAMP has been shown to stimulate growth. Certain
mitogenic effects of various hormones e.g. TSH, beta-adrenergic
agonists and glucagon, on differentiated cell systems are mediated
by cAMP (Roger et al.,1983). However, this effect is reversed in
many conventional cell culture systems and there is no evidence
for cAMP stimulating growth of breast cancer cells or rat mammary
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tumours. A single study (Dere et al.,1986) reported an increase in
ras mRNA in a thyroid cell line stimulated by cAMP. Otherwise,
cAMP has been observed to inhibit p21 expression in both rat
mammary tumours and ras transfected cell lines (Huang &
Cho-Chung, 1984; Tagliaferri et al.,1985).
Several questions for future research are identified in this
thesis. Firstly, prospective studies involving larger numbers of
patients must be performed in order to confirm the value of cAMP
binding proteins 1) as a new prognostic parameter in early breast
cancer and 2) in the prediction of endocrine responsiveness in
advanced disease.
This should help to distinguish those biologically aggressive
tumours which require, and will benefit from, aggressive therapy,
from those which offer a chance of prolonged survival with the use
of minimal unpleasant treatment.
Results have shown that cAMP binding activity is of prognostic
value independent of established predictive factors. This suggests
that it may be possible to select those factors of major
importance (e.g. lymph node metastases) and use them in
combination with cAMP binding to create a "prognostic index". This
approach may provide additional information in selecting treatment
for the individual patient.
In addition to the more conventional modes of treatment, various
novel therapies, relevant to this study, may be postulated for the
future.
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For example, it may also become possible to control mammary tumour
growth by regulating expression of the ras oncogene. This might
be achieved by the use of immunotherapy regimes with monoclonal
antibodies against p21 or its putative target.
Futhermore, recent studies (Tagliaferri et al.,1985) have
demonstrated that the cAMP binding proteins have two different
binding sites. New powerful site-selective cAMP analogs have been
developed which can cause growth inhibition, even in hormone
independent breast cancer cells, previously not responsive to the
analog dBcAMP.
It has been suggested that in cancer cells which contain a
non-functional binding protein, a decrease in the affinity or loss
of one of the two cAMP binding sites might have occured. Only
high-affinity binding ligands, such as these site-selectived cAMP
analogs, may be able to induce growth inhibition by binding to
these aberrant binding proteins.
Should such altered binding proteins be identified in breast




a) Hypothetical model of action of cAMP in controlled mammary
tumour growth.
During growth, levels of cAMP and its binding protein are low,
translocation to the nucleus is steady, and levels of p21 are
controlled.
On regression, (e.g. induced by administration of dBcAMP or
oophorectomy) there is an increase in the level of cAMP and
increased translocation of a complex consisting of cAMP and its
binding protein to the nucleus. There, events such as suppression
of p21 expression occur, leading to inhibition.
b) In autonomously growing, hormone independent mammary tumours,
however, this translocation mechanism may be aberrant, resulting
in high cytosolic levels of both cAMP and its binding protein,
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Cyclic AMP binding proteins in human breast cancer
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Summary The characteristics of a method for measuring cyclic AMP binding proteins in cytosols of human
breast cancer are described. Using the assay, binding proteins were demonstrable in all of 100 tumour
cytosols. Levels of binding in individual tumours varied from 0.8 to 15pmolmg""' cytosol protein (mean
value 5pmolmg~' cytosol protein) and the dissociation constant ranged from 0.5 to 5.2xI0~8M (mean
1.73 x 10~" m). Whilst replicate measurements within a single portion of tumour were reproducible (intra-
assay coefficient of variation was between 4.5 and 7.8% and that for inter-assay variation was between 2.1
and 4.0%) there were often considerable differences in levels of binding proteins between different portions of
the same tumour. Similar intra-tumour variations have been reported for other binding proteins and steroid
receptors. The inter-relationships with such parameters may elucidate whether the differences are associated
with variations in cellularity, cell type, or other specific factors.
In experimental animals, cyclic AMP binding
proteins are implicated in the growth of mammary
tumours (Clio-Chung, el al., 1978b; Bodwin, et a!.,
1980; Bodwin et al., 1981). The corresponding
evidence in human breast cancers has yet to be
fully documented. In the present paper we describe
a method for measuring total cyclic AMP binding
proteins in human breast tumour cytosols and some
characteristics of the assay.
Materials and methods
Reagents
(5'8'-3H) Adenosine 3',5'-cyclic phosphate,
ammonium salt (45Cimmol) was obtained from
Radiochemical Centre, Amersham, and radioinert
adenosine 3'5'-cyclic phosphate, sodium salt from
Sigma (Poole, UK). The following buffers were
employed using analytical reagents - Buffer A
20 mM Tris, 0.25 m sucrose, 2mm magnesium
chloride, 1 mm calcium chloride, 10mM potassium
chloride, !6.26mm HC1 pH 7.5; Buffer B 55 mm
potassium phosphate to which 11 mm theophylline
was added immediately before use; Buffer C as
Buffer B but with the addition of lOntM
magnesium chloride.
Tissues
Breast cancers were obtained at mastectomy or
biopsy from patients with histologically proven
disease. All material was transported on ice to a
cold room and processed immediately unless stated
Correspondence: W.R. Miller
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otherwise. The tumours represented 100 consecutive
cases in which sufficient material was available for
assay after tissue had been taken for routine
histopathological examination and for oestrogen
receptor analysis. Specimens were obtained from
patients with T stage 1 to 4, although the number
of T1 tumours was small.
Cytosol preparation
All procedures were performed at 0-4°C. Tumour
was dissected from surrounding fat and connective
tissue, finely cut with scissors and homogenized in
Buffer A (w/vl:10) using a Silverson homogenizer
at maximum speed for 20 sec then 15 sec, with 1
rnin interval for cooling. The homogenate was
centrifuged at 105,000# for 1 h in a MSE
Superspecd 50 centrifuge and the resulting super¬
natant was used as cytosol.
Binding measuremen ts
Cytosol (50 /tl) was incubated with 100 p\ 5',8'-[3H]
cyclic AMP (25 nM to give a final concentration in
the incubation system of 10 nM) and Buffer B
(100/tl) containing radioinert cyclic AMP (final
concentration 0,10,20,40,80, and 10,000 nM). Each
system was set up in duplicate and incubated at
room temperature for 3h. To separate protein-
bound cyclic AMP from free nucleotide, 2 ml
Buffer B was added to each tube. The contents
were then mixed and filtered through a Millipore
filter (HAWP 0.45 pm) at 5 mm Hg negative
pressure followed by 20 ml Buffer C at 10 mm Hg
negative pressure. The filters were transferred to
scintillation vials and dried under a stream of air.
Micellar fluor NE 260, Nuclear Enterprises (5ml)
was added to each vial. The vials were then
© The Macmillan Press Ltd., 1985
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incubated at 37"C for 2 h and radioactivity was
measured in a Tricarb liquid scintillation counter
(Packard).
Cytosol protein
The protein content of each cytosol was determined
by the method of.Bradford (1976) using bovine
serum albumin as standard.
Results
Assay conditions
Tumour cytosols were incubated with [3H] cyclic
AMP in the absence and presence of 10,000nM
radioinert cyclic AMP for varying times, either at
0 C or 20"C. A typical result is presented in Figure
I. Maximum binding at 20 C was achieved by 2h.
Binding at 0 C was lower than at 20 C at each time
point studied but was still increasing al 5 h
incubation. Overnight incubation at either 0 C or
20 C produced similar binding (data not shown).
For routine assays it was decided to incubate at
20 C for 3 h. The amount of binding under these
conditions was linear with respect to increasing
cytosol protein concentrations up to at least
3.0mgml 1 (Figure 2). The effect of radioinert
cyclic AMP on the binding of [3H] cyclic AMP is
shown in Figure 3(a). Low concentrations of
radioinert cyclic AMP were able to compete with
[3H] cyclic AMP for binding, and there remained
only a low level of non-specific binding in the
presence of a thousand-fold excess of competitor.
The data plotted according to Scatchard (1949),
showed that the dissociation constant of binding
was 2.7xI0~sM and that the maximum
concentration of binding sites within the assay
system was about 2.0 nM (Figure 3b). Similar
results were also obtained by performing the assay
with increasing concentrations of radio-labelled
ligand and assessing the non-specific binding by
including a 100-fold excess of cold competitor at
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Figure 1 The effect of time of incubation on the
binding of [3H] cyclic AMP to a cytosol of breast
carcinoma either at 20°C (•> or 0"C (O). Each point
represents the amount of [3H] cyclic AMP bound in
the absence of radioinert cyclic AMP corrected for
that in the presence of 10,000 nM cold competitor.
Remaining assay conditions as described in Materials
and methods.
Cytosol protein (mg ml 1)
Figure 2 The effect of cytosol concentration on the
binding of [3H] cyclic AMP to cytosols of 2 different
breast carcinomas. Cytosols were prepared as
described in Materials and methods and serially diluted
to give the protein concentrations indicated. The
diluted cytosols were incubated for 3 h at 20°C with
increasing concentrations of radioinert cyclic AMP.
The data were analysed by Scatchard plot and each
point represents the maximum number of binding sites
for each system.
Values in breast cancer cytosols
Cytosols from 100 primary breast cancers have
been assayed for cyclic AMP binding proteins. The
results are presented in Table 1, and the concen¬
tration of binding sites in individual tumours are
plotted in Figure 4. All tumours showed cyclic
AMP binding but levels varied greatly between
individual tumours, from 0.8 to l5pmolmg_1
cytosol protein.
Table I Levels and dissociation constants of cyclic AMP
binding proteins in cytosols of 100 primary breast cancers
Level Dissociation Constant
pmolnig 1 cytosol protein (M x 10"8)
Mean + sd 4.99 + 3.07 1.72 ±0.96
Range 0.80 -15.05 0.5-5.2
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Concentration of cold Bound (nM)
competitor (nM)
Figure 3 The effect of radioinert cyclic AMP on the binding of [3H] cyclic AMP to a cytosol of human
breast cancer. Assay conditions were as described in Materials and methods, data plotted as (a) radioactivity



















Figure 4 Levels of cyclic AMP binding proteins in
cytosols of 100 primary breast cancers. Horizontal line
represents mean value.
Reproducibility ofmeasurements and effect of
storage
In order to determine the intra-assay precision of
cyclic AMP binding measurements in tumours,
large breast cancers were finely minced. Five
portions, each of ~ 500 mg, were accurately
weighed and cytosols were prepared separately and
assayed. Two tumours were processed in this way;
one possesed a mean value for cyclic AMP binding
proteins from the 5 replicate estimations of
1.38pmolmg_1 cytosol protein with an intra-assay
coefficient of variation of 7.9%, the other cancer
had a mean value of 7.48pmolmg~1 cytosol
protein with an intra-assay coefficient of variation
of 4.5%.
To ascertain the interassay variation, 3 tumours
were divided into 5 portions, as described for the
study of intra-assay varitaion. One portion of each
tumour was assayed for cyclic AMP binding
proteins immediately (day 0) and the remaining
portions were stored in separate vials in liquid
nitrogen for 1,3,7 and 14 days until assayed. The
results are shown in Figure 5. There appeared to be
no observable decline in level of binding proteins
with storage, and considering measurements within
the same tumour as replicate estimates, the interassay
coefficients of variation were 2.1%, 2.5% and 4.0%
(that these values are lower than those for the inlra-
assay variation is probably a reflection of the larger
number of simultaneous estimations performed in the
study of intra-assay variation).
An estimate of the variation in cyclic AMP
binding protein levels within individual cancers was
obtained by dissecting out portions of tumours
from central, intermediate and peripheral zones
across each of 12 large breast cancers. These were
assayed by the routine method and the results are
presented in Figure 6 as ratios of the values relative
to that in the peripheral zone. Whilst the mean of
the 12 values found in each tumour zone were
similar (and hence the mean value for the zone
ratio was unity), there were often large variations in
cyclic AMP binding protein levels between different
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Figure 5 The effect of storage in liquid nitrogen on
reproducibility of cyclic AMP binding protein levels in









Figure 6 Variation in cyclic AMP binding protein
levels across 12 breast cancers. For experimental
details, see text. Results have been expressed as a ratio
of the value obtained from the intermediate area (I) or
the central area (C) to that in the peripheral area (P).
areas in an individual tumour. This variation was
invariably greater when comparing central and
peripheral zones.
Discussion
Measurements of cyclic AMP binding proteins in
experimental animal cancers have yielded useful
information regarding the state of automony of the
tumours (Cho-Chung et al., 1980a; Bodwin et al.,
1980). Similar data in human breast cancers has not
yet been fully assessed. In the present paper we
describe the characteristics of an assay which might
be used routinely to measure total binding sites for
cyclic AMP in cytosols of human breast cancers.
This method involves incubating tumour cytosol
with radioactively labelled cyclic AMP in the
absence and presence of increasing concentrations
of radioinert competitor. At 20°C, maximum
binding was achieved by 2 It and was linear between
cytosol protein concentrations of 0.4 and
3mgml_I. Under these conditions the non-specific
binding assessed by adding 1000-fold excess of
radioincrt cyclic AMP was negligible (<0.1% of
the added radioactivity). The binding capacity was
not affected by storage up to 14 days in liquid
nitrogen. The intra-assay coefficent of variation, as
determined on aliquots from minced large tumours,
was between 4.5 and 7.9%, and the inter-assay
value was between 2.1 and 4.0%. These results are
similar to those obtained by others using a different
method (Kvinnsland et al., 1983).
Using the present method, cytosols of 100 human
breast cancers have been assayed for cyclic AMP
binding. All possessed binding activity, levels
varying from 0.8 to 15.0pmolmg~' cytosol protein
(mean value 5pmolmg 1 cytosol protein). These
values fall within the range for human breast
cancer cytosols reported by others using different
methods (Eppenberger et al., 1980; Kvinnsland et
al., 1983), and are also similar to those found in rat
mammary tumours (Cho-Chung 1978a; Cho-
Chung et al., 19786). The mean dissociation
constant of 1.73xlCU8M is also in keeping with
data from experimental animal tumours (Cho-
Chung et al., 19786).
It remains to determine which factors influence
the levels of cyclic AMP binding proteins in
cytosols of individual human breast cancers and, in
particular, whether these levels are related to
prognosis or endocrine responsiveness, as has been
suggested by others (Kvinnsland et al., 1983) and as
is the case in rat mammary tumours (Cho-Chung
1978a, b, 1980). Assessments in breast cancers will
have to take into account the variation in cyclic
AMP binding proteins between different areas of
the same tumour. Data from the present study
shows that there may be considerable differences in
the level of cyclic AMP binding between each of
three different areas (central, peripheral and inter¬
mediate) of large tumours. No consistent pattern of
variation across the tumours was evident and the
mean value for cyclic AMP binding in this group of
cancers was similar, irrespective of the area of
tumour upon which the estimation was performed.
At present, it is not known whether these
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differences within tumours are associated with
variations in cellularity, cell type or other factors.
Similar intra-tumour variations have been noted
with other binding proteins such as the oestrogen
receptor (Hawkins et al., 1977; Silversward et al.,
1980) and the inter-relationship with these different
types of binding protein may help to elucidate the
problem.
The authors thank Professor A.P.M. forrest for allow¬
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R.A. Hawkins for his helpful suggestions and comments.
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SHORT COMMUNICATION
Tumour cyclic AMP binding proteins and endocrine responsiveness in
patients with inoperable breast cancer
D.M.A. Watson, R.A. Hawkins, N.J. Bundred, H.J. Stewart & W.R. Miller
University Department of Clinical Surgery, Royal Infirmary, Lauriston Place, Edinburgh EH3 9YW, UK.
The mere presence of oestrogen receptors (ER) is not a
reliable criterion for the response of mammary tumours to
endocrine therapy. While patients with undetectable levels of
tumour ER rarely respond to endocrine therapy, only 50
60% of ER-posilive human breast tumours regress following
hormone treatment (McGuire et ah, 1975). There is,
therefore, a need to identify hormone dependent cancers
within the group of ER positive tumours.
In rat mammary tumours, a better assessment of hormone
dependency can be achieved by using the ratio of ER to
cyclic AMP binding proteins (cAMP BP) compared with
either parameter alone (Bodwin et ah, 1980). The aim of this
study was to determine whether this ratio would also
improve prediction of response to endocrine therapy in
patients with advanced breast cancer.
Thirty-one women with ER-positive advanced breast
cancer were studied. Premenopausal patients with regular
menstrual periods (4 women) were treated by oophorectomy.
The remaining 27 postmenopausal patients (more than 2
years since their last menstrual period) received tamoxifen
(20mg/day) and/or aminoglutcthimide (lg/day) plus hydro¬
cortisone (40mg/day) as primary endocrine treatment (except
for one patient who had previously received tamoxifen and
one women who had undergone a previous oophorectomy).
Response to treatment was classified according to UICC
criteria by an independent objective assessment of clinical
records and without knowledge of the results of the
biochemical analysis.
The biopsy material, which was obtained prior to
endocrine treatment, consisted of 26 primary tumours, 4
invaded lymph nodes and I mastectomy scar recurrence.
Cyclic AMP binding was determined as described previ¬
ously (Miller et ah, 1985) and the activity expressed on the
basis of cytosol protein which has been reported to reduce
intra-tumoral variation (Senbanjo et ah, 1986). Concen¬
tration of oestrogen receptors was determined (in a portion
of tumour adjacent to that taken for cAMP BP) by satura¬
tion analysis (Hawkins et ah, 1981). Activities in excess of
5fmolmg~' cytosol protein were designated receptor
positive. Protein content of each cytosol was assayed by the
method of Bradford (1976) using bovine albumin as
standard.
Of 31 patients, 2 had a complete remission (CR), 12 a
partial remission (PR), 2 a static response (NC) and 15
progressive disease (PD). This represented an overall
response rate of 45% (CR-f PR).
The level of ER in tumours, subdivided according to
response to endocrine therapy, is shown in Figure 1. Concen¬
trations of ER were significantly higher in tumours from
responding patients as compared with those from the non-
responding group (PcIO 4, by Wileoxon Rank Test) and
all rcspondcrs had an ER level above lOOfmolmg 1 protein.
However, one third of the patients whose tumour contained
ER in excess of lOOfmolmg"1 protein did not respond to
endocrine treatment.
Correspondence: W.R. Miller.
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Figure I Levels of oestrogen receptors (ER), cyclic AMP
binding proteins (CAMP BP) and the ratio of ER to ( AMP BP
in endocrine responsive (R) and non-responsive (NR) tumours.
Horizontal bars represent median values. Significance values are
derived from Wilcoxon Rank Test.
cAMP BP was detected in all tumours, with concen¬
trations from 990 to 13,452Imolmg~ 1 cytosol protein.
Levels of cAMP BP, subdivided into two groups according
to endocrine responsiveness, arc shown in Figure 1. No
significant difference was observed between tumour cAMP
BP levels in responding and non-responding patients. The
ratio of ER to cAMP BP for each tumour within the
response groups is also presented in Figure I. There was a
highly significant difference (P< 10 7) between the two
groups of patients. This difference was significantly greater
than that obtained by using ER alone, and it was possible to
discriminate totally between the patient groups. All subjects
responding to therapy had tumour ER/'cAMP BP ratios
greater than 45xl0~3 compared with non-responding
patients in whom values were less than this discriminatory
level.
These results show, as have others (Edwards et ah, 1979;
Leclercq & Heuson, 1979), that patients with tumours having
a high concentration of ER arc more likely to respond to
endocrine therapy than those with ER-poor tumours.
However, whilst a statistical difference in ER levels exists
between responding and non-responding groups, this does
not provide discrimination for individual patients. The
presence of progestogen receptors (PgR) in ER positive
tumours has been reported to improve the prediction of
endocrine responsiveness (Knight et al., 1975) but in the
present scries of patients PgR did not enhance prediction.
(Of the 22 patients in which PgR was measured 5/8 PgR-
positive tumours and 6 of 14 PgR-negative tumours re¬
sponded to treatment.) The presence of PgR, therefore, does
not necessarily improve the predictive value of ER.
Additional discriminating factors are clearly required.
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Evidence that cAMP BP may represent such a parameter
has come from studies in which regression of hormone-
dependent rat mammary tumours followed administration of
dibutyry! eAMP, the effect being apparently mediated by
cAMP BP (Cho-Chung & Redler, 1077). An inverse relation¬
ship has also been described between the binding activities of
cAMP and oestrogen during growth and regression of rat
mammary tumours (Cho-Chung el til., 1078). cAMP BPs
appear to be a marker of tumour sensitivity to hormonal
manipulation, in that by using a ratio of tumour ER to
eAMP BP, Bodwin el al. (1080) were able to discriminate by
95% between hormone-dependent and independent rat
mammary tumours as compared with a value of 60% using
ER alone. A preliminary report from Kvinnsland el al.
(1983) suggests that cAMP binding may also be of value in
human breast cancers. Results from our study support this
contention. Thus, the ratio of ER to cAMP completely
discriminated between responders and non-respondcrs in
patients with ER-positive tumours. The cut-off point
between the two groups was 45x10 3 which is different
from that used by Kvinnsland el al. (1983). However, the
methodology employed to measure cAMP BP was different
in the two studies and is likely to account for the dissimilar
ranges of values reported. It is necessary to emphasise that
in both studies patient numbers were small and
discriminatory levels have been decided retrospectively.
These observations require to be extended in a prospective
study using a predetermined cut-off point so that the useful¬
ness of the ER to eAMP BP ratio in predicting endocrine
responsiveness can be confirmed.
The authors thank Professor Sir Patrick Forrest and Mr U. Chetty
for allowing us to study patients under their care. This work was
supported by a grant from the Medical Research Council
(G860I495CA).
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